FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Dutra, BM
   Rodrigues, NLD
   Fonseca, FRM
   de Moura, TR
   de Almeida, RP
   de Jesus, AR
   Abreu, TM
   Pompeu, MMD
   Teixeira, CR
   Teixeira, MJ
AF Dutra, Brunheld Maia
   Rodrigues, Naya Lucia de Castro
   Fonseca, Francisco Rafael Marciano
   de Moura, Tatiana Rodrigues
   Pacheco de Almeida, Roque
   de Jesus, Amelia Ribeiro
   Abreu, Ticiana Monteiro
   Pompeu, Margarida Maria de Lima
   Teixeira, Clarissa Romero
   Teixeira, Maria Jania
TI CXCL10 immunomodulatory effect against infection caused by an antimony
   refractory isolate of Leishmania braziliensis in mice
SO PARASITE IMMUNOLOGY
LA English
DT Article; Early Access
DE antimony resistance; CXCL10; Leishmania braziliensis; treatment
ID CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; INTERFERON-GAMMA;
   AMAZONENSIS; PROTECTION; CHEMOKINES; CELL; IMMUNOCHEMOTHERAPY; VECTOR;
   IP-10
AB Leishmania braziliensis is the main causative agent of American tegumentary leishmaniasis in Brazil. Current treatment includes different drugs that have important side effects and identification of cases of parasite resistance to treatment support the search for new therapeutic strategies. Recent findings have indicated that CXCL10, a chemokine that recruits and activates Th1 cells, NK cells, macrophages, dendritic cells and B lymphocytes, is a potential alternative to treat Leishmania infection. Here, we tested CXCL10 immunotherapy against experimental infection caused by an antimony-resistant isolate of Leishmania braziliensis. Following infection, mice were treated with CXCL10 for 7 days after onset of lesions. We demonstrate that mice treated with CXCL10 controlled lesion progression and parasite burden more efficiently comparing to controls. An increased IFN-gamma, IL-10, TGF-beta and low IL-4 production combined with a distinct inflammatory infiltrate composed by activated macrophages, lymphocytes and granulomas was observed in the CXCL10-treated group comparing to controls. However, CXCL10 and Glucantime combined therapy did not improve CXCL10-induced protective effect. Our findings reinforce the potential of CXCL10 immunotherapy as an alternative treatment against infection caused by L. braziliensis resistant to conventional chemotherapy.
C1 [Dutra, Brunheld Maia; Rodrigues, Naya Lucia de Castro; Fonseca, Francisco Rafael Marciano; Abreu, Ticiana Monteiro; Pompeu, Margarida Maria de Lima; Teixeira, Maria Jania] Univ Fed Ceara, Dept Pathol & Legal Med, Fortaleza, Ceara, Brazil.
   [de Moura, Tatiana Rodrigues; Pacheco de Almeida, Roque; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Internal Med & Pathol, Aracaju, Brazil.
   [Teixeira, Clarissa Romero] Fundacao Oswaldo Cruz, Fiocruz Ceara, Eusebio, Brazil.
RP Teixeira, MJ (corresponding author), Univ Fed Ceara, Dept Pathol & Legal Med, Fortaleza, Ceara, Brazil.
EM mjteixeira601@gmail.com
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao Cearense de Apoio ao
   Desenvolvimento Cientifico e Tecnologico (FUNCAP)
FX This work was supported by Brazilian grants from Conselho Nacional de
   Pesquisa (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) and Fundacao Cearense de Apoio ao Desenvolvimento
   Cientifico e Tecnologico (FUNCAP).
CR Abdoli A, 2017, COMP IMMUNOL MICROB, V51, P15, DOI 10.1016/j.cimid.2017.02.001
   Almeida RP, 2005, AM J TROP MED HYG, V73, P79, DOI 10.4269/ajtmh.2005.73.79
   BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2
   Conceicao J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004715
   Costa DL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000965
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   de Oliveira CI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00145
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   El-On J, 2009, ISR MED ASSOC J, V11, P623
   Figueiredo WME, 2017, MEM I OSWALDO CRUZ, V112, P561, DOI 10.1590/0074-02760160529
   Figueiredo WME, 2019, EXP PARASITOL, V207
   Gupta G, 2011, MED MICROBIOL IMMUN, V200, P241, DOI 10.1007/s00430-011-0197-y
   Gupta G, 2009, J INFECT DIS, V200, P1300, DOI 10.1086/605895
   Hailu A, 2004, AM J TROP MED HYG, V71, P561, DOI 10.4269/ajtmh.2004.71.561
   Kevric I, 2015, DERMATOL CLIN, V33, P579, DOI 10.1016/j.det.2015.03.018
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Diaz NL, 2013, MEM I OSWALDO CRUZ, V108, P446, DOI 10.1590/S0074-0276108042013008
   Majumder S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048727
   Mastroianni A, 2004, Infez Med, V12, P197
   Minodier Philippe, 2007, Travel Med Infect Dis, V5, P150, DOI 10.1016/j.tmaid.2006.09.004
   Montakhab-Yeganeh H, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12461
   Muller K, 2001, MED MICROBIOL IMMUN, V190, P73
   Peters NC, 2009, CELL MICROBIOL, V11, P1290, DOI 10.1111/j.1462-5822.2009.01348.x
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Silva SC, 2018, ACTA TROP, V178, P34, DOI 10.1016/j.actatropica.2017.10.010
   Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
   Singh Sarman, 2004, Journal of Infection and Chemotherapy, V10, P307, DOI 10.1007/s10156-004-0348-9
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666
   SUNDAR S, 1995, J INFECT DIS, V171, P992, DOI 10.1093/infdis/171.4.992
   Taslimi Y, 2018, PARASITOLOGY, V145, P497, DOI 10.1017/S003118201600216X
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Vargas-Inchaustegui DA, 2010, INFECT IMMUN, V78, P301, DOI 10.1128/IAI.00959-09
   Vasquez RE, 2008, INFECT IMMUN, V76, P161, DOI 10.1128/IAI.00825-07
   Vasquez RE, 2006, INFECT IMMUN, V74, P6769, DOI 10.1128/IAI.01073-06
NR 39
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
AR e12805
DI 10.1111/pim.12805
EA NOV 2020
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA OS6QQ
UT WOS:000590286300001
PM 33131089
DA 2020-12-08
ER

PT J
AU Santos, CNO
   de Jesus, AR
AF Santos, Camilla N. O.
   de Jesus, Amelia R.
TI Exploring the Genetic Predisposition to Zika Virus Congenital Syndrome
   Response
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID SINGLE NUCLEOTIDE POLYMORPHISM; ASSOCIATION; BRAIN
C1 [Santos, Camilla N. O.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [Santos, Camilla N. O.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Grad Program Hlth Sci, Aracaju, Brazil.
   [de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Dept Med, Aracaju, Brazil.
RP de Jesus, AR (corresponding author), Rua Claudio Batista, BR-49060108 Aracaju, Sergipe, Brazil.
EM ameliaribeirodejesus@gmail.com
FU Financiadora de Estudos e ProjetosCiencia Tecnologia e Inovacao (FINEP)
   [0116005600]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior-BrasilCAPES; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq)
FX This work was supported by Financiadora de Estudos e Projetos (grant
   0116005600), Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior-Brasil (fellowship to C. N. O. S.), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (A. R. d. J.).
CR Alagarasu K, 2015, CYTOKINE, V74, P130, DOI 10.1016/j.cyto.2015.03.021
   Barkhash AV, 2012, ANTIVIR RES, V93, P64, DOI 10.1016/j.antiviral.2011.10.017
   de Barros PVM, 2020, J INFECT DIS, V222, P1062, DOI 10.1093/infdis/jiaa038
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Santos CNO, 2019, J INFECT DIS, V220, P1797, DOI 10.1093/infdis/jiz392
   Veldhuis TB, 2003, J CEREBR BLOOD F MET, V23, P1060, DOI 10.1097/01.WCB.0000080701.47016.24
   Xavier-Carvalho C, 2017, HUM IMMUNOL, V78, P649, DOI 10.1016/j.humimm.2017.07.013
   Xu ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054174
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 9
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 15
PY 2020
VL 222
IS 6
BP 1063
EP 1064
DI 10.1093/infdis/jiaa039
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5WB
UT WOS:000577174800026
PM 32112647
DA 2020-12-08
ER

PT J
AU Santos, CNO
   Ribeiro, DR
   Alves, JC
   Cazzaniga, RA
   Magalhaes, LS
   de Souza, MSF
   Fonseca, ABL
   Bispo, AJB
   Porto, RLS
   dos Santos, CA
   da Silva, AM
   Teixeira, MM
   de Almeida, RP
   de Jesus, AR
AF Santos, Camilla N. O.
   Ribeiro, Danielle R.
   Alves, Juliana Cardoso
   Cazzaniga, Rodrigo A.
   Magalhaes, Lucas S.
   de Souza, Mercia S. F.
   Fonseca, Adriana B. L.
   Bispo, Ana J. B.
   Porto, Roseane L. S.
   dos Santos, Cliomar Alves
   da Silva, Angela M.
   Teixeira, Mauro M.
   de Almeida, Roque P.
   de Jesus, Amelia R.
TI Association Between Zika Virus Microcephaly in Newborns With the
   rs3775291 Variant in Toll-Like Receptor 3 and rs1799964 Variant at Tumor
   Necrosis Factor-alpha Gene
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE congenital Zika syndrome; microcephaly; polymorphism; TLR3; TNF alpha
ID POLYMORPHISM; TLR3
AB Congenital Zika syndrome (CZS) is a cluster of malformation, and the mechanisms that lead it are still unclear. Using hypothesis-driven candidate genes and their function in viral infections, single-nucleotide polymorphisms (SNPs) were genotyped by quantitative polymerase chain reaction in a sample population from Sergipe State, Brazil. This study shows that rs3775291 SNP at Toll-like receptor 3, which triggers type I interferon antiviral responses in mothers infected by Zika virus during pregnancy, is associated with CZS occurrence (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.158-4.148). Moreover, rs1799964 SNP at tumor necrosis factor-alpha gene in CZS babies is associated with severe microcephaly (OR, 2.63; 95% CI, 1.13-6.21).
C1 [Santos, Camilla N. O.; Alves, Juliana Cardoso; Magalhaes, Lucas S.; de Almeida, Roque P.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Med Biol Lab, Aracaju, Brazil.
   [Santos, Camilla N. O.; Alves, Juliana Cardoso; Magalhaes, Lucas S.; de Almeida, Roque P.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Grad Program Hlth Sci, Aracaju, Brazil.
   [Ribeiro, Danielle R.; Cazzaniga, Rodrigo A.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [Fonseca, Adriana B. L.; Bispo, Ana J. B.; Porto, Roseane L. S.] Univ Fed Sergipe, Univ Hosp, Microcephaly Clin, Pediat Div, Aracaju, Brazil.
   [da Silva, Angela M.] Univ Fed Sergipe, Univ Hosp, Infect Dis Div, Aracaju, Brazil.
   [de Almeida, Roque P.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Dept Med, Aracaju, Brazil.
   [de Souza, Mercia S. F.] Secretaria Estado Saude Sergipe, Aracaju, Brazil.
   [dos Santos, Cliomar Alves] Cent Publ Hlth Lab Sergipe, Aracaju, Brazil.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Immunopharmacol, Belo Horizonte, MG, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Hosp Univ, Lab Imunol & Biol Mol, Predio Patol,Rua Claudio Batista S-N, BR-19060108 Aracaju, Sergipe, Brazil.
EM ameliaribeirodejesuse@gmail.com
RI Teixeira, Mauro M/A-4587-2008; Cazzaniga, Rodrigo/AAV-6694-2020
OI Teixeira, Mauro M/0000-0002-6944-3008; 
FU Financiadora de Estudos e Projetos -BrazilCiencia Tecnologia e Inovacao
   (FINEP) [0116005600]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - BrasilCAPES; Conselho Nacional de Pesquisa e Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq); Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq)
FX This work was funded by the Financiadora de Estudos e Projetos -Brazil
   (Grant Number 0116005600), Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - Brasil (fellowship to C. N. O. S., J. C. A., and R. A.
   C.), Conselho Nacional de Pesquisa e Desenvolvimento Cientifico e
   Tecnologico (fellowship to D. R. R.), and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (to A. R. d. J., R. P. d. A.,
   and M. M. T.).
CR Alagarasu K, 2015, IMMUNOBIOLOGY, V220, P164, DOI 10.1016/j.imbio.2014.09.020
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Caires LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03497-1
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Higuchi T, 1998, TISSUE ANTIGENS, V51, P605, DOI 10.1111/j.1399-0039.1998.tb03002.x
   Kasztelewicz B, 2017, EUR J CLIN MICROBIOL, V36, P1811, DOI 10.1007/s10096-017-2996-6
   Kindberg E, 2011, J INFECT DIS, V203, P523, DOI 10.1093/infdis/jiq082
   Phillips JA, 2016, WORKPLACE HEALTH SAF, V64, P396, DOI 10.1177/2165079916657109
   Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y
   Sironi M, 2012, J IMMUNOL, V188, P818, DOI 10.4049/jimmunol.1102179
   Studzinska M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169420
   SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 14
TC 4
Z9 4
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC
PY 2019
VL 220
IS 11
BP 1797
EP 1801
DI 10.1093/infdis/jiz392
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA JI4XB
UT WOS:000493469600012
PM 31352487
DA 2020-12-08
ER

PT J
AU Santos, MB
   dos Santos, AD
   Barreto, AS
   Souza, MD
   Goes, MAD
   Alves, JAB
   Barreto, IDC
   Silva, JRS
   de Oliveira, DT
   de Araujo, KCGM
   Duthie, MS
   de Jesus, AR
AF Santos, Marcio Bezerra
   dos Santos, Allan Dantas
   Barreto, Aline Silva
   Souza, Mariana do Rosario
   de Oliveira Goes, Marco Aurelio
   Barreto Alves, Jose Antonio
   Carvalho Barreto, Ikaro Daniel
   Silva, Jose-Rodrigo S.
   de Oliveira, Daniela Teles
   Machado de Araujo, Karina C. G.
   Duthie, Malcolm S.
   de Jesus, Amelia Ribeiro
TI Clinical and epidemiological indicators and spatial analysis of leprosy
   cases in patients under 15 years old in an endemic area of Northeast
   Brazil: an ecological and time series study
SO BMJ OPEN
LA English
DT Article
ID ELIMINATION; CHILDREN; SERGIPE
AB Objective This study aimed to analyse the clinical and epidemiological indicators, temporal trends and the spatial distribution of leprosy in patients under 15 years old in an endemic area of Northeast Brazil.
   Design Regional surveillance study of all reported cases.
   Setting State of Sergipe, endemic area of Northeast Brazil.
   Methods An ecological and time series study was conducted, based on secondary data reported by the Brazilian Information System on Notifiable Diseases for leprosy cases diagnosed in Sergipe state (2002-2015). The analysis of temporal trends was performed using the Joinpoint Regression Programme through Poisson regression. We performed spatial analysis by Kernel estimator and Moran index.
   Results The incidence rate was reduced from 6.29 to 3.78 cases per 100 000 inhabitants in 2002 and 2015, respectively. However, Sergipe was still classified as highly endemicity in 2015. The mean number of household contacts (HHC) examined was significantly lower than those registered. Clinical data indicated that 21.4% of the patients developed leprosy reactions, and 31.3% presented with some physical disability in the multibacillary groups. Patients diagnosed by examination within the HHC presented better indicators, such as lower percentage of leprosy reaction and physical disability. Spatial analysis showed the most risk areas distributed on the northeast and cities around the capital, Aracaju.
   Conclusion The data indicate that there is a persistence of active Myobacterium leprae transmission and a delay in disease detection, following a pattern of high endemicity in many municipalities. The early detection by HHC examination is important to stop transmission and also to detect the cases in a less severe state.
C1 [Santos, Marcio Bezerra] Univ Fed Sergipe, Dept Hlth Educ, Lagarto, SE, Brazil.
   [Santos, Marcio Bezerra; Barreto, Aline Silva; Souza, Mariana do Rosario; de Oliveira, Daniela Teles; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Lab Immunol & Mol Biol, Sao Cristovao, SE, Brazil.
   [dos Santos, Allan Dantas; Barreto Alves, Jose Antonio] Univ Fed Sergipe, Dept Nursing, Lagarto, SE, Brazil.
   [de Oliveira Goes, Marco Aurelio] Univ Fed Sergipe, Dept Med Lagarto, Lagarto, SE, Brazil.
   [Carvalho Barreto, Ikaro Daniel] Univ Fed Rural Pernambuco, Programa Posgrad Biometria & Estat Aplicada, Recife, PE, Brazil.
   [Silva, Jose-Rodrigo S.] Univ Fed Sergipe, Stat & Actuarial Sci, Sao Cristovao, SE, Brazil.
   [Machado de Araujo, Karina C. G.] Univ Fed Sergipe, Dept Morphol, Sao Cristovao, SE, Brazil.
   [Duthie, Malcolm S.] Infect Dis Res Inst, Seattle, WA USA.
   [de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Sao Cristovao, SE, Brazil.
RP Santos, MB (corresponding author), Univ Fed Sergipe, Dept Hlth Educ, Lagarto, SE, Brazil.; Santos, MB (corresponding author), Univ Fed Sergipe, Lab Immunol & Mol Biol, Sao Cristovao, SE, Brazil.
EM bio_marcio2006@hotmail.com
RI Barreto, Ikaro Daniel/R-8476-2018; Santos, Allan/Z-1616-2019; Silva,
   Jose Rodrigo S/A-2784-2016
OI Barreto, Ikaro Daniel/0000-0001-7253-806X; Santos,
   Allan/0000-0002-6529-1887; Bezerra-Santos, Marcio/0000-0001-9962-6537;
   Santos Silva, Jose Rodrigo/0000-0002-1918-7122; Duthie,
   Malcolm/0000-0002-8515-5516
CR Alencar CH, 2012, TROP MED INT HEALTH, V17, P518, DOI 10.1111/j.1365-3156.2011.02945.x
   Barreto AS, 2016, J NURS UFPE, P10
   de Oliveira MBB, 2016, AN BRAS DERMATOL, V91, P196, DOI 10.1590/abd1806-4841.20163661
   Barth-Jaeggi T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013633
   Brito Aline Lima, 2016, Rev. bras. epidemiol., V19, P194, DOI 10.1590/1980-5497201600010017
   Chen Y, 2013, PROCEEDINGS OF THE TWELFTH INTERNATIONAL SYMPOSIUM - MANAGEMENT SCIENCE & ENGINEERING (2013), P9
   de Oliveira DT, 2012, GEOSPATIAL HEALTH, V6, pS125
   dos Santos AD, 2016, REV SOC BRAS MED TRO, V49, P608, DOI 10.1590/0037-8682-0137-2016
   Duarte-Cunha M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0924-x
   Durrheim DN, 2003, J EPIDEMIOL COMMUN H, V57, P316, DOI 10.1136/jech.57.5.316
   Duthie MS, 2012, MEM I OSWALDO CRUZ, V107, P190, DOI 10.1590/S0074-02762012000900027
   Duthie MS, 2011, HUM VACCINES, V7, P1172, DOI 10.4161/hv.7.11.16848
   Lana FCF, 2007, REV BRAS ENFERM, V60, P696, DOI 10.1590/S0034-71672007000600014
   Fernandes C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079072
   Fischer EAJ, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-125
   Freitas LRS, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1798-2
   Fulton N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010608
   Goes JAP, 2018, GEOSPAT HLTH, P13
   Khan OA, 2010, ANN TROP MED PARASIT, V104, P303, DOI 10.1179/136485910X12743554759867
   Kumar A, 2012, BMJ OPEN, V2
   Kumar A, 2012, BMJ OPEN, V2
   Lockwood DNJ, 2007, LEPROSY REV, V78, P317
   de Alencar CHM, 2008, REV BRAS ENFERM, V61, P694, DOI 10.1590/S0034-71672008000700007
   Pires Carla Andrea A., 2012, Rev. paul. pediatr., V30, P292, DOI 10.1590/S0103-05822012000200022
   Queiros MI, 2016, AN BRAS DERMATOL, V91, P311, DOI 10.1590/abd1806-4841.20164102
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Santos MB, 2017, REV SOC BRAS MED TRO, V50, P383, DOI 10.1590/0037-8682-0411-2016
   Santos SD, 2016, MEM I OSWALDO CRUZ, V111, P359, DOI 10.1590/0074-02760160002
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Vieira GD, 2014, EPIDEMIOL SERV SAUDE, V23, P269, DOI 10.5123/S1679-49742014000200008
NR 30
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD AUG
PY 2019
VL 9
IS 7
AR e023420
DI 10.1136/bmjopen-2018-023420
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA IW8US
UT WOS:000485269700086
PM 31352408
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vazquez, CMP
   Costa, JO
   Bomfim, LGS
   Pires, LV
   da Silva, DG
   Fukutani, KF
   de Jesus, AR
   Silva, ND
   Santana, GD
   de Moura, TR
   Barbosa, K
AF Passos Vazquez, Cecilia Maria
   Costa, Jamille Oliveira
   Santos Bomfim, Lays Gisele
   Pires, Liliane Viana
   da Silva, Danielle Goes
   Fukutani, Kiyoshi Ferreira
   de Jesus, Amelia Ribeiro
   Silva, Natanael de Jesus
   Santana, Gleiciane de Jesus
   de Moura, Tatiana Rodrigues
   Barbosa, Kiriaque
TI Oxidized Low-Density Lipoprotein (Ox-LDL) and Triggering
   Receptor-Expressed Myeloid Cell (TREM-1) Levels Are Associated with
   Cardiometabolic Risk in Nonobese, Clinically Healthy, and Young Adults
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID SWEETENED BEVERAGE INTAKE; BODY-MASS INDEX; METABOLIC SYNDROME;
   OXIDATIVE STRESS; WAIST CIRCUMFERENCE; ABDOMINAL OBESITY;
   BLOOD-PRESSURE; POPULATION; PREVALENCE; INFLAMMATION
AB Oxidative and inflammatory substances play an important role in the genesis of processes related to cardiometabolic risk. High levels of oxidized low-density lipoprotein (Ox-LDL) and of triggering receptor-expressed myeloid cells (TREM-1) are associated with cardiovascular and inflammatory diseases. In this study, we evaluate the association of the plasma concentrations of Ox-LDL and serum levels of circulating TREM-1 (sTREM-1) with the components of cardiometabolic risk (CMR) and other associated risk parameters. Although the individuals in this study were young, nonobese, and did not have signs, symptoms, and diagnosis of diseases, they already presented components of CMR. Ox-LDL lipid fraction correlated positively with CMR-related markers: body mass index (BMI), waist circumference (WC), body fat percentage, total cholesterol, LDL-c, VLDL-c, triglycerides, atherogenic cholesterol, and atherogenic index. Among these parameters, atherogenic cholesterol had a greater predictive effect for Ox-LDL alterations. Individuals with higher serum concentrations of sTREM-1 presented higher values for BMI, WC, triglycerides, VLDL-c, and atherogenic cholesterol. WC showed an effect on the association between the sTREM-1's inflammatory response and the components of CMR. The association of oxidative and inflammatory markers with anthropometric parameters and atherogenic cholesterol in nonobese, clinically healthy, and young individuals suggests the importance of early evaluation of these markers in order to prevent future cardiac events.
C1 [Passos Vazquez, Cecilia Maria; Costa, Jamille Oliveira; Santos Bomfim, Lays Gisele; Pires, Liliane Viana; da Silva, Danielle Goes; de Jesus, Amelia Ribeiro; Santana, Gleiciane de Jesus; de Moura, Tatiana Rodrigues; Barbosa, Kiriaque] Fed Univ Sergipe UPS, Aracaju, SE, Brazil.
   [Fukutani, Kiyoshi Ferreira] Sao Paulo Univ USP, Ribeirao Preto, SP, Brazil.
   [Silva, Natanael de Jesus] Fed Univ Bahia UFBA, Salvador, BA, Brazil.
RP Barbosa, K (corresponding author), Fed Univ Sergipe UPS, Aracaju, SE, Brazil.
EM kiribarra@yahoo.com.br
RI Fukutani, Kiyoshi/T-1630-2019; , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; PIRES, LILIANE/0000-0003-1710-0836; de
   Jesus Silva, Natanael/0000-0003-3002-1032
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe
FX This study was funded by Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe.
CR Al Dhaheri AS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159378
   Alkahtani S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2578-4
   Arts RJW, 2013, J LEUKOCYTE BIOL, V93, P209, DOI 10.1189/jlb.0312145
   Bae Yun-Jung, 2013, Clin Nutr Res, V2, P91, DOI 10.7762/cnr.2013.2.2.91
   Barbosa KBF, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-61
   Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114
   Carrier A, 2017, ANTIOXID REDOX SIGN, V26, P429, DOI 10.1089/ars.2016.6929
   Chatterjee A, 2012, CAN FAM PHYSICIAN, V58, P389
   Costa JO, 2017, ARQ BRAS CARDIOL, V109, P140, DOI 10.5935/abc.20170095
   D'Archivio M, 2012, EUR J CLIN INVEST, V42, P70, DOI 10.1111/j.1365-2362.2011.02558.x
   de Freitas RWF, 2013, J CLIN NURS, V22, P1291, DOI 10.1111/jocn.12015
   Despres JP, 2008, ARTERIOSCL THROM VAS, V28, P1039, DOI 10.1161/ATVBAHA.107.159228
   Echida Y, 2012, CLIN EXP NEPHROL, V16, P767, DOI 10.1007/s10157-012-0615-5
   Feingold K.R., 2000, ENDOTEXT
   Barbosa KBF, 2010, REV NUTR, V23, P629, DOI 10.1590/S1415-52732010000400013
   Finlayson G, 2012, APPETITE, V58, P1091, DOI 10.1016/j.appet.2012.03.003
   Fried SK, 2003, AM J CLIN NUTR, V78, p873S
   Fuentes E, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/136584
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]
   Gasparotto GS, 2013, MEDICINA RIBEIRAO PR, V46, P154, DOI DOI 10.11606/issn.2176-7262.v46i2p154-163
   Gharipour M, 2013, CHOLESTEROL, DOI 10.1155/2013/198384
   Gottlieb MGV, 2005, GENET MOL RES, V4, P691
   Gropper SS, 2012, APPL PHYSIOL NUTR ME, V37, P1118, DOI [10.1139/h2012-139, 10.1139/H2012-139]
   Harmon ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0143102
   International Diabetes Federation, 2005, OBESITY METABOLISM, V2, P47, DOI [10.14341/2071-8713-4854, DOI 10.14341/2071-8713-4854]
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Kell KP, 2014, AM J CLIN NUTR, V100, P46, DOI 10.3945/ajcn.113.076505
   Kelli HM, 2017, AM J CARDIOL, V120, P2289, DOI 10.1016/j.amjcard.2017.08.053
   Kim J, 2013, SLEEP, V36, P923, DOI 10.5665/sleep.2726
   Kosova EC, 2013, J ACAD NUTR DIET, V113, P219, DOI 10.1016/j.jand.2012.10.020
   Lee CMY, 2008, J CLIN EPIDEMIOL, V61, P646, DOI 10.1016/j.jclinepi.2007.08.012
   Leiter LA, 2011, CAN J CARDIOL, V27, P124, DOI 10.1016/j.cjca.2011.01.016
   Levy E, 2017, EJIFCC, V28, P6
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   Meller FD, 2014, CIENC SAUDE COLETIVA, V19, P75, DOI 10.1590/1413-81232014191.2000
   Miot Hélio Amante, 2011, J. vasc. bras., V10, P275, DOI 10.1590/S1677-54492011000400001
   Moreno González Manuel Ignacio, 2010, Rev Chil Cardiol, V29, P85, DOI 10.4067/S0718-85602010000100008
   Motamed N, 2017, DIABETES METAB SYND, V11, P173, DOI 10.1016/j.dsx.2016.08.024
   Parks EJ, 2000, AM J CLIN NUTR, V71, P412
   PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460
   Volp ACP, 2008, ARQ BRAS ENDOCRINOL, V52, P537, DOI 10.1590/S0004-27302008000300015
   Reiner Zeljko, 2011, Rev Esp Cardiol, V64, DOI 10.1016/j.recesp.2011.09.014
   Ribeiro Filho Fernando F., 2006, Arq Bras Endocrinol Metab, V50, P230, DOI 10.1590/S0004-27302006000200009
   Nieto CIR, 2015, NUTR HOSP, V31, P1574, DOI 10.3305/nh.2015.31.4.8371
   Santana G. D., 2015, J HLTH SCI I, V33, P63
   Schiffrin EL, 2008, HYPERTENSION, V51, P31, DOI 10.1161/HYPERTENSIONAHA.107.103226
   Subramanian S, 2017, OBESITY, V25, P527, DOI 10.1002/oby.21714
   Sverdlov AL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8254590
   Tope AM, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-2
   Trpkovic A, 2015, CRIT REV CL LAB SCI, V52, P70, DOI 10.3109/10408363.2014.992063
   Van Rompay MI, 2015, J NUTR, V145, P2389, DOI 10.3945/jn.115.212662
   da Silva ARV, 2014, REV LAT-AM ENFERM, V22, P1041, DOI 10.1590/0104-1169.0129.2514
   World Health Organization, 1997, SWITZ OB PREV MAN GL
NR 53
TC 2
Z9 2
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2019
VL 2019
AR 7306867
DI 10.1155/2019/7306867
PG 8
WC Cell Biology
SC Cell Biology
GA HO4TW
UT WOS:000460916600001
PM 30944697
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bezerra-Santos, M
   do Vale-Simon, M
   Barreto, AS
   Cazzaniga, RA
   de Oliveira, DT
   Barrios, MR
   Ferreira, AR
   Santos-Bio, NC
   Reed, SG
   de Almeida, RP
   Correa, CB
   Duthie, MS
   de Jesus, AR
AF Bezerra-Santos, Marcio
   do Vale-Simon, Marise
   Barreto, Aline Silva
   Cazzaniga, Rodrigo Anselmo
   de Oliveira, Daniela Teles
   Barrios, Monica Rueda
   Ferreira, Alex Ricardo
   Santos-Bio, Nanci C.
   Reed, Steven G.
   de Almeida, Roque Pacheco
   Correa, Cristiane Bani
   Duthie, Malcolm S.
   de Jesus, Amelia Ribeiro
TI Mycobacterium leprae Recombinant Antigen Induces High Expression of
   Multifunction T Lymphocytes and Is Promising as a Specific Vaccine for
   Leprosy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE leprosy; Mycobacterium leprae; ML2028; Multifunctional T cells;
   immunopathogenesis
ID IMMUNE-RESPONSES; CELLS; PROTECTION; CYTOKINES; DIAGNOSIS; TH17
AB Leprosy is a chronic disease caused by M. leprae infection that can cause severe neurological complications and physical disabilities. A leprosy-specific vaccine would be an important component within control programs but is still lacking. Given that multifunctional CD4 T cells [i.e., those capable of simultaneously secreting combinations of interferon (IFN)-gamma, interleukin (IL)-2, and tumor necrosis factor (TNF)] have now been implicated in the protective response to several infections, we tested the hypothesis if a recombinant M. leprae antigen-specific multifunctional T cells differed between leprosy patients and their healthy contacts. We used whole blood assays and peripheral blood mononuclear cells to characterize the antigen-specific T cell responses of 39 paucibacillary (PB) and 17 multibacillary (MB) leprosy patients and 31 healthy household contacts (HHC). Cells were incubated with either crude mycobacterial extracts (M. leprae cell sonicate-MLCS) and purified protein derivative (PPD) or recombinant ML2028 protein, the homolog of M. tuberculosis Ag85B. Multiplex assay revealed antigen-specific production of IFN-gamma and IL-2 from cells of HHC and PB, confirming a Th1 bias within these individuals. Multiparameter flow cytometry then revealed that the population of multifunctional ML2028-specific T cells observed in HHC was larger than that observed in PB patients. Taken together, our data suggest that these multifunctional antigen-specific T cells provide a more effective response against M. leprae infection that prevents the development of leprosy. These data further our understanding of M. leprae infection/leprosy and are instructive for vaccine development.
C1 [Bezerra-Santos, Marcio; do Vale-Simon, Marise; Barreto, Aline Silva; Cazzaniga, Rodrigo Anselmo; de Oliveira, Daniela Teles; Barrios, Monica Rueda; Ferreira, Alex Ricardo; Santos-Bio, Nanci C.; de Almeida, Roque Pacheco; Correa, Cristiane Bani; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Lab Immunol & Mol Biol, Aracaju, Brazil.
   [Bezerra-Santos, Marcio] Univ Fed Sergipe, Dept Hlth Educ, Lagarto, Brazil.
   [Ferreira, Alex Ricardo; Santos-Bio, Nanci C.; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Infect Dis Res Inst, Seattle, WA USA.
   [Reed, Steven G.; Duthie, Malcolm S.] INCT CNPq, Inst Invest Imunol, Sao Paulo, Brazil.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
RP Bezerra-Santos, M (corresponding author), Univ Fed Sergipe, Lab Immunol & Mol Biol, Aracaju, Brazil.; Bezerra-Santos, M (corresponding author), Univ Fed Sergipe, Dept Hlth Educ, Lagarto, Brazil.
EM bio_marcio2006@hotmail.com
RI Correa, Cristiane Bani/AAR-9384-2020; Cazzaniga, Rodrigo/AAV-6694-2020
OI Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq); CNPqNational Council for Scientific and
   Technological Development (CNPq) [12/2009, 019.203.02712/2009-8];
   MCTI/CNPQ/Universal [454848/2014-5]
FX Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Grants: CNPq no 12/2009, no
   019.203.02712/2009-8 (AdJ). AdJ and RPA are CNPq investigators.
   MCTI/CNPQ/Universal 14/2014, no 454848/2014-5 (AdJ).
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P501
   Attia EAS, 2014, ARCH DERMATOL RES, V306, P793, DOI 10.1007/s00403-014-1486-2
   Balaram P, 2009, INT J MED MICROBIOL, V299, P177, DOI 10.1016/j.ijmm.2008.08.004
   Santos MLB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00227
   Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217
   Carrillo E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00750
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Fonseca ABD, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-016-0229-3
   de Oliveira DT, 2012, GEOSPAT HLTH, V6, P130, DOI [10.4081/gh.2012.130, DOI 10.4081/GH.2012.130]
   de Sousa JR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01635
   Dupnik KM, 2015, J INFECT DIS, V211, P1658, DOI 10.1093/infdis/jiu612
   Duthie MS, 2008, CLIN VACCINE IMMUNOL, V15, P1659, DOI 10.1128/CVI.00234-08
   Duthie MS, 2007, CLIN VACCINE IMMUNOL, V14, P1400, DOI 10.1128/CVI.00299-07
   Duthie MS, 2016, APPL MICROBIOL BIOT, V100, P3267, DOI 10.1007/s00253-016-7328-8
   Duthie MS, 2014, INFECT IMMUN, V82, P3979, DOI 10.1128/IAI.02145-14
   Duthie MS, 2012, MEM I OSWALDO CRUZ, V107, P190, DOI 10.1590/S0074-02762012000900027
   Duthie MS, 2011, HUM VACCINES, V7, P1172, DOI 10.4161/hv.7.11.16848
   Escamilla-Tilch M, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/920491
   Guha R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006406
   Kim WS, 2016, ONCOTARGET, V7, P24962, DOI 10.18632/oncotarget.8771
   Kohli S, 2015, INT J MED MICROBIOL, V305, P322, DOI 10.1016/j.ijmm.2015.01.001
   Leung-Theung-Long S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143552
   Lichtner M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/217287
   Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531
   Macedo ABB, 2012, CLIN EXP IMMUNOL, V167, P505, DOI 10.1111/j.1365-2249.2011.04536.x
   Mazini PS, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00658
   Merle CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI [10.1586/erv.09.161, 10.1586/ERV.09.161]
   Omosa-Manyonyi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125954
   Polycarpou A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00233
   Raman VS, 2009, INFECT IMMUN, V77, P5623, DOI 10.1128/IAI.00508-09
   Reyes PR, 2016, INT J MED MICROBIOL, V306, P624, DOI 10.1016/j.ijmm.2016.10.002
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Saini C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004592
   Sampaio LH, 2012, EUR J CLIN MICROBIOL, V31, P1443, DOI 10.1007/s10096-011-1462-0
   Santos MB, 2017, SCAND J IMMUNOL, V86, P40, DOI 10.1111/sji.12558
   Santos MB, 2017, RESPOSTA IMUNE ANTIG
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Singh OP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001874
   Stober CB, 2005, J IMMUNOL, V175, P2517, DOI 10.4049/jimmunol.175.4.2517
   Talker SC, 2015, VET RES, V46, DOI 10.1186/s13567-015-0182-3
NR 42
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 12
PY 2018
VL 9
AR 2920
DI 10.3389/fimmu.2018.02920
PG 10
WC Immunology
SC Immunology
GA HE2IY
UT WOS:000453101300001
PM 30631322
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Magalhaes, LS
   Bomfim, LGS
   Mota, SG
   Cruz, GS
   Correa, CB
   Tanajura, DM
   Lipscomb, MW
   Borges, VM
   de Jesus, AR
   de Almeida, RP
   de Moura, TR
AF Magalhaes, Lucas S.
   Bomfim, Lays G. S.
   Mota, Sthefanne G.
   Cruz, Geydson S.
   Correa, Cristiane B.
   Tanajura, Diego M.
   Lipscomb, Michael W.
   Borges, Valeria M.
   de Jesus, Amelia R.
   de Almeida, Roque P.
   de Moura, Tatiana R.
TI Increased thiol levels in antimony-resistant Leishmania infantum
   isolated from treatment-refractory visceral leishmaniasis in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Leishmania; visceral leishmaniasis; antimony; drug resistance
ID DRUG-RESISTANCE; NITRIC-OXIDE; DONOVANI; CHEMOTHERAPY; SUSCEPTIBILITY;
   PROMASTIGOTES; TRANSPORTER; VERAPAMIL
AB BACKGROUND Treatment-refractory visceral leishmaniasis (VL) has become an important problem in many countries.
   OBJECTIVES We evaluated the antimony-resistance mechanisms of Leishmania infantum isolated from VL patients refractory or responsive to treatment with pentavalent antimony.
   METHODS Strains isolated from antimony-refractory patients (in vitro antimony-resistant isolates) and antimony-responsive patients (in vitro antimony-sensitive isolates) were examined. Morphological changes were evaluated by transmission electron microscopy after trivalent antimony exposure. P-glycoprotein (P-gp) efflux pump activity was evaluated using the pump-specific inhibitor verapamil hydrochloride, and the role of thiol in trivalent antimony resistance was investigated using the enzymatic inhibitor L-buthionine sulfoximine.
   FINDINGS Antimony treatment induced fewer alterations in the cellular structure of L. infantum resistant isolates than in that of sensitive isolates. P-gp efflux activity was not involved in antimony resistance in these isolates. Importantly, the resistant isolates contained higher levels of thiol compared to the sensitive isolates, and inhibition of thiol synthesis in the resistant isolates recovered their sensitivity to trivalent antimony treatment, and enhanced the production of reactive oxygen species in promastigotes exposed to the drug.
   MAIN CONCLUSIONS Our results demonstrate that isolates from patients with antimony-refractory VL exhibited higher thiol levels than antimony-sensitive isolates. This indicates that redox metabolism plays an important role in the antimony-resistance of New World VL isolates.
C1 [Magalhaes, Lucas S.; Bomfim, Lays G. S.; Mota, Sthefanne G.; Cruz, Geydson S.; Correa, Cristiane B.; Tanajura, Diego M.; de Jesus, Amelia R.; de Almeida, Roque P.; de Moura, Tatiana R.] Univ Fed Sergipe, Hosp Univ, Lab Biol Mol, Aracaju, SE, Brazil.
   [Lipscomb, Michael W.] Howard Univ, Dept Biol, Washington, DC 20059 USA.
   [Borges, Valeria M.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
RP de Moura, TR (corresponding author), Univ Fed Sergipe, Hosp Univ, Lab Biol Mol, Aracaju, SE, Brazil.
EM tmoura.ufs@gmail.com
RI Cruz, Geydson S/O-6835-2017; Borges, Valeria/G-2009-2014; Borges,
   Val/N-6647-2019; Correa, Cristiane Bani/AAR-9384-2020; Cruz,
   Geydson/AAM-8400-2020
OI Borges, Val/0000-0002-2775-5409; Cruz, Geydson/0000-0001-9392-0321;
   Santos Bomfim, Lays Gisele/0000-0002-4773-6889; Sousa Magalhaes,
   Lucas/0000-0002-2169-7463
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [MCTI/CNPQ/Universal 14/2014 (460743/2014-7), PROCAD/CASADINHO
   (552721/2011-5)]; FAPITEC/SE/FUNTEC/CNPq [12/2009
   (019.203.02712/2009-8)]; CAPESCAPES; Programa Nacional de Incentivo a
   Pesquisa em Parasitologia Basica [032/2010]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [SC2GM103741]; Department of Defense (DOD)United States Department of
   Defense [W911NF-14-1-0123]; National Science Foundation (NSF)National
   Science Foundation (NSF) [1428768]; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [SC2GM103741, SC2GM103741,
   SC2GM103741] Funding Source: NIH RePORTER
FX CNPq, MCTI/CNPQ/Universal 14/2014 (460743/2014-7 TRM) and
   PROCAD/CASADINHO (552721/2011-5 RPA); FAPITEC/SE/FUNTEC/CNPq No. 12/2009
   (019.203.02712/2009-8 ARJ); CAPES; Programa Nacional de Incentivo a
   Pesquisa em Parasitologia Basica, Edital No. 032/2010 (ARJ); NIH (grant
   # SC2GM103741 - MWL); the Department of Defense (DOD) (grant #
   W911NF-14-1-0123 - MWL); and the National Science Foundation (NSF)
   (grant # 1428768 - MWL).
CR Bocedi A, 2010, FASEB J, V24, P1035, DOI 10.1096/fj.09-146407
   Borges VM, 2005, PARASITOL RES, V95, P90, DOI 10.1007/s00436-004-1248-8
   Campos R, 2017, GEOSPATIAL HEALTH, V12, P67, DOI 10.4081/gh.2017.503
   Croft SL, 2011, CLIN MICROBIOL INFEC, V17, P1478, DOI 10.1111/j.1469-0691.2011.03630.x
   da Luz RI, 2011, J ANTIMICROB CHEMOTH, V66, P677, DOI 10.1093/jac/dkq508
   de Moura TR, 2016, PARASITOL RES, V115, P713, DOI 10.1007/s00436-015-4793-4
   Essodaigui M, 1999, MOL BIOCHEM PARASIT, V100, P73, DOI 10.1016/S0166-6851(99)00036-5
   Fonseca-Silva F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014666
   Forster S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033253
   Frezard F, 2009, MOLECULES, V14, P2317, DOI 10.3390/molecules14072317
   Jeddi F, 2014, ANTIMICROB AGENTS CH, V58, P4866, DOI 10.1128/AAC.02521-13
   Kapoor P, 2000, TROP MED INT HEALTH, V5, P438, DOI 10.1046/j.1365-3156.2000.00565.x
   Mandal G, 2007, PARASITOLOGY, V134, P1679, DOI 10.1017/S0031182007003150
   Manzano JI, 2013, ANTIMICROB AGENTS CH, V57, P3719, DOI 10.1128/AAC.00211-13
   Martins-Melo FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093770
   Messaritakis I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065467
   Mishra J, 2007, CURR MED CHEM, V14, P1153, DOI 10.2174/092986707780362862
   Mukherjee A, 2007, J ANTIMICROB CHEMOTH, V59, P204, DOI 10.1093/jac/dkl494
   Mukherjee B, 2013, P NATL ACAD SCI USA, V110, pE575, DOI [10.1073/pnas.1213839110, 10.]
   NEAL RA, 1989, T ROY SOC TROP MED H, V83, P197, DOI 10.1016/0035-9203(89)90642-1
   Ouellette M, 1998, DRUG RESIST UPDATE, V1, P43, DOI 10.1016/S1368-7646(98)80213-6
   Perez-Victoria Jose M., 2001, International Microbiology, V4, P159
   Ponte-Sucre A, 2013, DRUG RESISTANCE LEIS
   Rai S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074862
   Santos DM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003275
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Sarkar A, 2009, EXP PARASITOL, V122, P299, DOI 10.1016/j.exppara.2009.04.012
   Seblova V, 2014, ANTIMICROB AGENTS CH, V58, P6273, DOI 10.1128/AAC.02406-13
   Singh N, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0596-1
   Valiathan R, 2006, EXP PARASITOL, V114, P103, DOI 10.1016/j.exppara.2006.02.015
   Vannier-Santos MA, 2009, CURR DRUG TARGETS, V10, P246, DOI 10.2174/138945009787581168
   WHO, 2010, M WHO EXP COMM CONTR
NR 32
TC 3
Z9 3
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2018
VL 113
IS 2
BP 119
EP 125
DI 10.1590/0074-02760170289
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA FP8AM
UT WOS:000417861700007
PM 29236925
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santos, MB
   de Oliveira, DT
   Cazzaniga, RA
   Varjao, CS
   dos Santos, PL
   Santos, MLB
   Correia, CB
   Faria, DR
   Simon, MD
   Silva, JS
   Dutra, WO
   Reed, SG
   Duthie, MS
   de Almeida, RP
   de Jesus, AR
AF Santos, M. B.
   de Oliveira, D. T.
   Cazzaniga, R. A.
   Varjao, C. S.
   dos Santos, P. L.
   Santos, M. L. B.
   Correia, C. B.
   Faria, D. R.
   Simon, M. do V.
   Silva, J. S.
   Dutra, W. O.
   Reed, S. G.
   Duthie, M. S.
   de Almeida, R. P.
   de Jesus, A. R.
TI Distinct Roles of Th17 and Th1 Cells in Inflammatory Responses
   Associated with the Presentation of Paucibacillary Leprosy and Leprosy
   Reactions
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY T-CELLS; VISCERAL LEISHMANIASIS; DIFFERENTIATION; EXPRESSION;
   CYTOKINES; DISEASES; VACCINE
AB It is well established that helper T cell responses influence resistance or susceptibility to Mycobacterium leprae infection, but the role of more recently described helper T cell subsets in determining severity is less clear. To investigate the involvement of Th17 cells in the pathogenesis of leprosy, we determined the immune profile with variant presentations of leprosy. Firstly, IL-17A, IFN- and IL-10 were evaluated in conjunction with CD4(+) T cell staining by confocal microscopy of lesion biopsies from tuberculoid (TT) and lepromatous leprosy (LL) patients. Secondly, inflammatory cytokines were measured by multiplex assay of serum samples from Multibacillary (MB, n=28) and Paucibacillary (PB, n=23) patients and household contacts (HHC, n=23). Patients with leprosy were also evaluated for leprosy reaction occurrence: LR+ (n=8) and LR- (n=20). Finally, peripheral blood mononuclear cells were analysed by flow cytometry used to determine the phenotype of cytokine-producing cells. Lesions from TT patients were found to have more CD4(+)IL-17A(+) cells than those from LL patients. Higher concentrations of IL-17A and IL-1 were observed in serum from PB than MB patients. The highest serum IFN- concentrations were, however, detected in sera from MB patients that developed leprosy reactions (MB LR+). Together, these results indicate that Th1 cells were associated with both the PB presentation and also with leprosy reactions. In contrast, Th17 cells were associated with an effective inflammatory response that is present in the PB forms but were not predictive of leprosy reactions in MB patients.
C1 [Santos, M. B.; de Oliveira, D. T.; Cazzaniga, R. A.; Varjao, C. S.; dos Santos, P. L.; Santos, M. L. B.; Correia, C. B.; Simon, M. do V.; de Almeida, R. P.; de Jesus, A. R.] Univ Fed Sergipe, Mol Biol Lab, Sao Cristovao, Brazil.
   [Santos, M. B.; Reed, S. G.; Duthie, M. S.] IDRI, Seattle, WA USA.
   [Faria, D. R.; Dutra, W. O.] Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morphol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Silva, J. S.] Univ Sao Paulo, FMRP, Dept Biochem & Immunol, Ribeirao Preto, Brazil.
   [de Almeida, R. P.; de Jesus, A. R.] UFS, Dept Med, Sergipe, Brazil.
   [de Almeida, R. P.; de Jesus, A. R.] CNPq, Inst Invest Imunol INCT, Sao Paulo, Brazil.
RP Santos, MB (corresponding author), UFS, Mol Biol Lab, Univ Hosp, Rua Claudio Batista S-N, BR-49060100 Aracaju, Sergipe, Brazil.
EM bio_marcio2006@hotmail.com
RI Silva, Joao S/A-4484-2008; Cazzaniga, Rodrigo/AAV-6694-2020
OI Silva, Joao S/0000-0002-3410-3927; Duthie, Malcolm/0000-0002-8515-5516;
   Bezerra-Santos, Marcio/0000-0001-9962-6537
FU Fundacao de Apoioa Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq, Brazil) [12/2009, 019.203.02712/2009-8]
FX This work was funded by Fundacao de Apoioa Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), Grants: CNPq
   no 12/2009, Process no 019.203.02712/2009-8 (ARJ). ARJ and RPA are CNPq
   investigators. MCTI/CNPQ/Universal 14/2014, Process: 454848/2014-5
   (ARJ). We would like to thank also the residents and dermatologists of
   Dermatology Clinic-HU/UFS. The funders had no role in study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript. We also thank Professor Michael W. Lipscomb for excellent
   suggestions on the manuscript.
CR Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
   Attia EAS, 2014, ARCH DERMATOL RES, V306, P793, DOI 10.1007/s00403-014-1486-2
   Bellemore SM, 2015, CLIN EXP IMMUNOL, V182, P261, DOI 10.1111/cei.12691
   Bi Y, 2012, SCAND J IMMUNOL, V75, P543, DOI 10.1111/j.1365-3083.2012.02686.x
   Bretscher PA, 2014, SCAND J IMMUNOL, V79, P361, DOI 10.1111/sji.12175
   Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017
   Aardo TLD, 2016, MICROB PATHOGENESIS, V90, P64, DOI 10.1016/j.micpath.2015.11.019
   desOliveira DT, 2012, GEOSPAT HLTH, V6, pS125
   Dupnik KM, 2015, J INFECT DIS, V211, P1658, DOI 10.1093/infdis/jiu612
   Duthie MS, 2016, APPL MICROBIOL BIOT, V100, P3267, DOI 10.1007/s00253-016-7328-8
   Duthie MS, 2011, HUM VACCINES, V7, P1172, DOI 10.4161/hv.7.11.16848
   Duthie MS, 2012, MEM I O CRUZ, V2012, P7
   Eysteinsdottir JH, 2013, SCAND J IMMUNOL, V78, P529, DOI 10.1111/sji.12114
   Faleiro RJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002914
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Gulia A, 2010, F1000 MED REP, V2, P1
   Halvorsen EH, 2011, SCAND J IMMUNOL, V73, P243, DOI 10.1111/j.1365-3083.2010.02498.x
   Jadidi-Niaragh F, 2011, SCAND J IMMUNOL, V74, P1, DOI 10.1111/j.1365-3083.2011.02536.x
   Jayakumar A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001204
   Khadge S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1128-0
   Lee DJ, 2010, J INFECT DIS, V201, P558, DOI 10.1086/650318
   Martiniuk F, 2012, J DRUGS DERMATOL, V11, P5
   Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038
   Netea MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000661
   Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282
   Palermo ML, 2012, AM J TROP MED HYG, V86, P878, DOI 10.4269/ajtmh.2012.12-0088
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Sadhu S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004338
   Saini C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004592
   Saini C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002338
   Sampaio LH, 2012, EUR J CLIN MICROBIOL, V31, P1443, DOI 10.1007/s10096-011-1462-0
   Schmidt RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045186
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Singh OP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001874
   Soong L, 2012, SEMIN IMMUNOPATHOL, V34, P735, DOI 10.1007/s00281-012-0350-8
   Stober CB, 2005, J IMMUNOL, V175, P2517, DOI 10.4049/jimmunol.175.4.2517
   Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004
   Wang X, 2014, SCAND J IMMUNOL, V80, P180, DOI 10.1111/sji.12201
   Yang C, 2015, SCAND J IMMUNOL, V82, P345, DOI 10.1111/sji.12334
NR 39
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JUL
PY 2017
VL 86
IS 1
BP 40
EP 49
DI 10.1111/sji.12558
PG 10
WC Immunology
SC Immunology
GA EY1JL
UT WOS:000403722100005
PM 28426172
OA Bronze
DA 2020-12-08
ER

PT J
AU Fonseca, ABD
   Simon, MD
   Cazzaniga, RA
   de Moura, TR
   de Almeida, RP
   Duthie, MS
   Reed, SG
   de Jesus, AR
AF de Lima Fonseca, Adriana Barbosa
   Simon, Marise do Vale
   Cazzaniga, Rodrigo Anselmo
   de Moura, Tatiana Rodrigues
   de Almeida, Roque Pacheco
   Duthie, Malcolm S.
   Reed, Steven G.
   de Jesus, Amelia Ribeiro
TI The influence of innate and adaptative immune responses on the
   differential clinical outcomes of leprosy
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Review
DE Leprosy; Clinical presentation; Immunology; Innate immunity; Immune
   pathogenesis
ID TUMOR-NECROSIS-FACTOR; PERIPHERAL-NERVE PREDILECTION; TOLL-LIKE
   RECEPTOR-2; MYCOBACTERIUM-LEPRAE; SCAVENGER RECEPTOR; CYTOKINE PROFILES;
   DENDRITIC CELLS; IN-VITRO; TYPE-1; EXPRESSION
AB Leprosy is a chronic infectious disease caused by Mycobacterium leprae. According to official reports from 121 countries across five WHO regions, there were 213 899 newly diagnosed cases in 2014. Although leprosy affects the skin and peripheral nerves, it can present across a spectrum of clinical and histopathological forms that are strongly influenced by the immune response of the infected individuals. These forms comprise the extremes of tuberculoid leprosy (TT), with a M. leprae-specific Th1, but also a Th17, response that limits M. leprae multiplication, through to lepromatous leprosy (LL), with M. leprae-specific Th2 and T regulatory responses that do not control M. leprae replication but rather allow bacterial dissemination. The interpolar borderline clinical forms present with similar, but less extreme, immune biases. Acute inflammatory episodes, known as leprosy reactions, are complications that may occur before, during or after treatment, and cause further neurological damages that can cause irreversible chronic disabilities. This review discusses the innate and adaptive immune responses, and their interactions, that are known to affect pathogenesis and influence the clinical outcome of leprosy.
C1 [de Lima Fonseca, Adriana Barbosa; Simon, Marise do Vale; Cazzaniga, Rodrigo Anselmo; de Moura, Tatiana Rodrigues; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Dept Med, Sao Cristovao, Sergipe, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] Infect Dis Res Inst, Seattle, WA USA.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, SP, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Dept Med, Sao Cristovao, Sergipe, Brazil.; de Jesus, AR (corresponding author), CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, SP, Brazil.
EM ameliaribeirodejesus@gmail.com
RI , Tatiana/AAN-1194-2020; Cazzaniga, Rodrigo/AAV-6694-2020
OI , Tatiana/0000-0002-7442-4434; Duthie, Malcolm/0000-0002-8515-5516
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [Edital MCT/CNPq No 14/2009 - Universal]; Fundacao de Apoio a Pesquisa e
   a Inovacao Tecnologica do Estado de Sergipe - FAPITEC/SE/Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq; EDITAL
   FAPITEC/SE/FUNTEC/CNPq [12/2009, 019.203.02712/2009-8]; American Leprosy
   Missions; CAPESCAPES
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq, Edital MCT/CNPq No 14/2009 - Universal,
   the Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe - FAPITEC/SE/Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPq, EDITAL FAPITEC/SE/FUNTEC/CNPq No. 12/2009 (Programa
   de Nucleos de Excelencia - PRONEX), Process no. 019.203.02712/2009-8 and
   American Leprosy Missions. MS and RAC received a fellowship from CAPES.
   ARJ is a CNPq investigator.
CR Aiba Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/258164
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P461
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V847, P1
   BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992
   Belgaumkar VA, 2007, LEPROSY REV, V78, P223
   Bhat Ramesh Marne, 2012, Interdiscip Perspect Infect Dis, V2012, P181089, DOI 10.1155/2012/181089
   Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785
   Bratschi MW, 2015, LEPROSY REV, V86, P142
   Buhl T, 2015, J INVEST DERMATOL, V135, P2198, DOI 10.1038/jid.2015.141
   Cho SN, 2001, CLIN DIAGN LAB IMMUN, V8, P138, DOI 10.1128/CDLI.8.1.138-142.2001
   Cruz D, 2008, J CLIN INVEST, V118, P2917, DOI 10.1172/JCI34189
   de Mattos KA, 2012, MEM I OSWALDO CRUZ, V107, P156, DOI 10.1590/S0074-02762012000900023
   Fava VM, 2015, J INFECT DIS, V211, P968, DOI 10.1093/infdis/jiu566
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002
   Gaschignard J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004345
   Hagge DA, 2009, AM J PATHOL, V174, P1379, DOI 10.2353/ajpath.2009.080550
   Halvorsen B, 2005, J LIPID RES, V46, P211, DOI 10.1194/jlr.M400324-JLR200
   Hirai KE, 2016, MICROB PATHOGENESIS, V91, P18, DOI 10.1016/j.micpath.2015.11.013
   Jardim MR, 2007, ARQ NEURO-PSIQUIAT, V65, P969, DOI 10.1590/S0004-282X2007000600009
   JOB C K, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P251
   JOB CK, 1970, ARCH PATHOL, V89, P195
   JOB CK, 1989, INT J LEPROSY, V57, P532
   Jullien D, 1997, J IMMUNOL, V158, P800
   Kahawita IP, 2008, T ROY SOC TROP MED H, V102, P329, DOI 10.1016/j.trstmh.2008.01.004
   KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993
   Khadge S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1128-0
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246
   Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864
   Lastoria JC, 2014, AN BRAS DERMATOL, V89, P205, DOI 10.1590/abd1806-4841.20142450
   LOCKWOOD DNJ, 1993, INT J LEPROSY, V61, P8
   Maeda Y, 2005, INFECT IMMUN, V73, P2744, DOI 10.1128/IAI.73.5.2744-2750.2005
   Massone C, 2011, BRIT J DERMATOL, V165, P321, DOI 10.1111/j.1365-2133.2011.10412.x
   Massone C, 2010, AM J DERMATOPATH, V32, P251, DOI 10.1097/DAD.0b013e3181b7fc56
   Misch EA, 2010, MICROBIOL MOL BIOL R, V74, P589, DOI 10.1128/MMBR.00025-10
   Modlin RL, 2002, SKIN PHARMACOL APPL, V15, P1, DOI 10.1159/000058177
   Modlin RL, 2010, CURR OPIN IMMUNOL, V22, P48, DOI 10.1016/j.coi.2009.12.001
   Moraes MO, 1999, SCAND J IMMUNOL, V50, P541
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Motta Ana Carolina F., 2010, Braz. Dent. J., V21, P158, DOI 10.1590/S0103-64402010000200012
   Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2
   Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282
   Oliveira RB, 2003, INFECT IMMUN, V71, P1427, DOI 10.1128/IAI.71.3.1427-1433.2003
   Palermo ML, 2012, AM J TROP MED HYG, V86, P878, DOI 10.4269/ajtmh.2012.12-0088
   PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537
   Partida-Sanchez S, 1998, INT ARCH ALLERGY IMM, V116, P60, DOI 10.1159/000023926
   Penna GO, 2008, REV SOC BRAS MED TRO, V41, P575, DOI 10.1590/S0037-86822008000600006
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456
   Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3
   Rambukkana A, 2001, CURR OPIN MICROBIOL, V4, P21, DOI 10.1016/S1369-5274(00)00159-4
   Ranque B, 2007, CLIN INFECT DIS, V44, P33, DOI 10.1086/509923
   Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881
   Richard AC, 2015, J LEUKOCYTE BIOL, V98, P333, DOI 10.1189/jlb.3RI0315-095R
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   RIDLEY DS, 1974, B WORLD HEALTH ORGAN, V51, P451
   RIENECK K, 1993, IMMUNOL LETT, V37, P131, DOI 10.1016/0165-2478(93)90022-T
   Rodrigues IA, 2016, INT J INFECT DIS, V45, P118, DOI 10.1016/j.ijid.2016.02.018
   Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781
   Sadhu S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004338
   Saini C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004592
   SALGAME P, 1992, CHEM IMMUNOL, V54, P44
   SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408
   SARNO EN, 1991, CLIN EXP IMMUNOL, V84, P103
   Scollard DM, 2006, CLIN INFECT DIS, V43, pE19, DOI 10.1086/505222
   Scollard DM, 2015, CLIN DERMATOL, V33, P46, DOI 10.1016/j.clindermatol.2014.07.008
   Scollard DM, 2008, LEPROSY REV, V79, P242
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Shen JP, 2009, LEPROSY REV, V80, P164
   Quaresma JAS, 2009, AM J DERMATOPATH, V31, P527, DOI 10.1097/DAD.0b013e31819f1997
   Smith WCS, 2004, BMJ-BRIT MED J, V328, P1459, DOI 10.1136/bmj.38107.645926.AE
   Stefani MM, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-75
   Stefani MMA, 2003, J INFECT DIS, V188, P1024, DOI 10.1086/378410
   Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806
   Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338
   Triccas JA, 1998, INFECT IMMUN, V66, P2684, DOI 10.1128/IAI.66.6.2684-2690.1998
   TRIPP CS, 1995, J CLIN INVEST, V95, P1628, DOI 10.1172/JCI117837
   TUNG KSK, 1987, CLIN EXP IMMUNOL, V69, P10
   Van Veen NHJ, 2008, LEPROSY REV, V79, P361
   Vieira AP, 2016, AM J TROP MED HYG, V94, P721, DOI 10.4269/ajtmh.15-0673
   Wheat WH, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003405
   YAMAMURA M, 1992, J IMMUNOL, V149, P1470
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
NR 83
TC 26
Z9 27
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD FEB 6
PY 2017
VL 6
AR 5
DI 10.1186/s40249-016-0229-3
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EL0EA
UT WOS:000394294500001
PM 28162092
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Campos, R
   Santos, M
   Tunon, G
   Cunha, L
   Magalhaes, L
   Moraes, J
   Ramalho, D
   Lima, S
   Pacheco, JA
   Lipscomb, M
   de Jesus, AR
   de Almeida, RP
AF Campos, Roseane
   Santos, Marcio
   Tunon, Gabriel
   Cunha, Luana
   Magalhaes, Lucas
   Moraes, Juliana
   Ramalho, Danielle
   Lima, Sanmy
   Pacheco, Jose Antonio
   Lipscomb, Michael
   de Jesus, Amelia Ribeiro
   de Almeida, Roque Pacheco
TI Epidemiological aspects and spatial distribution of human and canine
   visceral leishmaniasis in an endemic area in northeastern Brazil
SO GEOSPATIAL HEALTH
LA English
DT Article
DE Leishmaniasis; Epidemiological monitoring; Dog diseases; Spatial
   distribution; Brazil
ID INFANTUM INFECTION; RURAL AREA; SAND FLIES; DOGS; TRANSMISSION;
   RESERVOIR
AB Visceral leishmaniasis (VL) is a systemic disease endemic in tropical countries and transmitted through sand flies. In particular, Canis familiaris (or domesticated dogs) are believed to be a major urban reservoir for the parasite causing the disease Leishmania. The average number of human VL cases was 58 per year in the state of Sergipe. The city of Aracaju, capital of Sergipe in Northeastern Brazil, had 159 cases of VL in humans. Correlatively, the percentage of serologically positive dogs for leishmaniasis increased from 4.73% in 2008 to 12.69% in 2014. Thus, these studies aimed to delineate the spatial distribution and epidemiological aspects of human and canine VL as mutually supportive for increased incidence. The number of human cases of VL and the frequency of canine positive serology for VL both increased between 2008 and 2014. Spatial distribution analyses mapped areas of the city with the highest concentration of human and canine VL cases. The neighbourhoods that showed the highest disease frequency were located on the outskirts of the city and in urbanised areas or subjected to development. Exponential increase in VL-positive dogs further suggests that the disease is expanding in urban areas, where it can serve as a reservoir for transmission of dogs to humans via the sand fly vector.
C1 [Campos, Roseane; Santos, Marcio; Tunon, Gabriel; Cunha, Luana; Magalhaes, Lucas; Moraes, Juliana; Ramalho, Danielle; de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Mol Biol Lab, Sergipe, Brazil.
   [Lima, Sanmy; Pacheco, Jose Antonio] Univ Fed Sergipe, Dept Geol, Sergipe, Brazil.
   [Lipscomb, Michael] Howard Univ, Dept Biol, Washington, DC 20059 USA.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, Sergipe, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Ave Doutor Eneas de Carvalho Aguiai 44, Sao Paulo, SP, Brazil.
RP de Almeida, RP (corresponding author), Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Ave Doutor Eneas de Carvalho Aguiai 44, Sao Paulo, SP, Brazil.
EM roquepachecoalmeida@gmail.com
OI Sousa Magalhaes, Lucas/0000-0002-2169-7463; Campos,
   Roseane/0000-0001-6217-9278
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [032/2010]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [552721/2011-5]
FX this work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Edital No 032/2010 (ARJ); CNPq). Grants:
   PROCAD/CASADINHO- no 552721/2011-5 (RPA). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amóra Sthenia Santos Albano, 2006, Cienc. Rural, V36, P1854, DOI 10.1590/S0103-84782006000600029
   Belo VS, 2013, VET PARASITOL, V195, P1, DOI 10.1016/j.vetpar.2013.03.010
   Bhunia GS, 2010, GEOSPATIAL HEALTH, V4, P155, DOI 10.4081/gh.2010.197
   Dantas-Torres F, 2014, ACTA TROP, V137, P67, DOI 10.1016/j.actatropica.2014.04.034
   Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P531, DOI 10.1016/j.pt.2012.08.007
   de Almeida AS, 2011, AM J TROP MED HYG, V84, P681, DOI 10.4269/ajtmh.2011.10-0325
   de Alvarenga DG, 2010, REV SOC BRAS MED TRO, V43, P194, DOI 10.1590/S0037-86822010000200017
   de Oliveira AG, 2008, ACTA TROP, V107, P238, DOI 10.1016/j.actatropica.2008.06.002
   De Oliveira EF, 2013, J MED ENTOMOL, V50, P277, DOI 10.1603/ME12082
   Faye B, 2011, T ROY SOC TROP MED H, V105, P333, DOI 10.1016/j.trstmh.2011.02.009
   Felipe K, 2014, REV SOC BRAS MED TRO, V47, P607
   Fischer D, 2010, GEOSPATIAL HEALTH, V5, P59, DOI 10.4081/gh.2010.187
   Góes Marco Aurélio de Oliveira, 2012, Rev. bras. epidemiol., V15, P298, DOI 10.1590/S1415-790X2012000200007
   Gouvea MV, 2007, ACTA TROP, V104, P99, DOI 10.1016/j.actatropica.2007.07.010
   Gramiccia M, 2011, VET PARASITOL, V181, P23, DOI 10.1016/j.vetpar.2011.04.019
   Harhay MO, 2011, TRENDS PARASITOL, V27, P403, DOI 10.1016/j.pt.2011.04.001
   Lara-Silva FD, 2015, ACTA TROP, V148, P128, DOI 10.1016/j.actatropica.2015.04.002
   Lopes EGP, 2010, ARQ BRAS MED VET ZOO, V62, P1062, DOI 10.1590/S0102-09352010000500007
   Quinnell RJ, 2003, IMMUNOGENETICS, V55, P23, DOI 10.1007/s00251-003-0545-1
   Ribeiro VM, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-8
   Silva Alba Valéria Machado da, 2005, Cad. Saúde Pública, V21, P324, DOI 10.1590/S0102-311X2005000100036
   Travi BL, 2002, RES VET SCI, V72, P83, DOI 10.1053/rvsc.2001.0527
   Tsegaw T, 2013, GEOSPATIAL HEALTH, V7, P299, DOI 10.4081/gh.2013.88
   Werneck GL, 2014, REV SAUDE PUBL, V48, P851, DOI 10.1590/S0034-8910.2014048005615
   WHO, 2010, 1 WHO REP NEGL TROP
NR 25
TC 9
Z9 9
U1 0
U2 0
PU UNIV NAPLES FEDERICO II
PI NAPLES
PA FAC VET MED, DEP PATHOLOGY & ANIMAL HEALTH, VET PARASITOLOGY, VIA DELLA
   VETERINARIA 1, NAPLES, 80137, ITALY
SN 1827-1987
EI 1970-7096
J9 GEOSPATIAL HEALTH
JI Geospatial Health
PY 2017
VL 12
IS 1
BP 67
EP 73
AR 503
DI 10.4081/gh.2017.503
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA EU6DL
UT WOS:000401124100008
PM 28555473
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Campos, VC
   Barrios, MR
   Salvatori, R
   de Almeida, RP
   de Melo, EV
   Nascimento, ACS
   de Jesus, AR
   Aguiar-Oliveira, MH
AF Campos, Viviane C.
   Barrios, Monica R.
   Salvatori, Roberto
   de Almeida, Roque Pacheco
   de Melo, Enaldo V.
   Nascimento, Ana C. S.
   de Jesus, Amelia Ribeiro
   Aguiar-Oliveira, Manuel H.
TI Infectious diseases and immunological responses in adult subjects with
   lifetime untreated, congenital GH deficiency
SO ENDOCRINE
LA English
DT Article
DE Cellular and humoral immune response; Isolated GH deficiency; Vaccines
   and skin tests; Infectious diseases
ID GROWTH-HORMONE DEFICIENCY; X-LINKED HYPOGAMMAGLOBULINEMIA; FACTOR-I;
   IMMUNE-SYSTEM; RECEPTOR GENE; HOMOZYGOUS MUTATION; BINDING-PROTEINS;
   CELL DEVELOPMENT; PROLACTIN; INSENSITIVITY
AB Growth hormone is important for the development and function of the immune system, but there is controversy on whether growth hormone deficiency is associated to immune disorders. A model of isolated growth hormone deficiency may clarify if the lack of growth hormone is associated with increased susceptibility to infections, or with an altered responsiveness of the immune system. We have studied the frequency of infectious diseases and the immune function in adults with congenital, untreated isolated growth hormone deficiency. In a cross-sectional study, 35 adults with isolated growth hormone deficiency due to a homozygous mutation in the growth hormone releasing hormone receptor gene and 31 controls were submitted to a clinical questionnaire, physical examination serology for tripanosomiasis, leishmaniasis, HIV, tetanus, hepatitis B and C, and serum total immunoglobulin G, M, E and A measurement. The immune response was evaluated in a subset of these subjects by skin tests and response to vaccination for hepatitis B, tetanus, and bacillus Calmette-Gu,rin. There was no difference between the groups in history of infectious diseases and baseline serology. Isolated growth hormone deficiency subjects had lower total IgG, but within normal range. There was no difference in the response to any of the vaccinations or in the positivity to protein Purified Derived, streptokinase or candidin. Adult untreated isolated growth hormone deficiency does not cause an increased frequency of infectious diseases, and does not alter serologic tests, but is associated with lower total IgG levels, without detectable clinical impact.
C1 [Campos, Viviane C.; de Melo, Enaldo V.; Nascimento, Ana C. S.; Aguiar-Oliveira, Manuel H.] Univ Fed Sergipe, Div Endocrinol, BR-49060100 Aracaju, Sergipe, Brazil.
   [Barrios, Monica R.; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Div Immunol, BR-49060100 Aracaju, Sergipe, Brazil.
   [Barrios, Monica R.; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Mol Biol Lab, BR-49060100 Aracaju, Sergipe, Brazil.
   [Salvatori, Roberto] Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA.
RP Salvatori, R (corresponding author), Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA.
EM salvator@jhmi.edu
FU Foundation Research and Technological Innovation of
   Sergipe-FAPITEC/SE/FUNTEC/CNPq [12/2009]
FX This work was supported by Foundation Research and Technological
   Innovation of Sergipe-FAPITEC/SE/FUNTEC/CNPq No. 12/2009 (to A.R.J.).
CR ABBASSI V, 1985, PEDIATR RES, V19, P299, DOI 10.1203/00006450-198503000-00009
   Aguiar-Oliveira MH, 2010, J CLIN ENDOCR METAB, V95, P714, DOI 10.1210/jc.2009-1879
   Aguiar-Oliveira MH, 1999, J CLIN ENDOCR METAB, V84, P4118, DOI 10.1210/jc.84.11.4118
   AHMED AR, 1983, ARCH DERMATOL, V119, P934, DOI 10.1001/archderm.119.11.934
   Alba M, 2005, GROWTH HORM IGF RES, V15, P275, DOI 10.1016/j.ghir.2005.05.001
   Auernhammer CJ, 1995, EUR J ENDOCRINOL, V133, P635, DOI 10.1530/eje.0.1330635
   Auernhammer CJ, 2002, HORM RES, V57, P15, DOI 10.1159/000057941
   BLUMING AZ, 1971, CLIN EXP IMMUNOL, V9, P713
   Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016
   Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157
   De Bellis Annamaria, 2005, Pituitary, V8, P25
   Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292
   FLEISHER TA, 1980, NEW ENGL J MED, V302, P1429, DOI 10.1056/NEJM198006263022601
   FU YK, 1992, J CLIN INVEST, V89, P451, DOI 10.1172/JCI115605
   Guevara-Aguirre J, 2007, HORM RES, V68, P175
   Hattori N, 2001, J CLIN ENDOCR METAB, V86, P4284, DOI 10.1210/jc.86.9.4284
   Hattori N, 2009, GROWTH HORM IGF RES, V19, P187, DOI 10.1016/j.ghir.2008.12.001
   Hwa V, 2016, GROWTH HORM IGF RES, V28, P16, DOI 10.1016/j.ghir.2015.12.006
   Jan CF, 2010, HEPATOLOGY, V51, P1547, DOI 10.1002/hep.23543
   KANARIOU M, 1995, PEDIATR ALLERGY IMMU, V6, P24, DOI 10.1111/j.1399-3038.1995.tb00253.x
   Kecha O, 2000, ENDOCRINOLOGY, V141, P1209, DOI 10.1210/en.141.3.1209
   Kelley KW, 2007, BRAIN BEHAV IMMUN, V21, P384, DOI 10.1016/j.bbi.2006.11.010
   Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926
   Laron Z, 2011, LARON SYNDROME - FROM MAN TO MOUSE: LESSONS FROM CLINICAL AND EXPERIEMENTAL EXPERIENCE, P341, DOI 10.1007/978-3-642-11183-9_41
   Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53
   LINDSAY R, 1994, J PEDIATR-US, V125, P29, DOI 10.1016/S0022-3476(94)70117-2
   Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EUJMI-D-14-00035, 10.1556/EuJMI-D-14-00035]
   Lithgow D, 2015, BIOL RES NURS, V17, P49, DOI 10.1177/1099800414524619
   Matera L, 1996, LIFE SCI, V59, P599, DOI 10.1016/0024-3205(96)00225-1
   Menezes M, 2008, MENOPAUSE, V15, P743, DOI 10.1097/gme.0b013e31815b97d4
   Menezes M, 2013, ENDOCRINE, V44, P207, DOI 10.1007/s12020-013-9896-z
   Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia das Doencas Transmissiveis (Brasil), 2014, TECN APL LEIT PROV T
   Mukherjee A, 2009, CLIN EXP IMMUNOL, V156, P271, DOI 10.1111/j.1365-2249.2009.03881.x
   Oberlin D, 2009, IMMUNOLOGY, V128, P342, DOI 10.1111/j.1365-2567.2009.03136.x
   Ogershok PR, 2006, ANN ALLERG ASTHMA IM, V97, P653, DOI 10.1016/S1081-1206(10)61096-4
   Oliveira CRP, 2008, CLIN ENDOCRINOL, V69, P153, DOI 10.1111/j.1365-2265.2007.03148.x
   Prakash Charu, 2000, Journal of Communicable Diseases, V32, P17
   ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369
   Salvatori R, 2006, J ENDOCRINOL INVEST, V29, P805, DOI 10.1007/BF03347374
   Salvatori R, 1999, J CLIN ENDOCR METAB, V84, P917, DOI 10.1210/jc.84.3.917
   Scalco RC, 2013, ARQ BRAS ENDOCRINOL, V57, P333, DOI 10.1590/S0004-27302013000500001
   Shohreh R, 2011, ENDOCRINOLOGY, V152, P3803, DOI 10.1210/en.2011-1317
   Smith PE, 1930, ANAT REC, V47, P119, DOI 10.1002/ar.1090470110
   SPADONI GL, 1991, ACTA PAEDIATR SCAND, V80, P75, DOI 10.1111/j.1651-2227.1991.tb11733.x
   Stewart DM, 2008, IMMUNOL RES, V40, P262, DOI 10.1007/s12026-007-0028-9
   Taguchi T, 2006, EXP HEMATOL, V34, P508, DOI 10.1016/j.exphem.2006.01.009
   Thomas RJ, 2015, INDIAN J MED MICROBI, V33, pS32, DOI 10.4103/0255-0857.150877
   van Bilsen K, 2008, NETH J MED, V66, P368
   Yang Y, 1999, HORM METAB RES, V31, P380, DOI 10.1055/s-2007-978759
   Zhao LT, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00645
   Zuckerman JN, 2006, J MED VIROL, V78, P169, DOI 10.1002/jmv.20524
NR 51
TC 11
Z9 12
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD OCT
PY 2016
VL 54
IS 1
BP 182
EP 190
DI 10.1007/s12020-016-1061-z
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EA4WL
UT WOS:000386616300021
PM 27484773
DA 2020-12-08
ER

PT J
AU de Souza, LD
   Vendrame, CMV
   de Jesus, AR
   Carvalho, MDT
   Magalhaes, AS
   Schriefer, A
   Guimaraes, LH
   de Carvalho, EM
   Goto, H
AF de Souza, Luana Dias
   Vieira Vendrame, Celia Maria
   de Jesus, Amelia Ribeiro
   Teixeira Carvalho, Marcia Dias
   Magalhaes, Andrea Santos
   Schriefer, Albert
   Guimaraes, Luiz Henrique
   de Carvalho, Edgar Marcelino
   Goto, Hiro
TI Insulin-like growth factor-I serum levels and their biological effects
   on Leishmania isolates from different clinical forms of American
   tegumentary leishmaniasis
SO PARASITES & VECTORS
LA English
DT Article
DE Leishmania braziliensis; Tegumentary leishmaniasis; THP-1; IGF-I level
ID CUTANEOUS LEISHMANIASIS; MUCOSAL LEISHMANIASIS; IMMUNE-RESPONSES;
   T-CELLS; BRAZILIENSIS; AMAZONENSIS; MACROPHAGES; EXPRESSION; PATHOLOGY;
   RECEPTOR
AB Background: American tegumentary leishmaniasis (ATL) in Brazil is mostly caused by Leishmania (Viannia) braziliensis, with known forms of the disease being cutaneous (CL), mucosal (ML) and disseminated (DL) leishmaniasis. The development of the lesion in ATL is related both to the persistence of the Leishmania in the skin and to the parasite-triggered immune and inflammatory responses that ensue lesions. In this context one factor with expected role in the pathogenesis is insulin-like growth factor (IGF)-I with known effects on parasite growth and healing and inflammatory processes. In the present study, we addressed the effect of IGF-I on intracellular amastigote isolates from CL, ML and DL patients within human macrophage and we evaluated the IGF-I and IGF-binding protein-3 (IGFBP3) serum levels in patients presenting different clinical forms and controls from the endemic area.
   Methods: We evaluated biological variability in the responses of intracellular amastigotes of Leishmania isolates derived from CL, ML, and DL patients from an area for ATL in response to IGF-I. Intracellular amastigote growth was evaluated using the human macrophage cell line THP-1. Arginase activity in infected cells was evaluated quantifying the generated urea concentration. Serum samples from patients and controls were assayed using chemiluminescent immunometric assay to determine IGF-I and IGFBP3 levels.
   Results: We observed an increase in intracellular parasitism upon IGF-I stimulus in 62.5 % of isolates from CL, in 85.7 % from ML and only 42.8 % from DL cases. In DL, the basal arginase activity was lower than that of CL. We then evaluated the IGF-I and IGFBP3 serum levels in patients, and we observed significantly lower levels in ML and DL than in CL and control samples.
   Conclusions: The data suggest that IGF-I is modulated distinctly in different clinical forms of tegumentary leishmaniasis. IGF-I seemingly exerts effect on parasite growth likely contributing to its persistence in the skin in earlier phase. In addition the decreased IGF-I serum levels may affect the modulation of inflammation and lesion healing in chronic phase. In view of potential role of IGF-I in the pathogenesis of ATL we can speculate on therapeutic procedures taking into account the local IGF-I level.
C1 [de Souza, Luana Dias; Vieira Vendrame, Celia Maria; Teixeira Carvalho, Marcia Dias; Goto, Hiro] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Soroepidemiol & Imunobiol, Ave Dr Eneas De Carvalho Aguiar 470,Predio II, BR-05403000 Sao Paulo, SP, Brazil.
   [Goto, Hiro] Univ Sao Paulo, Fac Med, Dept Prevent Med, Ave Dr Eneas De Carvalho Aguiar 470,Predio II, BR-05403000 Sao Paulo, SP, Brazil.
   [Vieira Vendrame, Celia Maria; Magalhaes, Andrea Santos; Schriefer, Albert; Guimaraes, Luiz Henrique; de Carvalho, Edgar Marcelino] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   [de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med Interna & Patol, Lab Biol Mol, Aracaju, SE, Brazil.
RP Goto, H (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Soroepidemiol & Imunobiol, Ave Dr Eneas De Carvalho Aguiar 470,Predio II, BR-05403000 Sao Paulo, SP, Brazil.; Goto, H (corresponding author), Univ Sao Paulo, Fac Med, Dept Prevent Med, Ave Dr Eneas De Carvalho Aguiar 470,Predio II, BR-05403000 Sao Paulo, SP, Brazil.
EM hgoto@usp.br
RI Goto, Hiro/B-5745-2009; Henrique, Luiz/ABA-2621-2020; Schriefer,
   Albert/AAP-2765-2020
OI Goto, Hiro/0000-0001-7048-562X; Schriefer, Albert/0000-0002-5496-6789
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2008/2209-6]; Fundacao de
   Amparo a Pesquisa do Estado da Bahia [1780-2007]; Conselho Nacional de
   Pesquisa [484499/2006]; Soroepidemiology and Immunobiology Laboratory
   (HC-FMUSP) [LIM/38]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (research fellowship 2008/2209-6 to LDS), Fundacao de Amparo a
   Pesquisa do Estado da Bahia (research fellowship 1780-2007 to CMW),
   Conselho Nacional de Pesquisa (fellowship to EMC, ARJ and HG, and grant
   484499/2006) and the Soroepidemiology and Immunobiology Laboratory
   LIM/38 (HC-FMUSP).
CR Aydin F, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/567834
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Blakytny Robert, 2000, Journal of Pathology, V190, P589, DOI 10.1002/(SICI)1096-9896(200004)190:5<589::AID-PATH553>3.0.CO;2-T
   Cantanhede LM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004079
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Carvalho LP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00301
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2
   Cunningham AC, 2002, EXP MOL PATHOL, V72, P132, DOI 10.1006/exmp.2002.2418
   CUPOLILLO E, 1994, AM J TROP MED HYG, V50, P296, DOI 10.4269/ajtmh.1994.50.296
   Da-Cruz AM, 2002, CLIN DIAGN LAB IMMUN, V9, P251, DOI 10.1128/CDLI.9.2.251-256.2002
   de Oliveira CI, 2004, MICROBES INFECT, V6, P977, DOI 10.1016/j.micinf.2004.05.009
   Elmlinger MW, 2004, CLIN CHEM LAB MED, V42, P654, DOI 10.1515/CCLM.2004.112
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Gollob KJ, 2014, PARASITE IMMUNOL, V36, P367, DOI 10.1111/pim.12100
   Gomes CMD, 2000, INT J EXP PATHOL, V81, P249, DOI 10.1046/j.1365-2613.2000.00157.x
   Goto H, 1998, P NATL ACAD SCI USA, V95, P13211, DOI 10.1073/pnas.95.22.13211
   Goto H, 2012, INFECT DIS CLIN N AM, V26, P293, DOI 10.1016/j.idc.2012.03.001
   Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795
   KRATZ G, 1994, SCAND J PLAST RECONS, V28, P107, DOI 10.3109/02844319409071187
   Leopoldo PTG, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-75
   Achar RAN, 2014, ACTA CIR BRAS, V29, P125, DOI 10.1590/S0102-86502014000200009
   Oliveira FS, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-189
   Pereira-Carvalho R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081529
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Rocha PN, 1999, J INFECT DIS, V180, P1731, DOI 10.1086/315071
   Saravia NG, 1998, AM J TROP MED HYG, V59, P86, DOI 10.4269/ajtmh.1998.59.86
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
   Sharp LL, 2005, NAT IMMUNOL, V6, P73, DOI 10.1038/ni1152
   Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
   Soong L, 2012, SEMIN IMMUNOPATHOL, V34, P735, DOI 10.1007/s00281-012-0350-8
   Sukhanov S, 2007, ARTERIOSCL THROM VAS, V27, P2684, DOI 10.1161/ATVBAHA.107.156257
   Tavakkol A, 1999, ARCH DERMATOL RES, V291, P643, DOI 10.1007/s004030050469
   TSUCHIYA S, 1982, CANCER RES, V42, P1530
   Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
   Vendrame CMV, 2007, SCAND J IMMUNOL, V66, P287, DOI 10.1111/j.1365-3083.2007.01950.x
   Vendrame C. M. V., 2014, MEDIAT INFLAMM, V2014
   Vendrame CMV, 2010, T ROY SOC TROP MED H, V104, P566, DOI 10.1016/j.trstmh.2010.03.007
NR 38
TC 3
Z9 3
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD JUN 11
PY 2016
VL 9
AR 335
DI 10.1186/s13071-016-1619-x
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DP2GD
UT WOS:000378305400001
PM 27286813
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Moura, TR
   Santos, MLB
   Braz, JM
   Santos, LFVC
   Aragao, MT
   de Oliveira, FA
   Santos, PL
   da Silva, AM
   de Jesus, AR
   de Almeida, RP
AF de Moura, Tatiana R.
   Barbosa Santos, Micheli Luize
   Braz, Juciene M.
   Santos, Luis Felipe V. C.
   Aragao, Matheus T.
   de Oliveira, Fabricia A.
   Santos, Priscila L.
   da Silva, Angela Maria
   de Jesus, Amelia Ribeiro
   de Almeida, Roque P.
TI Cross-resistance of Leishmania infantum isolates to nitric oxide from
   patients refractory to antimony treatment, and greater tolerance to
   antileishmanial responses by macrophages
SO PARASITOLOGY RESEARCH
LA English
DT Article
DE Visceral leishmaniasis; Leishmania infantum; Antimony resistance; Nitric
   oxide; Clinical isolate; Antileishmanial responses
ID VISCERAL LEISHMANIASIS; AMPHOTERICIN-B; MEGLUMINE ANTIMONIATE;
   PENTAVALENT ANTIMONY; VIANNIA BRAZILIENSIS; DRUG-RESISTANCE; IN-VITRO;
   SODIUM STIBOGLUCONATE; TRIVALENT ANTIMONY; DONOVANI
AB Visceral leishmaniasis is a life-threatening disease characterized by intense parasitism of the spleen, liver, and bone marrow. Antimonials have served as front-line antileishmanial therapeutics for decades, but the increasing failure rates under antimonial treatment have challenged the continued use of these drugs. Pentavalent antimonials are known to reinforce the killing mechanisms of macrophages, although the associated mechanism remains unclear. Here, for the first time, we determined whether Leishmania infantum strains isolated from patients refractory to antimony treatment (relapse cases) were cross-resistant to antimonials, liposomal amphotericin B, and/or nitric oxide, and also whether these strains modulate macrophage infection. We selected four clinical isolates from relapse cases and two clinical isolates from antimony-responsive patients (control group) for the present study. The L. infantum promastigotes from all four relapse cases were resistant to trivalent antimonial treatment and nitric oxide, while only one isolate was resistant to liposomal amphotericin B. We evaluated whether the resistant strains from relapse cases showed enhanced infectivity and amastigote survival in macrophages, or macrophage-killing mechanisms in macrophages activated by lipopolysaccharide plus interferon gamma. Infection indexes calculated using macrophages infected with isolates from relapse were higher than those observed with control strains that were stimulated independently. Macrophage infection was higher with L. infantum isolates from relapse cases and correlated with enhanced interleukin 1-beta production but showed similar nitrite production. Our results demonstrate that L. infantum field isolates from relapse cases were resistant to antimonials and nitric oxide and that these parasites stimulated inflammatory cytokines and were resistant to macrophage-killing mechanisms, factors that may contribute to disease severity.
C1 [de Moura, Tatiana R.; Barbosa Santos, Micheli Luize; Braz, Juciene M.; Santos, Luis Felipe V. C.; Aragao, Matheus T.; de Oliveira, Fabricia A.; Santos, Priscila L.; da Silva, Angela Maria; de Jesus, Amelia Ribeiro; de Almeida, Roque P.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-4906010 Aracaju, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque P.] Inst Invest Imunol, BR-01246903 Sao Paulo, Brazil.
RP de Moura, TR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-4906010 Aracaju, Brazil.
EM tmoura.ufs@gmail.com
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434
CR Ait-Oudhia K, 2011, PARASITOL RES, V109, P1225, DOI 10.1007/s00436-011-2555-5
   ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Carrio J, 2001, ACTA TROP, V79, P179, DOI 10.1016/S0001-706X(01)00125-5
   Carrio Jaume, 2002, BMC Pharmacol, V2, P11, DOI 10.1186/1471-2210-2-11
   Carter KC, 2006, ANTIMICROB AGENTS CH, V50, P88, DOI 10.1128/AAC.50.1.88-95.2006
   Carter KC, 2003, ANTIMICROB AGENTS CH, V47, P1529, DOI 10.1128/AAC.47.5.1529-1535.2003
   Chandra D, 2008, CLIN EXP IMMUNOL, V154, P224, DOI 10.1111/j.1365-2249.2008.03741.x
   COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   de Azevedo AF, 2014, PARASITOL RES, V113, P19, DOI 10.1007/s00436-013-3621-y
   de Melo EC, 2013, J TROP MED-US, V2013, DOI 10.1155/2013/319234
   Decuypere S, 2005, ANTIMICROB AGENTS CH, V49, P4616, DOI 10.1128/AAC.49.11.4616-4621.2005
   Decuypere S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001514
   Di Giorgio C, 1999, J ANTIMICROB CHEMOTH, V44, P71, DOI 10.1093/jac/44.1.71
   Erfan MBK, 2013, IRAN J PARASITOL, V8, P359
   Escobar P, 2002, ACTA TROP, V81, P151, DOI 10.1016/S0001-706X(01)00197-8
   FarautGambarelli F, 1997, ANTIMICROB AGENTS CH, V41, P827, DOI 10.1128/AAC.41.4.827
   Feng GJ, 1999, J IMMUNOL, V163, P6403
   Genestra M, 2006, ARCH MED RES, V37, P328, DOI 10.1016/j.arcmed.2005.07.011
   Giudice A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-7
   Goyeneche-Patino DA, 2008, ANTIMICROB AGENTS CH, V52, P4503, DOI 10.1128/AAC.01075-08
   GRAMICCIA M, 1992, ANN TROP MED PARASIT, V86, P613, DOI 10.1080/00034983.1992.11812717
   Holzmuller P, 2005, ANTIMICROB AGENTS CH, V49, P4406, DOI 10.1128/AAC.49.10.4406-4409.2005
   Jeddi F, 2014, ANTIMICROB AGENTS CH, V58, P4866, DOI 10.1128/AAC.02521-13
   Kothari H, 2007, PARASITOL INT, V56, P77, DOI 10.1016/j.parint.2006.10.005
   Lachaud L, 2002, J CLIN MICROBIOL, V40, P210, DOI 10.1128/JCM.40.1.210-215.2002
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Lonardoni MVC, 2000, INFECT IMMUN, V68, P6355, DOI 10.1128/IAI.68.11.6355-6361.2000
   MAUEL J, 1987, EUR J IMMUNOL, V17, P203, DOI 10.1002/eji.1830170209
   Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3
   MISHRA M, 1992, LANCET, V340, P1256, DOI 10.1016/0140-6736(92)92952-C
   Mittal MK, 2007, AM J TROP MED HYG, V76, P681, DOI 10.4269/ajtmh.2007.76.681
   Mukherjee B, 2013, P NATL ACAD SCI USA, V110, pE575, DOI [10.1073/pnas.1213839110, 10.]
   Ouellette M, 2004, DRUG RESIST UPDATE, V7, P257, DOI 10.1016/j.drup.2004.07.002
   Purkait B, 2012, ANTIMICROB AGENTS CH, V56, P1031, DOI 10.1128/AAC.00030-11
   RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0
   Romero GAS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000584
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121
   Sundar S, 2007, CLIN INFECT DIS, V45, P556, DOI 10.1086/520665
   Sundar S, 2013, EXPERT OPIN PHARMACO, V14, P53, DOI 10.1517/14656566.2013.755515
   t'Kindt R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000904
   Teixeira AC, 2008, REV INST MED TROP SP, V50, P157, DOI 10.1590/S0036-46652008000300005
   Vanaerschot M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023120
   Zauli-Nascimento RC, 2010, TROP MED INT HEALTH, V15, P68, DOI 10.1111/j.1365-3156.2009.02414.x
NR 47
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD FEB
PY 2016
VL 115
IS 2
BP 713
EP 721
DI 10.1007/s00436-015-4793-4
PG 9
WC Parasitology
SC Parasitology
GA DE8EO
UT WOS:000370868800030
PM 26481489
DA 2020-12-08
ER

PT J
AU dos Santos, PL
   de Oliveira, FA
   Santos, MLB
   Cunha, LCS
   Lino, MTB
   de Oliveira, MFS
   Bomfim, MOM
   Silva, AM
   de Moura, TR
   de Jesus, AR
   Duthie, MS
   Reed, SG
   de Almeida, RP
AF dos Santos, Priscila L.
   de Oliveira, Fabricia A.
   Santos, Micheli Luize B.
   Cunha, Luana Celina S.
   Lino, Michelle T. B.
   de Oliveira, Michelle F. S.
   Bomfim, Manuela O. M.
   Silva, Angela Maria
   de Moura, Tatiana R.
   de Jesus, Amelia R.
   Duthie, Malcolm S.
   Reed, Steven G.
   de Almeida, Roque P.
TI The Severity of Visceral Leishmaniasis Correlates with Elevated Levels
   of Serum IL-6, IL-27 and sCD14
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INTERFERON-GAMMA; IFN-GAMMA; CLINICAL EVOLUTION; CYTOKINE PROFILE;
   IMMUNE-RESPONSE; PLASMA-LEVELS; SOLUBLE CD14; RISK-FACTORS; KALA-AZAR;
   PATHOGENESIS
AB Background
   Visceral leishmaniasis (VL) is a severe disease caused by infection with protozoa of the genus Leishmania. Classic VL is characterized by a systemic infection of phagocytic cells and an intense activation of the inflammatory response. It is unclear why 90% of infected individuals do not develop the disease while a minority develop the classical form. Furthermore, among those that develop disease, a small group progresses to more severe form that is unresponsive to treatment. The presence of inflammatory mediators in serum could theoretically help to control the infection. However, there is also a release of anti-inflammatory mediators that could interfere with the control of parasite multiplication. In this study, we took advantage of the spectrum of outcomes to test the hypothesis that the immune profile of individuals infected with Leishmania (L.) infantum is associated with the development and severity of disease.
   Methodology/Principal Findings
   Sera from patients with confirmed diagnosis of VL were evaluated for the presence of numerous molecules, and levels compared with healthy control and asymptomatic infected individuals.
   Conclusions/Principal Findings
   Although differences were not observed in LPS levels, higher levels of sCD14 were detected in VL patients. Our data suggest that L. infantum may activate the inflammatory response via CD14, stimulating a generalized inflammatory response with production of several cytokines and soluble molecules, including IFN-., IL-27, IL-10, IL-6 and sCD14. These molecules were strongly associated with hepatosplenomegaly, neutropenia and thrombocytopenia. We also observed that IL-6 levels greater than 200 pg/ml were strongly associated with death. Together our data reinforce the close relationship of IFN-gamma, IL-10, IL-6, TNF-alpha and IL-27 in the immune dynamics of VL and suggest the direct participation of sCD14 in the activation of the immune response against L. infantum.
C1 [dos Santos, Priscila L.; de Oliveira, Fabricia A.; Santos, Micheli Luize B.; Cunha, Luana Celina S.; Lino, Michelle T. B.; de Oliveira, Michelle F. S.; Bomfim, Manuela O. M.; Silva, Angela Maria; de Moura, Tatiana R.; de Jesus, Amelia R.; de Almeida, Roque P.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [de Jesus, Amelia R.; de Almeida, Roque P.] Univ Fed Sergipe, Programa Posgrad Ciencias Saude, Aracaju, Brazil.
   [de Jesus, Amelia R.; de Almeida, Roque P.] Inst Invest Imunol, Sao Paulo, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] IDRI, Washington, DC USA.
RP de Almeida, RP (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.; de Almeida, RP (corresponding author), Univ Fed Sergipe, Programa Posgrad Ciencias Saude, Aracaju, Brazil.; de Almeida, RP (corresponding author), Inst Invest Imunol, Sao Paulo, Brazil.
EM roquepachecoalmeida@gmail.com
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico [019.203.02712/2009-8, 019.203.01157/2011-9];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Programa Nacional de Incentivo a Pesquisa em Parasitologia
   Basica [032/2010]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) PROCAD/CASADINHO [552721/2011-5]; Edital/Chamada:
   Universal [483540/2011-0]
FX This work was supported by: Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico, Grants: CNPq no 12/2009
   Processo no 019.203.02712/2009-8 (ARJ); CNPq no 04/2011 Processo n.
   019.203.01157/2011-9 (TRdM). Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES), Grant: Programa Nacional de Incentivo a
   Pesquisa em Parasitologia Basica, Edital No 032/2010 (ARdJ). Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Grants:
   PROCAD/CASADINHO- no 552721/2011-5 (RPdA); Edital/Chamada: Universal
   14/2011 Processo n. 483540/2011-0 (TRdM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ADERKA D, 1989, J IMMUNOL, V143, P3517
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877
   Gama MEA, 2013, REV SOC BRAS MED TRO, V46, P741, DOI 10.1590/0037-8682-0203-2013
   Costa ASA, 2012, MEM I OSWALDO CRUZ, V107, P735, DOI 10.1590/S0074-02762012000600005
   ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
   Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Bacellar O, 2005, GAZETA MED BAHIA, P75
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Belkhelfa M, 2014, J INTERFERON CYTOKIN
   Belo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982
   Belo VS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002182
   Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113
   CARVALHO EM, 1994, J IMMUNOL, V152, P5949
   Clark IA, 2004, CLIN MICROBIOL REV, V17, P509, DOI 10.1128/CMR.17.3.509-539.2004
   COSTA CHN, 1990, REV SAUDE PUBL, V24, P361, DOI 10.1590/S0034-89101990000500003
   Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
   de Oliveira FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-331
   Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Diro E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002869
   Duthie MS, 2014, EUR J CLIN MICROBIOL, V33, P639, DOI 10.1007/s10096-013-1999-1
   Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461
   Gluck T, 2001, EUR J MED RES, V6, P351
   Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
   Hailu A, 2004, AM J TROP MED HYG, V71, P561, DOI 10.4269/ajtmh.2004.71.561
   Hunter CA, 2012, IMMUNITY, V37, P960, DOI 10.1016/j.immuni.2012.11.003
   JANEWAY CA, 1988, CURR TOP MICROBIOL, V137, P171
   Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0
   Khoshdel A, 2009, BRAZ J INFECT DIS, V13, P44, DOI 10.1590/S1413-86702009000100010
   Kinra P, 2013, TROP BIOMED, V30, P645
   Landmann R, 1996, J INFECT DIS, V173, P661, DOI 10.1093/infdis/173.3.661
   Landmann R, 1996, INFECT IMMUN, V64, P1762, DOI 10.1128/IAI.64.5.1762-1769.1996
   Leite Alexandro Iris, 2013, Revista de Patologia Tropical, V42, P301, DOI 10.5216/rpt.v42i3.26928
   Liu LM, 2006, PARASITOL RES, V99, P189, DOI 10.1007/s00436-006-0168-1
   MAEGRAITH B, 1948, T ROY SOC TROP MED H, V41, P687, DOI 10.1016/S0035-9203(48)90678-6
   de Araujo VEM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001511
   Costa CHN, 2010, REV SOC BRAS MED TRO, V43, P386, DOI 10.1590/S0037-86822010000400010
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Peruhype-Magalhaes V, 2005, SCAND J IMMUNOL, V62, P487, DOI 10.1111/j.1365-3083.2005.01686.x
   Ramachandran G, 2014, VIRULENCE, V5, P213, DOI 10.4161/viru.27024
   Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002
   Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
   Saude BMd, 2006, MAN VIG CONTR LEISHM
   Silva JM, 2014, AM J TROP MED HYG, V90, P621, DOI 10.4269/ajtmh.13-0376
   Skraba CM, 2015, REV SOC BRAS MED TRO, V48, P437, DOI 10.1590/0037-8682-0067-2015
   Travi BL, 2002, INFECT IMMUN, V70, P2288, DOI 10.1128/IAI.70.5.2288-2296.2002
   Tuon FF, 2012, REV INST MED TROP SP, V54, P159, DOI 10.1590/S0036-46652012000300008
   Verma S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010107
   Wang SM, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/195453
   WHO, 2010, WHO TECH REP SER, V949, P1
   Wynick C, 2014, J INTERFERON CYTOKIN
   Xu C, 2014, KIDNEY INT, V85, P72, DOI 10.1038/ki.2013.286
NR 57
TC 31
Z9 33
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2016
VL 10
IS 1
AR e0004375
DI 10.1371/journal.pntd.0004375
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DH1SR
UT WOS:000372565700069
PM 26814478
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, FA
   Barreto, AS
   Bomfim, LGS
   Leite, TRS
   dos Santos, PL
   de Almeida, RP
   da Silva, AM
   Duthie, MS
   Reed, SG
   de Moura, TR
   de Jesus, AR
AF de Oliveira, Fabricia Alvisi
   Barreto, Aline Silva
   Bomfim, Lays G. S.
   Leite, Talita Rebeca S.
   dos Santos, Priscila Lima
   de Almeida, Roque Pacheco
   da Silva, Angela Maria
   Duthie, Malcolm S.
   Reed, Steven G.
   de Moura, Tatiana Rodrigues
   de Jesus, Amelia Ribeiro
TI Soluble CD40 Ligand in Sera of Subjects Exposed to Leishmania infantum
   Infection Reduces the Parasite Load in Macrophages
SO PLOS ONE
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; EXPERIMENTAL VISCERAL LEISHMANIASIS;
   NITRIC-OXIDE PRODUCTION; CELL-MEDIATED-IMMUNITY; NF-KAPPA-B; CD40-CD40
   LIGAND; DENDRITIC CELLS; HUMAN MONOCYTES; T-CELLS; DONOVANI INFECTIONS
AB Background
   While CD40L is typically a membrane glycoprotein expressed on activated T cells and platelets that binds and activates CD40 on the surface on antigen presenting cells, a soluble derivative (sCD40L) that appears to retain its biological activity after cleavage from cell membrane also exists. We recently reported that sCD40L is associated with clinical resolution of visceral leishmaniasis and protection against the disease. In the present study we investigated if this sCD40L is functional and exerts anti-parasitic effect in L. infantum-infected macrophages.
   Methodology/Principal Findings
   Macrophages from normal human donors were infected with L. infantum promastigotes and incubated with either sera from subjects exposed to L. infantum infection, monoclonal antibodies against human CD40L, or an isotype control antibody. We then evaluated infection by counting the number of infected cells and the number of parasites in each cell. We also measured a variety of immune modulatory cytokines in these macrophage culture supernatants by Luminex assay. The addition of sCD40L, either recombinant or from infected individuals' serum, decreased both the number of infected macrophages and number of intracellular parasites. Moreover, this treatment increased the production of IL-12, IL-23, IL27, IL-15, and IL1 beta such that negative correlations between the levels of these cytokines with both the infection ratio and number of intracellular parasites were observed.
   Conclusions/Significance
   sCD40L from sera of subjects exposed to L. infantum is functional and improves both the control of parasite and production of inflamatory cytokines of infected macrophages. Although the mechanisms involved in parasite killing are still unclear and require further exploration, these findings indicate a protective role of sCD40L in visceral leishmaniasis.
C1 [de Oliveira, Fabricia Alvisi; Barreto, Aline Silva; Bomfim, Lays G. S.; Leite, Talita Rebeca S.; dos Santos, Priscila Lima; de Almeida, Roque Pacheco; da Silva, Angela Maria; de Moura, Tatiana Rodrigues; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, Aracaju, Brazil.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Inst Invest Imunol, Sao Paulo, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] IDRI, Seattle, WA USA.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, Aracaju, Brazil.
EM ameliaribeirodejesus@gmail.com
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; Santos Bomfim, Lays
   Gisele/0000-0002-4773-6889; Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico [12/2009, 019.203.02712/2009-8]; CNPqNational
   Council for Scientific and Technological Development (CNPq) [04/2011,
   019.203.01157/2011-9]; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Grant: Programa Nacional de Incentivo a Pesquisa
   em Parasitologia Basica [032/2010]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq) [552721/2011-5]; Edital/Chamada:
   Universal [483540/2011-0]
FX This work was supported by: Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico, Grants: CNPq no 12/2009
   Processo no 019.203.02712/2009-8 (ARJ); CNPq no 04/2011 Processo n.
   019.203.01157/2011-9 (TRM). Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Grant: Programa Nacional de Incentivo a Pesquisa
   em Parasitologia Basica, Edital No 032/2010 (ARJ). Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Grants:
   PROCAD/CASADINHO- no552721/2011-5 (RPA); Edital/Chamada: Universal
   14/2011 Processo n. 483540/2011-0 (TRM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andrade RM, 2005, J IMMUNOL, V175, P6014, DOI 10.4049/jimmunol.175.9.6014
   Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747
   Chen G, 2001, INFECT IMMUN, V69, P3255, DOI 10.1128/IAI.69.5.3255-3263.2001
   D'Aversa TG, 2002, AM J PATHOL, V160, P559, DOI 10.1016/S0002-9440(10)64875-4
   de Oliveira FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-331
   Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004
   GHALIB HW, 1995, J IMMUNOL, V154, P4623
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639
   Grewal IS, 1997, CURR OPIN IMMUNOL, V9, P491, DOI 10.1016/S0952-7915(97)80100-8
   Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111
   Gurunathan S, 1998, J IMMUNOL, V161, P4563
   Guzzo C, 2010, J BIOL CHEM, V285, P24404, DOI 10.1074/jbc.M110.112599
   Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600
   Heinzel FP, 1998, CELL IMMUNOL, V184, P129, DOI 10.1006/cimm.1998.1267
   HO JL, 1992, J INFECT DIS, V165, P1094, DOI 10.1093/infdis/165.6.1094
   Indramohan M, 2012, INFECT IMMUN, V80, P4099, DOI 10.1128/IAI.00589-12
   Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200
   Kalliolias GD, 2008, J IMMUNOL, V180, P6325, DOI 10.4049/jimmunol.180.9.6325
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x
   Lieberman LA, 2004, J IMMUNOL, V173, P1887, DOI 10.4049/jimmunol.173.3.1887
   LIEW FY, 1990, IMMUNOLOGY, V71, P556
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Liu JG, 2007, J EXP MED, V204, P141, DOI 10.1084/jem.20061440
   Lorente L, 2011, CRIT CARE, V15, DOI 10.1186/cc10104
   Ludewig B, 1996, EUR J IMMUNOL, V26, P3137, DOI 10.1002/eji.1830261246
   Malik N, 1996, J IMMUNOL, V156, P3952
   Mathur RK, 2006, TRENDS PARASITOL, V22, P117, DOI 10.1016/j.pt.2006.01.003
   Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045
   McDowell MA, 2002, INFECT IMMUN, V70, P3994, DOI 10.1128/IAI.70.8.3994-4001.2002
   McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Murray HW, 2005, J IMMUNOL, V174, P4916, DOI 10.4049/jimmunol.174.8.4916
   Murray HW, 2003, INFECT IMMUN, V71, P6453, DOI 10.1128/IAI.71.11.6453-6462.2003
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Reinhard K, 2011, EUR J IMMUNOL, V41, P1388, DOI 10.1002/eji.201041056
   Ribbens C, 2000, IMMUNOLOGY, V99, P279, DOI 10.1046/j.1365-2567.2000.00948.x
   Shimizu M, 2013, IMMUNOBIOLOGY, V218, P628, DOI 10.1016/j.imbio.2012.07.028
   Sipsas NV, 2002, CLIN DIAGN LAB IMMUN, V9, P558, DOI 10.1128/CDLI.9.3.558-561.2002
   Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3
   Stager S, 2006, EUR J IMMUNOL, V36, P1764, DOI 10.1002/eji.200635937
   Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I
   Subauste CS, 2009, SEMIN IMMUNOL, V21, P273, DOI 10.1016/j.smim.2009.06.003
   Suttles J, 2009, SEMIN IMMUNOL, V21, P257, DOI 10.1016/j.smim.2009.05.011
   Tan ZY, 2009, INT J BIOCHEM CELL B, V41, P733, DOI 10.1016/j.biocel.2008.04.027
   TIAN LC, 1995, EUR J IMMUNOL, V25, P306, DOI 10.1002/eji.1830250152
   Tousoulis D, 2010, TRENDS CARDIOVAS MED, V20, P153, DOI 10.1016/j.tcm.2010.12.004
   Van Assche T, 2011, FREE RADICAL BIO MED, V51, P337, DOI 10.1016/j.freeradbiomed.2011.05.011
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
   Verma S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010107
   Watford WT, 2004, IMMUNOL REV, V202, P139, DOI 10.1111/j.0105-2896.2004.00211.x
   Wesa Amy, 2002, BMC Immunol, V3, P14, DOI 10.1186/1471-2172-3-14
   Xie P, 2006, J IMMUNOL, V176, P5388, DOI 10.4049/jimmunol.176.9.5388
   Yan JC, 2004, CLIN CHIM ACTA, V343, P155, DOI 10.1016/j.cccn.2004.01.012
NR 58
TC 10
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2015
VL 10
IS 10
AR e0141265
DI 10.1371/journal.pone.0141265
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0ZM
UT WOS:000363248400118
PM 26488744
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Tunon, GIL
   de Moura, TR
   de Jesus, AR
   de Almeida, RP
AF Lee Tunon, Gabriel Isaias
   de Moura, Tatiana Rodrigues
   de Jesus, Amelia Ribeiro
   de Almeida, Roque Pacheco
TI In vitro infection by Leishmania infantum in the peripheral blood
   mononuclear cell-derived macrophages from crab-eating foxes (Cerdocyon
   thous)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Epidemiology; Peripheral blood mononuclear cell-derived macrophage;
   Visceral leishmaniasis; Wild canids
ID CANINE VISCERAL LEISHMANIASIS; WILD CANIDS; BRAZIL; DOGS; CHAGASI;
   TRANSMISSION; ACTIVATION; STATE; SPP.
AB Wild canids are natural reservoirs of visceral leishmaniais (VL). In Brazil, only the crab-eating fox (Cerdocyon thous) is a natural reservoir of this zoonotic disease, but there is still a lack of understanding regarding the sylvatic transmission of the Leishmania infantum infection. This is the first study on the isolation, cultivation and infection with L. infantum in the peripheral blood mononuclear cell-derived macrophages from crab-eating foxes. It is also the first to compare macrophages from crab-eating foxes to other canine macrophages under the same conditions. Blood samples collected from crab-eating foxes held at the local zoo were processed to obtain macrophages that were subsequently infected with stationary phase L. infantum promastigotes. The percentage of infected macrophages and intracellular amastigotes per 100 macrophages were similar in both fox and dog blood samples at 2 h after infection. Unlike dog macrophages, in fox macrophages there was a significant reduction in the number of infected macrophages after 24 and 48 h. At 72 h after infection, the intracellular amastigotes were practically undetectable. These results indicate that crab-eating foxes have cellular mechanisms of infection control as efficient as the domestic dog. Further study is required to discern the potential epidemiologic role of crab-eating foxes in the visceral leishmaniasis transmission cycle. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Lee Tunon, Gabriel Isaias] Univ Fed Sergipe, Dept Med Vet, BR-49100000 Sao Cristovao, SE, Brazil.
   [de Moura, Tatiana Rodrigues] Univ Fed Sergipe, Dept Morfol, BR-49100000 Sao Cristovao, SE, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Univ Hosp, Dept Med, BR-49060100 Aracaju, SE, Brazil.
RP Tunon, GIL (corresponding author), Univ Fed Sergipe, Dept Med Vet, Cidade Univ Jose Aloisio de Campos, BR-49100000 Sao Cristovao, SE, Brazil.
EM glee@ufs.br
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434
FU Edital CNPq/Universal [477935/2009-5]; Pronex Edital
   FAPITEC/SE/FUNTEC/CNPq [12/2009, 019.203.02712/2009-8]
FX This research project was funded by Edital CNPq/Universal, 2009, Process
   number 477935/2009-5 and by Pronex Edital FAPITEC/SE/FUNTEC/CNPq number
   12/2009, Process 019.203.02712/2009-8.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Coura-Vital W, 2013, VET PARASITOL, V197, P411, DOI 10.1016/j.vetpar.2013.07.031
   Courtenay O, 2002, PARASITOLOGY, V125, P407, DOI 10.1017/S0031182002002238
   Courtenay O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002583
   Dantas-Torres F, 2007, VET PARASITOL, V149, P139, DOI 10.1016/j.vetpar.2007.07.007
   Dantas-Torres Filipe, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P151, DOI 10.1590/S0036-46652006000300007
   Dawit G, 2013, J BACTERIOL PARASITO, V4, P2, DOI DOI 10.4172/2155-9597.10001
   Leal GGD, 2014, VET PARASITOL, V205, P472, DOI 10.1016/j.vetpar.2014.08.022
   Diaz S, 2012, VET PARASITOL, V189, P137, DOI 10.1016/j.vetpar.2012.05.004
   Jusi MMG, 2011, REV BRAS PARASITOL V, V20, P219, DOI 10.1590/S1984-29612011000300008
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Khuls K., 2011, PLOS NEGLECT TROP D, V5, pe1155
   Luppi MM, 2008, VET PARASITOL, V155, P146, DOI 10.1016/j.vetpar.2008.04.024
   Madeira MF, 1999, MEM I OSWALDO CRUZ, V94, P645, DOI 10.1590/S0074-02761999000500015
   Marcondes M., 2013, Brazilian Journal of Veterinary Research and Animal Science, V50, P341, DOI 10.11606/issn.2318-3659.v50i5p341-352
   Melo LM, 2014, INT IMMUNOPHARMACOL, V18, P373, DOI 10.1016/j.intimp.2013.12.012
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Loria-Cervera EN, 2014, REV INST MED TROP SP, V56, P1, DOI 10.1590/S0036-46652014000100001
   Quinnell RJ, 2009, PARASITOLOGY, V136, P1915, DOI 10.1017/S0031182009991156
   Richini-Pereira VB, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-27
   Sampaio Weverton M, 2007, BMC Vet Res, V3, P11, DOI 10.1186/1746-6148-3-11
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Souza NP, 2010, REV SOC BRAS MED TRO, V43, P333, DOI 10.1590/S0037-86822010000300024
   Rodrigues CAT, 2009, VET IMMUNOL IMMUNOP, V127, P382, DOI 10.1016/j.vetimm.2008.10.324
   Viana KF, 2013, VET PARASITOL, V198, P62, DOI 10.1016/j.vetpar.2013.08.014
   Vouldoukis I, 2006, VET PARASITOL, V135, P137, DOI 10.1016/j.vetpar.2005.09.003
NR 26
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP 15
PY 2015
VL 212
IS 3-4
BP 417
EP 421
DI 10.1016/j.vetpar.2015.06.027
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA CU2LQ
UT WOS:000363355400055
PM 26194430
DA 2020-12-08
ER

PT J
AU Nascimento, MSL
   Carregaro, V
   Lima, DS
   Costa, DL
   Ryffel, B
   Duthie, MS
   de Jesus, A
   de Almeida, RP
   da Silva, JS
AF Lima Nascimento, Manuela Sales
   Carregaro, Vanessa
   Lima-Junior, Djalma Souza
   Costa, Diego Luis
   Ryffel, Bernhard
   Duthie, Malcolm S.
   de Jesus, Amelia
   de Almeida, Roque Pacheco
   da Silva, Joao Santana
TI Interleukin 17A Acts Synergistically With Interferon gamma to Promote
   Protection Against Leishmania infantum Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Leishmania infantum; visceral leishmaniasis; IL-17; nitric oxide
ID CHEMOKINE RECEPTOR EXPRESSION; HUMAN VISCERAL LEISHMANIASIS;
   IL-17-PRODUCING T-CELLS; DONOVANI INFECTIONS; HOST-DEFENSE; MICE;
   RESPONSES; IL-17; LYMPHOCYTES; DISEASE
AB Interleukin 17 (IL-17) is an inflammatory cytokine that plays a protective role against intracellular parasites. The role of IL-17 during Leishmania infection remains controversial and poorly defined. We evaluated whether IL-17 participates in the host immune response to Leishmania infantum. IL-17A is present in sera from patients with visceral leishmaniasis and decreases after successful treatment. In C57BL/6 infected mice, higher production of IL-17A coincided with the peak of parasitism gamma Il17ra(-/-) mice were more susceptible to infection and also exhibited reduced inflammatory infiltration and interferon gamma (IFN-gamma)-expressing CD4(+) T-cell frequencies than wild-type mice. The frequencies of FoxP3(+)CD4(+) T cells and interleukin 10 (IL-10)-expressing CD4(+) T cells were increased in Il17ra(-/-) mice. We also demonstrated that IL-17A acts synergistically with IFN-gamma to potentiate NO production and leishmanicidal activity in infected macrophages. Therefore, our results indicate that L. infantum induces IL-17A production, which promotes the control of parasite replication by strengthening T-helper type 1 responses and NO production and prevents regulatory T-cell and IL-10-expressing T-cell expansion.
C1 [Lima Nascimento, Manuela Sales; Carregaro, Vanessa; Lima-Junior, Djalma Souza; Costa, Diego Luis; da Silva, Joao Santana] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Aracaju, Brazil.
   [de Jesus, Amelia; de Almeida, Roque Pacheco] Univ Fed Sergipe, Ctr Biol & Hlth Sci, Aracaju, Brazil.
   [Ryffel, Bernhard] Univ Orleans, UMR6218, Orleans, France.
   [Ryffel, Bernhard] CNRS, F-45071 Orleans, France.
   [Duthie, Malcolm S.] Infect Dis Res Inst, Seattle, WA USA.
RP da Silva, JS (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Av Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM jsdsilva@fmrp.usp.br
RI Costa, Diego Luis/F-7168-2019; Carregaro, Vanessa/D-2913-2012;
   nascimento, manuela/C-8628-2018; Silva, Joao S/A-4484-2008; Souza Lima
   Junior, Djalma/H-4833-2013
OI Costa, Diego Luis/0000-0002-9440-2814; Silva, Joao
   S/0000-0002-3410-3927; nascimento, manuela/0000-0002-6887-8931;
   Carregaro, Vanessa/0000-0002-8435-0766; Souza Lima Junior,
   Djalma/0000-0002-2092-8047; Duthie, Malcolm/0000-0002-8515-5516
FU Nucleo de Apoio a Pesquisa em Doencas Inflamatorias [11.1.21625.01.0];
   Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2013/01967-2, 2012/14524-9]
FX This work was supported by Nucleo de Apoio a Pesquisa em Doencas
   Inflamatorias (grant 11.1.21625.01.0) and Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (grants 2013/01967-2 and 2012/14524-9).
CR Ayres JS, 2012, ANNU REV IMMUNOL, V30, P271, DOI 10.1146/annurev-immunol-020711-075030
   Bermejo DA, 2013, NAT IMMUNOL, V14, P514, DOI 10.1038/ni.2569
   BIRON CA, 1995, CURR OPIN IMMUNOL, V7, P485, DOI 10.1016/0952-7915(95)80093-X
   Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213
   BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167, DOI 10.1128/AAC.39.9.2167
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1994, J IMMUNOL, V152, P5949
   Guedes PMD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000604
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   ENGLEN MD, 1995, J IMMUNOL METHODS, V184, P281, DOI 10.1016/0022-1759(95)00136-X
   Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106
   Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Gardener P J, 1977, Trop Dis Bull, V74, P1069
   Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461
   GHALIB HW, 1995, J IMMUNOL, V154, P4623
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   Ghosh K, 2013, J INFECT DIS, V207, P1016, DOI 10.1093/infdis/jis771
   Gonzalez-Lombana C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003243
   Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980
   Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329
   Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009
   Kedzierski L, 2008, EUR J IMMUNOL, V38, P3090, DOI 10.1002/eji.200838423
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Kopf M, 1996, J EXP MED, V184, P1127, DOI 10.1084/jem.184.3.1127
   Kostka SL, 2009, J IMMUNOL, V182, P3039, DOI 10.4049/jimmunol.0713598
   Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249
   Kurasawa K, 2000, ARTHRITIS RHEUM-US, V43, P2455, DOI 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K
   Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025
   Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Qiu Z, 2009, IMMUNOBIOLOGY, V214, P835, DOI 10.1016/j.imbio.2009.06.007
   Rodrigues OR, 2009, IMMUNOBIOLOGY, V214, P101, DOI 10.1016/j.imbio.2008.07.001
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875
   Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2
   Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Vargas-Inchaustegui DA, 2008, J IMMUNOL, V180, P7537, DOI 10.4049/jimmunol.180.11.7537
   Yang Zheng-Sheng, 2011, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V27, P959
NR 45
TC 55
Z9 55
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2015
VL 211
IS 6
BP 1015
EP 1026
DI 10.1093/infdis/jiu531
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CC3CX
UT WOS:000350223300020
PM 25274569
OA Bronze
DA 2020-12-08
ER

PT J
AU Gardinassi, LG
   Dotz, V
   Ederveen, AH
   de Almeida, RP
   Costa, CHN
   Costa, DL
   de Jesus, AR
   Mayboroda, OA
   Garcia, GR
   Wuhrer, M
   Santosa, IKFD
AF Gardinassi, Luiz Gustavo
   Dotz, Viktoria
   Ederveen, Agnes Hipgrave
   de Almeida, Roque Pacheco
   Nery Costa, Carlos Henrique
   Costa, Dorcas Lamounier
   de Jesus, Amelia Ribeiro
   Mayboroda, Oleg A.
   Garcia, Gustavo Rocha
   Wuhrer, Manfred
   Ferreira de Miranda Santosa, Isabel Kinney
TI Clinical Severity of Visceral Leishmaniasis Is Associated with Changes
   in Immunoglobulin G Fc N-Glycosylation
SO MBIO
LA English
DT Article
ID CIRCULATING IMMUNE-COMPLEXES; B-CELL ACTIVATION; ANTIINFLAMMATORY
   ACTIVITY; RHEUMATOID-ARTHRITIS; DONOVANI INFECTION; STRUCTURAL-CHANGES;
   IGG GLYCOSYLATION; GAMMA RECEPTORS; ANTIBODY; BINDING
AB Visceral leishmaniasis (VL) has a high fatality rate if not treated; nevertheless, the majority of human infections with the causative agent, Leishmania infantum chagasi, are asymptomatic. Although VL patients often present with increased levels of serum immunoglobulins, the contribution of antibodies to resistance or progression to disease remains unknown. Effector and regulatory functions of antibodies rely on their interactions with type I and II Fc receptors, and these interactions are tuned by the patterns of antibody Fc N-glycosylation. In view of these facts, we applied a robust method of IgG Fc N-glycopeptide profiling of serum samples from 187 patients with VL, 177 asymptomatic individuals, 116 endemic controls (individuals residing in areas where VL is endemic) and 43 nonendemic controls (individuals living in an area where VL is not endemic). We show that, in comparison to the overall IgG Fc N-glycan profiles of asymptomatic or uninfected healthy individuals, those of patients with VL are profoundly altered. These changes correlate with levels of serum cytokines and the inflammation marker C-reactive protein. We also fitted univariate and multivariate ordinal logistic regression models to demonstrate the ability of IgG Fc N-glycosylation features and immunity regulators present in serum to predict disease severity in VL patients. Importantly, we show that Fc N-glycosylation profiles change after treatment of VL. This study introduces important concepts contributing to the understanding of antibody responses in infections with Leishmania parasites and provides new insights into the pathology of human VL.
   IMPORTANCE Immunoglobulins (Ig) have been shown to present pro-and anti-inflammatory functions according to the profile of carbohydrates attached to their Fc region. Glycosylation features of serum IgG have been examined in relation to several autoimmune and infectious diseases and provide a mechanistic basis for the protective or pathogenic role of antibodies. Leishmania infantum chagasi is the causative agent of visceral leishmaniasis (VL) in South America, and we show that VL patients produce IgG with patterns of Fc glycans similar to those found in other inflammatory conditions. Specific Fc N-glycosylation features and levels of serum cytokines and C-reactive protein are significantly associated with the development of severe clinical symptoms and, notably, Fc glycosylation changes after treatment. The modifications detected in the N-glycosylation features of IgG Fc from VL patients raise new perspectives on the effector or regulatory role of antibodies in immune responses elicited by infection with Leishmania parasites.
C1 [Gardinassi, Luiz Gustavo; Garcia, Gustavo Rocha; Ferreira de Miranda Santosa, Isabel Kinney] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim Imunol, BR-14049 Ribeirao Preto, Brazil.
   [Dotz, Viktoria; Wuhrer, Manfred] Vrije Univ Amsterdam, Div Bioanalyt Chem, Amsterdam, Netherlands.
   [Ederveen, Agnes Hipgrave; Mayboroda, Oleg A.; Wuhrer, Manfred] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
   [Nery Costa, Carlos Henrique; Costa, Dorcas Lamounier] Univ Fed Piaui, Inst Doencas Tropicais Natan Portela, Dept Med Comunitaria, Teresina, Brazil.
   [Wuhrer, Manfred] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.
RP Wuhrer, M (corresponding author), Vrije Univ Amsterdam, Div Bioanalyt Chem, Amsterdam, Netherlands.
EM m.wuhrer@lumc.nl; imsantos@fmrp.usp.br
RI Mayboroda, Oleg/B-5634-2008; Mayboroda, Oleg/N-4850-2019; Gardinassi,
   Luiz Gustavo Araujo/K-6276-2012; de Miranda Santos, Isabel K.
   F./D-5261-2016; Gardinassi, Luiz/V-2225-2019; Wuhrer,
   Manfred/ABE-9168-2020; de Miranda Santos, Isabel KF/B-7597-2012
OI Mayboroda, Oleg/0000-0001-8739-9875; Mayboroda,
   Oleg/0000-0001-8739-9875; Gardinassi, Luiz Gustavo
   Araujo/0000-0002-9027-2688; Gardinassi, Luiz/0000-0002-9027-2688;
   Wuhrer, Manfred/0000-0002-0814-4995; de Miranda Santos, Isabel
   KF/0000-0002-0438-4430; Hipgrave Ederveen, Agnes/0000-0003-1689-0442;
   Dotz, Viktoria/0000-0002-9888-7409
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [559603/2009-6]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/53645-3, 2012/06708-2]; European UnionEuropean Union (EU)
   [278535]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/23819-0, 2013/00382-0]
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (grant 559603/2009-6), the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP; grants 2009/53645-3,
   2012/06708-2, and 2012/06708-2), and by the European Union's Seventh
   Framework Program (FP7-Health-F5-2011) under grant agreement 278535
   (HighGlycan). L.G.G. and G.R.G. were supported by FAPESP (scholarships
   2011/23819-0 and 2013/00382-0, respectively).
CR Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708
   Ahmed AA, 2014, J MOL BIOL, V426, P3166, DOI 10.1016/j.jmb.2014.07.006
   Alonso DP, 2007, J INFECT DIS, V195, P1212, DOI 10.1086/512683
   Ansar W, 2009, GLYCOCONJUGATE J, V26, P1151, DOI 10.1007/s10719-009-9236-y
   Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   Bakovic MP, 2013, J PROTEOME RES, V12, P821, DOI 10.1021/pr300887z
   Biburger M, 2011, IMMUNITY, V35, P932, DOI 10.1016/j.immuni.2011.11.009
   Brasil Ministerio da Saude . Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2006, MAN VIG CONTR LEISHM
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chu NS, 2010, J IMMUNOL, V185, P6939, DOI 10.4049/jimmunol.1002484
   Collins ES, 2013, RHEUMATOLOGY, V52, P1572, DOI 10.1093/rheumatology/ket189
   Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
   Deak E, 2010, EUR J IMMUNOL, V40, P1355, DOI 10.1002/eji.200939455
   Duthie MS, 2014, EUR J CLIN MICROBIOL, V33, P639, DOI 10.1007/s10096-013-1999-1
   Elshafie AI, 2007, J IMMUNOL, V178, P5383, DOI 10.4049/jimmunol.178.8.5383
   EVANS TG, 1989, MEM I OSWALDO CRUZ, V84, P157, DOI 10.1590/S0074-02761989000200003
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461
   Gibson-Corley KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106426
   Hess C, 2013, J CLIN INVEST, V123, P3788, DOI 10.1172/JCI65938
   Ho CH, 2014, J INFECT DIS
   Huffman JE, 2014, MOL CELL PROTEOMICS, V13, P1598, DOI 10.1074/mcp.M113.037465
   Imafuku Y, 2003, CLIN CHIM ACTA, V334, P217, DOI 10.1016/S0009-8981(03)00245-6
   Jeddi P, 1999, IMMUNOLOGY, V98, P475, DOI 10.1046/j.1365-2567.1999.00896.x
   Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594
   Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862
   Lauc G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003225
   MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237
   Mauer J, 2014, NAT IMMUNOL, V15, P423, DOI 10.1038/ni.2865
   McCall LI, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003053
   Mehta AS, 2008, J VIROL, V82, P1259, DOI 10.1128/JVI.01600-07
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Costa CHN, 2010, REV SOC BRAS MED TRO, V43, P386, DOI 10.1590/S0037-86822010000400010
   Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Nimmerjahn F, 2007, P NATL ACAD SCI USA, V104, P8433, DOI 10.1073/pnas.0702936104
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   O'Regan NL, 2014, PARASITE IMMUNOL
   Osorio EY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002417
   Owens BMJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002827
   PAREKH R, 1989, J AUTOIMMUN, V2, P101, DOI 10.1016/0896-8411(89)90148-0
   PEARSON RD, 1983, J INFECT DIS, V147, P1102, DOI 10.1093/infdis/147.6.1102
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939
   Rombouts Y., 2013, ANN RHEUM DIS
   ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890
   Ryan JR, 2002, J CLIN MICROBIOL, V40, P1037, DOI 10.1128/JCM.40.3.1037-1043.2002
   Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484
   Santos IKFD, 2001, INFECT IMMUN, V69, P5212
   Sela-Culang I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00302
   Selman MHJ, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014563
   Selman MHJ, 2011, J PROTEOME RES, V10, P143, DOI 10.1021/pr1004373
   Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200
   Shikata K, 1998, GLYCOCONJUGATE J, V15, P683, DOI 10.1023/A:1006936431276
   Siberil S, 2006, CLIN IMMUNOL, V118, P170, DOI 10.1016/j.clim.2005.10.008
   Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681
   Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968
   Stadlmann J, 2009, PROTEOMICS, V9, P4143, DOI 10.1002/pmic.200800931
   Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0
   Troelsen LN, 2012, J RHEUMATOL, V39, P463, DOI 10.3899/jrheum.110584
   Tudor D, 2012, P NATL ACAD SCI USA, V109, P12680, DOI 10.1073/pnas.1200024109
   VANZEBEN D, 1994, BRIT J RHEUMATOL, V33, P36
   VELGE P, 1991, EUR J IMMUNOL, V21, P2145, DOI 10.1002/eji.1830210924
   Wang J, 2011, MOL CELL PROTEOMICS, V10, DOI [10.1074/mcp.M111.010017-1, 10.1074/mcp.M111.010017]
   WHITE AC, 1992, AM J TROP MED HYG, V46, P123, DOI 10.4269/ajtmh.1992.46.123
   Woelbing F, 2006, J EXP MED, V203, P177, DOI 10.1084/jem.20052288
   Wuhrer M, 2007, PROTEOMICS, V7, P4070, DOI 10.1002/pmic.200700289
   Xia YM, 2013, MOL IMMUNOL, V56, P28, DOI 10.1016/j.molimm.2013.04.004
   Yamada E, 1997, GLYCOCONJUGATE J, V14, P401, DOI 10.1023/A:1018582930906
   Zauner G, 2013, MOL CELL PROTEOMICS, V12, P856, DOI 10.1074/mcp.R112.026005
   ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826
   Zou GZ, 2011, J AM CHEM SOC, V133, P18975, DOI 10.1021/ja208390n
NR 73
TC 23
Z9 24
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2014
VL 5
IS 6
AR e01844
DI 10.1128/mBio.01844-14
PG 12
WC Microbiology
SC Microbiology
GA AX7CE
UT WOS:000347073600010
PM 25467439
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Duthie, MS
   Guderian, J
   Vallur, A
   Bhatia, A
   dos Santos, PL
   de Melo, EV
   de Jesus, AR
   Todt, M
   Mondal, D
   Almeida, R
   Reed, SG
AF Duthie, M. S.
   Guderian, J.
   Vallur, A.
   Bhatia, A.
   Lima dos Santos, P.
   Vieira de Melo, E.
   Ribeiro de Jesus, A.
   Todt, M.
   Mondal, D.
   Almeida, R.
   Reed, S. G.
TI Alteration of the serum biomarker profiles of visceral leishmaniasis
   during treatment
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article
ID LIPOSOMAL AMPHOTERICIN-B; KALA-AZAR; CYTOKINE PROFILES; GAMMA
   PRODUCTION; INTERLEUKIN-10; INTERFERON; INFECTION; DIAGNOSIS; INDIA;
   MILTEFOSINE
AB Until recently, chemotherapy for visceral leishmaniasis (VL; also known as kala-azar) was severely limited by factors such as high cost, route of administration, generation of side effects and potential for resistance. Although largely effective, chemotherapies have become available with the introduction of new drugs and multi-drug regimens for VL. These could be further improved by the identification of biomarkers that are altered during effective treatment. The identification of such biomarkers in the circulation would also simplify efficacy trials. In this study, we determined immunological signatures within the serum of ethnically and geographically distinct VL patients (from Bangladesh and Brazil). Our results indicate that inflammatory and regulatory cytokines (IFN gamma, TNF alpha, IL-10, IL-17), as well as levels of growth factors (FGF, VEGF), are elevated within the serum of VL patients from these sites. The examination of samples from Brazilian VL patients during and beyond standard treatment with meglumine antimoniate identified multiple parameters that revert to levels comparable to those of healthy endemic control individuals. The consolidation of these results provides a 'response to treatment' signature that could be used within efficacy trials to rapidly and simply determine successful interruption of VL.
C1 [Duthie, M. S.; Guderian, J.; Vallur, A.; Bhatia, A.; Reed, S. G.] Infect Dis Res Inst, Seattle, WA 98102 USA.
   [Mondal, D.] Int Ctr Diarrhoeal Dis Res, Parasitol Lab, Div Sci Lab, Dhaka 1000, Bangladesh.
   [Lima dos Santos, P.; Vieira de Melo, E.; Ribeiro de Jesus, A.; Todt, M.; Almeida, R.] Univ Fed Sergipe, Dept Med, Aracaju, Sergipe, Brazil.
RP Duthie, MS (corresponding author), Infect Dis Res Inst, 1616 Eastlake Ave East,Suite 400, Seattle, WA 98102 USA.
EM mduthie@idri.org
OI Duthie, Malcolm/0000-0002-8515-5516
FU Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [631,
   39129, 53053]; Oficina de Prioridades em Pesquisa para o Sistema Unico
   de Saude; Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do
   Estado de Sergipe; Brazilian Research National Council (CNPq)National
   Council for Scientific and Technological Development (CNPq); NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038] Funding Source: NIH RePORTER
FX This research was funded by grants from the Bill & Melinda Gates
   Foundation (631 and 39129 to SR and GCE Round 2 Award 53053 to DM),
   Oficina de Prioridades em Pesquisa para o Sistema Unico de Saude,
   Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe and Brazilian Research National Council (CNPq) (to R.A.). The
   authors thank all the patients and donors for their participation.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Costa ASA, 2012, MEM I OSWALDO CRUZ, V107, P735, DOI 10.1590/S0074-02762012000600005
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1994, J IMMUNOL, V152, P5949
   CENINI P, 1993, J INFECT DIS, V168, P986, DOI 10.1093/infdis/168.4.986
   CILLARI E, 1995, CYTOKINE, V7, P740, DOI 10.1006/cyto.1995.0088
   de Oliveira FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-331
   Duffy T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000419
   Elshafie AI, 2011, INT J PARASITOL, V41, P463, DOI 10.1016/j.ijpara.2010.11.005
   Gasim S, 1998, CLIN EXP IMMUNOL, V111, P64
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   Gidwani K, 2011, CLIN VACCINE IMMUNOL, V18, P346, DOI 10.1128/CVI.00473-10
   Hailu A, 2004, AM J TROP MED HYG, V71, P561, DOI 10.4269/ajtmh.2004.71.561
   HAILU A, 1990, T ROY SOC TROP MED H, V84, P673, DOI 10.1016/0035-9203(90)90141-Z
   HOLADAY BJ, 1993, J CLIN INVEST, V92, P2626, DOI 10.1172/JCI116878
   HOLADAY BJ, 1993, J INFECT DIS, V167, P411, DOI 10.1093/infdis/167.2.411
   Louis H, 2003, ACTA GASTRO-ENT BELG, V66, P7
   de Assis TSM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001542
   Maia Z, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001484
   Maretti-Mira AC, 2011, ACTA TROP, V119, P160, DOI 10.1016/j.actatropica.2011.05.009
   McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07
   Mondal S, 2010, EXPERT REV ANTI-INFE, V8, P919, DOI 10.1586/ERI.10.78
   Oliveira LF, 2011, ACTA TROP, V118, P87, DOI 10.1016/j.actatropica.2011.02.007
   Olliaro P, 2009, TROP MED INT HEALTH, V14, P88, DOI 10.1111/j.1365-3156.2008.02195.x
   Olliaro P, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001545
   Pattabhi S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000822
   Pedras MJ, 2008, T ROY SOC TROP MED H, V102, P172, DOI 10.1016/j.trstmh.2007.11.004
   Ridley R. C., 2007, Nature Reviews Microbiology, pS1, DOI 10.1038/nrmicro1765
   Sana G, 2013, CELL TRANSPLANT, V12
   Schulz A, 2003, J CLIN MICROBIOL, V41, P1529, DOI 10.1128/JCM.41.4.1529-1535.2003
   Singh OP, 2012, CLIN VACCINE IMMUNOL, V19, P961, DOI 10.1128/CVI.00143-12
   Srivastava P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019304
   Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394
   Sundar S, 2000, T ROY SOC TROP MED H, V94, P200, DOI 10.1016/S0035-9203(00)90277-3
   Sundar S, 2008, CLIN INFECT DIS, V47, P1000, DOI 10.1086/591972
   Sundar S, 2013, EXPERT OPIN PHARMACO, V14, P53, DOI 10.1517/14656566.2013.755515
   Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627
   VANDERPOLL T, 1995, CLIN IMMUNOL IMMUNOP, V77, P111, DOI 10.1016/0090-1229(95)90144-2
   Verma S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010107
   WHO, 2010, LEISHM BURD DIS SURV
NR 42
TC 11
Z9 11
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD APR
PY 2014
VL 33
IS 4
BP 639
EP 649
DI 10.1007/s10096-013-1999-1
PG 11
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA AD2IS
UT WOS:000333058800019
PM 24173820
OA Green Accepted
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   de Almeida, JAP
AF de Jesus, Amelia Ribeiro
   Pacheco de Almeida, Jose Antonio
TI Scientific progress versus ecological influence on Schistosoma mansoni
   transmission
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Editorial Material
C1 [de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Mol Biol Lab, Aracaju, SE, Brazil.
   [de Jesus, Amelia Ribeiro] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Invest Imunol, Inst Nacionais Ciencia & Tecnol, Sao Paulo, Brazil.
   [Pacheco de Almeida, Jose Antonio] Univ Fed Sergipe, Dept Geog, Aracaju, SE, Brazil.
RP de Jesus, AR (corresponding author), UFS, Univ Hosp, Mol Biol Lab, Rua Claudio Batista S-N, BR-49060100 Aracaju, SE, Brazil.
EM jesus-amelia@uol.com.br
CR BARBOSA F S, 1973, Malacologia, V14, P401
   Barboza DM, 2012, GEOSPATIAL HEALTH, V6, pS103
   Coutinho A. D., 1992, Cadernos de Saude Publica, V8, P302, DOI 10.1590/S0102-311X1992000300009
   FIGUEIREDO CCSB, 1989, MEM I OSWALDO CRUZ, V84, P383, DOI 10.1590/S0074-02761989000300014
   Guimaraes ICS, 2006, REV SOC BRAS MED TRO, V39, P451, DOI 10.1590/S0037-86822006000500006
   Hino Paula, 2006, Rev. Latino-Am. Enfermagem, V14, P939, DOI 10.1590/S0104-11692006000600016
   Lambertucci JR, 2014, REV SOC BRAS MED TRO, V47, P130, DOI 10.1590/0037-8682-0186-2013
   Mello DA, 1969, GAZ MED TROP, V21, P246
   Rollemberg Carla Virginia Vieira, 2011, Rev. Soc. Bras. Med. Trop., V44, P91, DOI 10.1590/S0037-86822011000100020
   Superintendencia de Recursos Hidricos, 2010, SUP REC HIDR
NR 10
TC 0
Z9 0
U1 0
U2 2
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD MAR-APR
PY 2014
VL 47
IS 2
BP 127
EP 129
DI 10.1590/0037-8682-0080-2014
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AI1SF
UT WOS:000336631700001
PM 24861283
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Vazquez, CMP
   Netto, RSM
   Barbosa, KBF
   de Moura, TR
   de Almeida, RP
   Duthie, MS
   de Jesus, AR
AF Passos Vazquez, Cecilia Maria
   Mendes Netto, Raquel Simoes
   Ferreira Barbosa, Kiriaque Barra
   Rodrigues de Moura, Tatiana
   Pacheco de Almeida, Roque
   Duthie, Malcolm S.
   Ribeiro de Jesus, Amelia
TI Micronutrients influencing the immune response in leprosy
SO NUTRICION HOSPITALARIA
LA English
DT Review
DE Nutrition; Leprosy; Oxidative stress and antioxidants
ID PULMONARY TUBERCULOSIS PATIENTS; D-RECEPTOR GENE; CD4(+) T-CELLS;
   VITAMIN-D; CATHELICIDIN LL-37; OXIDATIVE STRESS; HANSENS-DISEASE;
   GREATER VITORIA; ESPIRITO-SANTO; TRACE-ELEMENTS
AB Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an intracellular bacillus of airborne transmission. The disease affects the skin and peripheral nerves and can cause neurological sequelae. The bacillus multiplies slowly in the host and the disease probably occurs due to malfunctioning in host immune response. This review addresses the role of some specific micronutrients in the immune response, such as Vitamins A, D, E, C, Zinc and Selenium, detailing their mechanisms of actions in infectious diseases, and in leprosy. The immune response to pathogens releases harmful substances, which lead to tissue damage. This review discusses how a decreased level of antioxidants may contribute to an increased oxidative stress and complications of infectious diseases and leprosy. As the nutrients have a regulatory effect in the innate and adaptative immune responses, a perfect balance in their concentrations is important to improve the immune response against the pathogens.
C1 [Passos Vazquez, Cecilia Maria; Rodrigues de Moura, Tatiana; Pacheco de Almeida, Roque; Ribeiro de Jesus, Amelia] Univ Fed Sergipe, Dept Med, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [Mendes Netto, Raquel Simoes; Ferreira Barbosa, Kiriaque Barra] Univ Fed Sergipe, Dept Nutr, Aracaju, Brazil.
   [Pacheco de Almeida, Roque; Ribeiro de Jesus, Amelia] CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Brasilia, DF, Brazil.
   [Duthie, Malcolm S.] IDRI, Seattle, WA 98014 USA.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Dept Med, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
EM jesus-amelia@uol.com.br
RI Barbosa, Kiriaque/E-4269-2014; Mendes-Netto, Raquel/W-8120-2019
OI Duthie, Malcolm/0000-0002-8515-5516
FU Coordination of Improvement of Education Personnel (CAPES); Brazilian
   Council for Scientific and Technological Development (CNPq)/ Universal
   [477935/2009-5]; PRONEX, FAPITEC/SE/FUNTEC/CNPq [12/2009,
   019.203.02712/2009-8]
FX The research group is funded by Coordination of Improvement of Education
   Personnel (CAPES) and the Brazilian Council for Scientific and
   Technological Development (CNPq)/ Universal, 2009, Grant No.
   477935/2009-5 and by PRONEX, FAPITEC/SE/FUNTEC/CNPq, 12/2009, Grant No.
   019.203.02712/2009-8. ARJ and RPA are scientists from CNPq.
CR Afridi HI, 2011, CLIN LAB, V57, P171
   Albert B., 2004, BIOL MOL CELULA
   Alter A, 2008, HUM GENET, V123, P227, DOI 10.1007/s00439-008-0474-z
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   [Anonymous], 2010, NOT SDIDAD
   Aranha F. Q., 2000, Revista de Nutricao, V13, P89
   Azzini E, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-125
   Bakaev VV, 2004, INT J TUBERC LUNG D, V8, P263
   Barbosa E, 2007, REV NUTR, V20, P693, DOI 10.1590/S1415-52732007000600011
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bogdan C, 1998, BERL MUNCH TIERARZTL, V111, P409
   Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7
   Calder PC, 2000, NUTR RES REV, V13, P3, DOI 10.1079/095442200108728981
   Calder PC, 2002, BRIT J NUTR, V88, pS165, DOI 10.1079/BJN2002682
   CHANDRA RK, 1994, J NUTR, V124, pS1433, DOI 10.1093/jn/124.suppl_8.1433S
   Chocano-Bedoya P, 2009, NUTR REV, V67, P289, DOI 10.1111/j.1753-4887.2009.00195.x
   Coura J. R., 2005, DINAMICA DOENCAS INF
   Dawson HD, 1999, J NUTR, V129, P1510
   Fairweather-Tait SJ, 2011, ANTIOXID REDOX SIGN, V14, P1337, DOI 10.1089/ars.2010.3275
   Fujio K, 2010, ADV IMMUNOL, V105, P99, DOI 10.1016/S0065-2776(10)05004-2
   Gibney KB, 2008, CLIN INFECT DIS, V46, P443, DOI 10.1086/525268
   Jyothi P, 2008, Indian J Dermatol Venereol Leprol, V74, P80
   Kerr-Pontes LRS, 2006, INT J EPIDEMIOL, V35, P994, DOI 10.1093/ije/dyl072
   Koury Josely Correa, 2003, Rev. Nutr., V16, P433, DOI 10.1590/S1415-52732003000400007
   Kowalski Jan, 2004, Pol Merkur Lekarski, V16, P119
   Larnsal Madhab, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P695
   Leite H, 2003, REV BRAS NUTR CLIN, V18, P87
   Lima Emerson S., 2007, Rev. Inst. Med. trop. S. Paulo, V49, P211, DOI 10.1590/S0036-46652007000400003
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Luz K G, 2001, Rev Soc Bras Med Trop, V34, P381, DOI 10.1590/S0037-86822001000400013
   Maggini S, 2007, BRIT J NUTR, V98, pS29, DOI 10.1017/S0007114507832971
   Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S
   Martineau AR, 2007, J IMMUNOL, V178, P7190, DOI 10.4049/jimmunol.178.11.7190
   Matzner M, 2011, ACTA TROP, V117, P56, DOI 10.1016/j.actatropica.2010.09.007
   Meydani M, 1998, NUTR REV, V56, pS177
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Moulin CM, 2009, ARQ BRAS ENDOCRINOL, V53, P183, DOI 10.1590/S0004-27302009000200010
   MURRAY R. K, 2002, HARPER BIOQUIMICA
   Montenegro RMN, 2012, CAD SAUDE PUBLICA, V28, P31, DOI 10.1590/S0102-311X2012000100004
   Montenegro RMN, 2011, REV SOC BRAS MED TRO, V44, P228, DOI [10.1590/S0037-86822011005000016, 10.1590/s0037-86822011005000016]
   Neve J., 1997, PR MED BIOL A, V8, P985
   Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247
   Nogueira Carla, 2010, Rev. paul. pediatr., V28, P381, DOI 10.1590/S0103-05822010000400015
   Oh SY, 1998, INT J LEPROSY, V66, P34
   Palace VP, 1999, FREE RADICAL BIO MED, V26, P746, DOI 10.1016/S0891-5849(98)00266-4
   Palermo ML, 2012, AM J TROP MED HYG, V86, P878, DOI 10.4269/ajtmh.2012.12-0088
   Plit ML, 1998, INT J TUBERC LUNG D, V2, P590
   Prasad AS, 2000, J INFECT DIS, V182, pS62, DOI 10.1086/315916
   Ramakrishnan K, 2012, CLIN LAB, V58, P165
   Rivas-Santiago B, 2008, INFECT IMMUN, V76, P935, DOI 10.1128/IAI.01218-07
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   Scollard DM, 2008, SOUTH MED J, V101, P583, DOI 10.1097/SMJ.0b013e318172e077
   Scollard DM, 2008, LEPROSY REV, V79, P242
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Selvaraj P, 2004, J CLIN IMMUNOL, V24, P523, DOI 10.1023/B:JOCI.0000040923.07879.31
   Seyedrezazadeh E, 2008, RESPIROLOGY, V13, P294, DOI 10.1111/j.1440-1843.2007.01200.x
   Shaik-Dasthagirisaheb YB, 2013, J BIOL REG HOMEOS AG, V27, P291
   Shapira Y, 2010, CLIN REV ALLERG IMMU, V38, P169, DOI 10.1007/s12016-009-8150-1
   SIES H, 1995, AM J CLIN NUTR, V62, P1315
   Siest G, 2008, DRUG METAB DISPOS, V36, P182, DOI 10.1124/dmd.107.017228
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   Ueda N, 2009, J NEUROL SCI, V287, P216, DOI 10.1016/j.jns.2009.07.020
   van Lettow M, 2005, EUR J CLIN NUTR, V59, P526, DOI 10.1038/sj.ejcn.1602116
   Vannucchi Helio, 1998, Medicina (Ribeirao Preto), V31, P31
   Vijayaraghavan R, 2005, EUR J CLIN NUTR, V59, P1121, DOI 10.1038/sj.ejcn.1602221
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CMR.18.3.446-464.2005
   Waitzbertg D, 2006, NUTR ORAL ENTERAL PA
   Wanasen N, 2007, INFECT IMMUN, V75, P2802, DOI 10.1128/IAI.00026-07
   Wang QZ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-104
   Wang XC, 2007, J CLIN IMMUNOL, V27, P193, DOI 10.1007/s10875-006-9068-5
   WHO, 2011, LEPR TOD
   Wintergerst ES, 2006, ANN NUTR METAB, V50, P85, DOI 10.1159/000090495
   Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673
   Wood RJ, 2000, J NUTR, V130, p1350S, DOI 10.1093/jn/130.5.1350S
   World Health Organization, 2011, WEEKLY EPIDEMIOLOGIC
   Zaccone P, 2011, EUR J IMMUNOL, V41, P2709, DOI 10.1002/eji.201141429
   Zasloff M, 2006, NAT MED, V12, P388, DOI 10.1038/nm0406-388
NR 77
TC 5
Z9 6
U1 0
U2 7
PU ARAN EDICIONES, S L
PI MADRID
PA C/ CASTELLO, 128, 1O, MADRID, 28006, SPAIN
SN 0212-1611
EI 1699-5198
J9 NUTR HOSP
JI Nutr. Hosp.
PD JAN
PY 2014
VL 29
IS 1
BP 26
EP 36
DI 10.3305/nh.2014.29.1.6988
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AA8IV
UT WOS:000331340100005
PM 24483959
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Oliveira, DT
   Sherlock, J
   de Melo, EV
   Rollemberg, KCV
   da Paixao, TRS
   Abuawad, YG
   Simon, MD
   Duthie, M
   de Jesus, AR
AF de Oliveira, Daniela Teles
   Sherlock, Jonnia
   de Melo, Enaldo Vieira
   Vieira Rollemberg, Karla Caroline
   Santos da Paixao, Telma Rodrigues
   Abuawad, Yasmin Gama
   Simon, Marise do Vale
   Duthie, Malcolm
   de Jesus, Amelia Ribeiro
TI Clinical variables associated with leprosy reactions and persistence of
   physical impairment
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Leprosy; Leprosy reactions; Physical impairment; Corticosteroid
   treatment
ID DIAGNOSIS; NEUROPATHY; DISABILITY; STEROIDS; TYPE-1
AB Introduction: Leprosy is a chronic disease that affects skin and peripheral nerves. Disease complications include reactional episodes and physical impairment. One World Health Organization (WHO) goal of leprosy programs is to decrease the number of grade 2 impairment diagnoses by 2015. This study aims to evaluate clinical factors associated with the occurrence of leprosy reactions and physical impairment in leprosy patients. Methods: We conducted a retrospective study of data from medical records of patients followed in two important centers for the treatment of leprosy in Aracaju, Sergipe, Brazil, from 2005 to 2011. We used the chi-square test to analyze associations between the following categorical variables: gender, age, operational classification, clinical forms, leprosy reactions, corticosteroid treatment, and physical impairment at the diagnosis and after cure. Clinical variables associated with multibacillary leprosy and/or reactional episodes and the presence of any grade of physical impairment after cure were evaluated using the logistic regression model. Results: We found that men were more affected by multibacillary fauns, reactional episodes, and grade 2 physical impairment at diagnosis. Leprosy reactions were detected in a total of 40% of patients and all were treated with corticosteroids. However, physical impairment was observed in 29.8% of the patients analyzed at the end of the treatment and our multivariate analysis associated a low dose and short period of corticosteroid treatment with persistence of physical impairments. Conclusions: Physical impairment should receive an increased attention before and after treatment, and adequate treatment should be emphasized.
C1 [de Oliveira, Daniela Teles; Sherlock, Jonnia; de Melo, Enaldo Vieira; Vieira Rollemberg, Karla Caroline; Santos da Paixao, Telma Rodrigues; Abuawad, Yasmin Gama; Simon, Marise do Vale; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Univ Hosp, Mol Biol Lab, Aracaju, SE, Brazil.
   [Duthie, Malcolm] Infect Dis Res Inst, Seattle, WA USA.
RP de Jesus, AR (corresponding author), Univ Hosp, Rua Claudio Batista S-N, BR-49060100 Aracaju, SE, Brazil.
EM jesus-amelia@uol.com.br
OI do Vale Simon, Marise/0000-0002-7466-2002
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   UniversalNational Council for Scientific and Technological Development
   (CNPq) [477935/2009-5]; Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC/SE/CNPq, Edital
   FAPITEC/SE/FUNTEC/CNPq) [12/2009, 019.203.02712/2009-8]
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   Universal, Process no 477935/2009-5; Fundacao de Apoio a Pesquisa e a
   Inovacao Tecnologica do Estado de Sergipe (FAPITEC/SE/CNPq, Edital
   FAPITEC/SE/FUNTEC/CNPq No 12/2009 (Programa de Nucleos de Excelencia -
   PRONEX), Process no 019.203.02712/2009-8. ARJ is a scientist from CNPq.
CR Balagon MVF, 2010, AM J TROP MED HYG, V83, P637, DOI 10.4269/ajtmh.2010.09-0586
   Trindade MAB, 2009, BRAZ J INFECT DIS, V13, P155, DOI 10.1590/S1413-86702009000200017
   Brakel WH, 2008, PLOS NEGLECT TROP D, V2, P1
   de Oliveira DT, 2012, GEOSPATIAL HEALTH, V6, pS125
   Souza LWF, 2010, REV SOC BRAS MED TRO, V43, P737, DOI 10.1590/S0037-86822010000600029
   Foss Norma Tiraboschi, 2003, Medicina (Ribeirao Preto), V36, P453
   Garbino JA, 2008, ARQ NEURO-PSIQUIAT, V66, P861, DOI 10.1590/S0004-282X2008000600016
   Guerra JG, 2002, AN BRAS DERMATOL, V77, P389
   Jardim MR, 2007, ARQ NEURO-PSIQUIAT, V65, P969, DOI 10.1590/S0004-282X2007000600009
   Kahawita IP, 2008, AN BRAS DERMATOL, V83, P75, DOI 10.1590/S0365-05962008000100010
   Mastrangelo G, 2011, MEM I OSWALDO CRUZ, V106, P92, DOI 10.1590/S0074-02762011000100015
   Alves CJM, 2010, REV SOC BRAS MED TRO, V43, P460, DOI 10.1590/S0037-86822010000400025
   Ministerio da Saude (MS), 2010, PORT 3 125
   Moschioni C, 2010, REV SOC BRAS MED TRO, V43, P19, DOI 10.1590/S0037-86822010000100005
   Pinzan CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010757
   Ranque B, 2007, CLIN INFECT DIS, V44, P33, DOI 10.1086/509923
   Raposo MT, 2011, REV INST MED TROP SP, V53, P77, DOI 10.1590/S0036-46652011000200004
   Richardus JH, 2004, INT J EPIDEMIOL, V33, P337, DOI 10.1093/ije/dyg225
   Schuring RP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000283
   Slim FJ, 2010, J REHABIL MED, V42, P536, DOI 10.2340/16501977-0569
   Smith WCS, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000500
   Smith WCS, 2004, BMJ-BRIT MED J, V328, P1
   Travi BL, 2002, INFECT IMMUN, V70, P2288, DOI 10.1128/IAI.70.5.2288-2296.2002
   World Health Organization, 2011, WEEKLY EPIDEMIOLOGIC
NR 24
TC 9
Z9 12
U1 0
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD SEP-OCT
PY 2013
VL 46
IS 5
BP 600
EP 604
DI 10.1590/0037-8682-0100-2013
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 261NS
UT WOS:000327672500012
PM 24270251
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, FA
   Silva, CVO
   Damascena, NP
   Passos, RO
   Duthie, MS
   Guderian, JA
   Bhatia, A
   de Moura, TR
   Reed, SG
   de Almeida, RP
   de Jesus, AR
AF de Oliveira, Fabricia Alvisi
   Oliveira Silva, Carla Vanessa
   Damascena, Nayra Prata
   Passos, Rodrigo Oliveira
   Duthie, Malcolm S.
   Guderian, Jeffrey A.
   Bhatia, Ajay
   de Moura, Tatiana Rodrigues
   Reed, Steven G.
   de Almeida, Roque Pacheco
   de Jesus, Amelia Ribeiro
TI High levels of soluble CD40 ligand and matrix metalloproteinase-9 in
   serum are associated with favorable clinical evolution in human visceral
   leishmaniasis
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Visceral leishmaniasis; Soluble CD40 ligand; Matrix metalloproteinase-9;
   Biomarkers; Clinical outcome
ID TRYPANOSOMA-CRUZI INFECTION; ACUTE CORONARY SYNDROMES;
   CELL-MEDIATED-IMMUNITY; MATRIX METALLOPROTEINASES; ASYMPTOMATIC
   INFECTION; CD40-CD40 LIGAND; IFN-GAMMA; CHAGASI; ACTIVATION;
   INTERLEUKIN-10
AB Background: Soluble CD40 ligand (sCD40L) and matrix metalloproteinase 9 (MMP-9) are inflammation markers and have been poorly described in infectious disease. In this prospective study, we describe the sera kinetics of these two molecules in the course of treatment follow up in human visceral leishmaniasis (VL).
   Methods: Sera from VL patients were collected before and during follow up of regular Antimony treatment. sCD40L and MMP-9 were measured by Luminex assay. Paired analysis by Wilcoxon signed test was used for comparison of values of the same subjects before and after initiation of treatment. Correlations between clinical data and parasite load with the serum levels of sCD40L and MMP-9 were performed by Spearman test. Tests were considered statistically significant if the probability of a type I error was less than 5% (p-value <0.05).
   Results: While sCD40L and MMP-9 were not observed in sera from non endemic controls which are at low risk of Leishmania chagasi infection, elevated levels were observed in sera from VL patients, and an increase in sCD40L and MMP-9 levels were detectable during the follow-up of VL patients undergoing antimony treatment. sCD40L levels were also high in individuals living in endemic settings at high risk of infection (endemic controls). Additionally, negative correlations were found between spleen sizes and MMP-9 before treatment and sCD40L at day 15 of treatment. Negative correlations were also found between parasite load with both sCD40L and MMP-9.
   Conclusion: Serum sCD40L and MMP-9 are identified as new and simple biomarkers in two situations: (i) monitoring the success of therapy and (ii) predicting favorable clinical outcome of human VL.
C1 [de Oliveira, Fabricia Alvisi; Oliveira Silva, Carla Vanessa; Damascena, Nayra Prata; Passos, Rodrigo Oliveira; de Moura, Tatiana Rodrigues; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-4906010 Aracaju, Sergipe, Brazil.
   [Duthie, Malcolm S.; Guderian, Jeffrey A.; Bhatia, Ajay; Reed, Steven G.] IDRI Infect Dis Res Inst, Seattle, WA 98102 USA.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Rua Claudio Batista S-N, BR-4906010 Aracaju, Sergipe, Brazil.
EM jesus-amelia@uol.com.br
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/Brazilian Research National Council (CNPq)/Ministerio
   da Saude [019.203.02712/2009-8]; Bill & Melinda Gates Foundation,
   Seattle, USA [42387]; Programa Nacional de Incentivo a Pesquisa em
   Parasitologia Basica [032/2010]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES
FX We thank to the Pediatric and Infectious Disease Clinic Group from the
   University Hospital, Universidade Federal de Sergipe. This work was
   supported by: Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do
   Estado de Sergipe (FAPITEC)/Brazilian Research National Council
   (CNPq)/Ministerio da Saude (Programa de Apoio a Projetos para o Sistema
   Unico de Saude - PPSUS Edital 08/2009 and Programas de Nucleos de
   Excelencia - PRONEX, Processo no 019.203.02712/2009-8); Bill & Melinda
   Gates Foundation [grant number 42387], Seattle, USA. Programa Nacional
   de Incentivo a Pesquisa em Parasitologia Basica, Edital No 032/2010,
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). ARJ
   and RPA are scientists from the Brazilian Research National Council
   (CNPq).
CR Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   BARRALNETTO M, 1989, BRAZ J MED BIOL RES, V22, P1485
   Caldas AJM, 2002, T ROY SOC TROP MED H, V96, P21, DOI 10.1016/S0035-9203(02)90227-0
   Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   Costa JD, 2008, ACTA TROP, V106, P175, DOI 10.1016/j.actatropica.2008.03.006
   Donhauser N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033925
   Elmetwali T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-52
   Geurts N, 2012, PHARMACOL THERAPEUT, V133, P257, DOI 10.1016/j.pharmthera.2011.11.008
   Gong YQ, 2008, J CLIN INVEST, V118, P3012, DOI 10.1172/JCI32750
   Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
   GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639
   Haanen JBAG, 2007, NAT MED, V13, P248, DOI 10.1038/nm0307-248
   Habib M, 2007, J IMMUNOL, V178, P6700, DOI 10.4049/jimmunol.178.11.6700
   Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600
   Heymans S, 1999, NAT MED, V5, P1135
   HOLADAY BJ, 1993, J CLIN INVEST, V92, P2626, DOI 10.1172/JCI116878
   Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911
   Lima ID, 2012, AM J TROP MED HYG, V86, P99, DOI 10.4269/ajtmh.2012.10-0492
   Lorente L, 2011, CRIT CARE, V15, DOI 10.1186/cc10104
   Malik N, 1996, J IMMUNOL, V156, P3952
   Mathur RK, 2006, TRENDS PARASITOL, V22, P117, DOI 10.1016/j.pt.2006.01.003
   Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045
   McDyer JF, 1998, J IMMUNOL, V160, P1701
   Melo GD, 2011, VET J, V188, P243, DOI 10.1016/j.tvjl.2010.03.017
   Murray HW, 2000, J INFECT DIS, V182, P1497, DOI 10.1086/315890
   Murray HW, 2003, INFECT IMMUN, V71, P6453, DOI 10.1128/IAI.71.11.6453-6462.2003
   Murray HW, 2003, J INFECT DIS, V188, P458, DOI 10.1086/376510
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Olmo M, 2012, HIV MED, V13, P488, DOI 10.1111/j.1468-1293.2012.01000.x
   Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851
   Palombo D, 1999, J CARDIOVASC SURG, V40, P257
   Portillo JAC, 2007, IMMUNOBIOLOGY
   Rai AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031551
   Reichel CA, 2008, J LEUKOCYTE BIOL, V83, P864, DOI 10.1189/jlb.1007666
   Gutierrez FRS, 2008, J INFECT DIS, V197, P1468, DOI 10.1086/587487
   Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776
   Schulz A, 2003, J CLIN MICROBIOL, V41, P1529, DOI 10.1128/JCM.41.4.1529-1535.2003
   Sipsas NV, 2002, CLIN DIAGN LAB IMMUN, V9, P558, DOI 10.1128/CDLI.9.3.558-561.2002
   Subauste CS, 2009, SEMIN IMMUNOL, V21, P273, DOI 10.1016/j.smim.2009.06.003
   Subauste CS, 1999, J IMMUNOL, V162, P6690
   Sui Z, 2007, J IMMUNOL, V178, P3226, DOI 10.4049/jimmunol.178.5.3226
   Taylor JL, 2006, INFECT IMMUN, V74, P6135, DOI 10.1128/IAI.02048-05
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Tousoulis D, 2010, TRENDS CARDIOVAS MED, V20, P153, DOI 10.1016/j.tcm.2010.12.004
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
   Verma S, 2010, PLOS ONE, V5
NR 49
TC 14
Z9 14
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 19
PY 2013
VL 13
AR 331
DI 10.1186/1471-2334-13-331
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 194YN
UT WOS:000322668700001
PM 23870715
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, DT
   Bezerra, MM
   de Almeida, JAP
   Duthie, M
   Reed, S
   de Jesus, AR
AF de Oliveira, Daniela Teles
   Bezerra, Marilia Matos
   Pacheco de Almeida, Jose Antonio
   Duthie, Malcolm
   Reed, Steven
   de Jesus, Amelia Ribeiro
TI Neurological disability in leprosy: incidence and gender association in
   Sergipe, Brazil
SO GEOSPATIAL HEALTH
LA English
DT Article
DE Leprosy; epidemiology; neurological disability; Brazil
ID TUBERCULOSIS EPIDEMIOLOGY; RISK-FACTORS; DIAGNOSIS; NEUROPATHY
AB Leprosy remains a public health problem in many countries. The disease affects skin and peripheral nerves and can cause irreversible disabilities. In Brazil, the detection rate of new cases is 18.2/100,000 inhabitants and leprosy control is considered a priority in the state of Sergipe. Studies showing the epidemiological profile and geographical distribution of leprosy cases are needed for effective epidemiological control measures. The objective of this study was to assess the detection rate of new cases, the geographical distribution and association with gender and clinical forms in Sergipe. Data were obtained from the Brazilian Institute of Geography and Statistics and the Information System for Notifiable Diseases. Maps indicating the geographical distribution of leprosy cases and the degree of neurological disabilities of all municipalities of the state were created using Spring, version 5.1.8 and ArcGIS, version 9.3.1. Hyper-endemic leprosy municipalities exist in Sergipe, indicating that the disease remains a major public health problem. The leprosy cases were found to be in municipalities with a higher number of dwellings with nine people per house. A detection rate of 33.0/100,000 inhabitants was noted in 2005, followed by a progressive reduction in the number of new cases until 2010. However, in the same period, an increase of cases with neurological disability was observed. A significant association of males with the multi-bacillary form and neurological disability was observed. This predisposition to severe forms of leprosy in males may be due to a delay in diagnosis and treatment emphasising the need for special attention by the leprosy control programme.
C1 [de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, BR-49045100 Aracaju, Sergipe, Brazil.
   [de Oliveira, Daniela Teles] Univ Fed Sergipe, Dept Med, Univ Hosp, Lab Biol Mol, BR-49060100 Aracaju, Sergipe, Brazil.
   [Bezerra, Marilia Matos] Univ Fed Sergipe, Dept Geog, BR-49100000 Sao Cristovao, Sergipe, Brazil.
   [Pacheco de Almeida, Jose Antonio] Univ Fed Sergipe, Dept Geol, BR-49100000 Sao Cristovao, Sergipe, Brazil.
   [Duthie, Malcolm] Infectious Dis Res Inst, Seattle, WA 98104 USA.
   [Reed, Steven] CNPq, Inst Nacionais Ciencia & Tecnol, IInst Invest Imunol, BR-05403000 Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, Rua Claudio Batista,S-N Bairro Sanat, BR-49045100 Aracaju, Sergipe, Brazil.
EM jesus-amelia@uol.com.br
FU CNPq UniversalNational Council for Scientific and Technological
   Development (CNPq) [477935/2009-5]
FX Financial support from CNPq Universal, Process no 477935/2009-5; ARJ is
   a Scientist from CNPq.
CR Baboolal S, 2009, J CLIN MICROBIOL, V47, P1911, DOI 10.1128/JCM.00535-09
   Miranzi SDC, 2010, REV SOC BRAS MED TRO, V43, P62, DOI 10.1590/S0037-86822010000100014
   Costa ALF, 2002, 16 INT LEPR C SALV B
   Deepak Sunil, 2003, Indian J Lepr, V75, P127
   Dias A., 2007, Hansenologia Internationalis, V32, P9
   Dros J, 2009, ANN FAM MED, V7, P555, DOI 10.1370/afm.1016
   Garcia-Rodriguez JF, 2011, ENFERM INFEC MICR CL, V29, P502, DOI 10.1016/j.eimc.2011.03.005
   Teixeira MAG, 2010, REV SOC BRAS MED TRO, V43, P287, DOI 10.1590/S0037-86822010000300015
   Gomes FG, 2007, AN BRAS DERMATOL, V82
   Lana F. C. F., 2003, Hansenologia Internationalis, V28, P131
   Mastrangelo G, 2009, REV SOC BRAS MED TRO, V42, P629, DOI 10.1590/S0037-86822009000600003
   Alves CJM, 2010, REV SOC BRAS MED TRO, V43, P460, DOI 10.1590/S0037-86822010000400025
   Ministry of Health, 2010, SIT EP HANS BRAS
   MOCK BA, 1988, INFECT IMMUN, V56, P3316, DOI 10.1128/IAI.56.12.3316-3319.1988
   Moet FJ, 2004, LEPROSY REV, V75, P310
   Moschioni C, 2010, REV SOC BRAS MED TRO, V43, P19, DOI 10.1590/S0037-86822010000100005
   Pavani RAB, 2008, MEDICINA RIBEIRAO PR, V41, P188
   Penna GO, 2008, REV SOC BRAS MED TRO, V41, P575, DOI 10.1590/S0037-86822008000600006
   Pinzan CF, 2010, PLOS ONE, V21, P5
   Queiroz JW, 2010, AM J TROP MED HYG, V82, P306, DOI 10.4269/ajtmh.2010.08-0675
   Raposo MT, 2011, REV INST MED TROP SP, V53, P77, DOI 10.1590/S0036-46652011000200004
   Schuring RP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000283
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Travi BL, 2002, INFECT IMMUN, V70, P2288, DOI 10.1128/IAI.70.5.2288-2296.2002
   Van Brakel Wim H, 2004, Indian J Public Health, V48, P5
   van Brakel WH, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000212
   WHO, 2010, WKLY EPIDEMIOL REC, V35, P332
NR 28
TC 7
Z9 7
U1 0
U2 2
PU UNIV NAPLES FEDERICO II
PI NAPLES
PA FAC VET MED, DEP PATHOLOGY & ANIMAL HEALTH, VET PARASITOLOGY, VIA DELLA
   VETERINARIA 1, NAPLES, 80137, ITALY
SN 1827-1987
EI 1970-7096
J9 GEOSPATIAL HEALTH
JI Geospatial Health
PD SEP
PY 2012
VL 6
IS 3
SI SI
BP S125
EP S129
PG 5
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 011JC
UT WOS:000309159900016
PM 23032278
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Barboza, DM
   Zhang, C
   Santos, NC
   Silva, MMBL
   Rollemberg, CVV
   de Amorim, FJR
   Ueta, MT
   de Melo, CM
   de Almeida, JAP
   Jeraldo, VDS
   de Jesus, AR
AF Barboza, Delmany Moitinho
   Zhang, Cangjie
   Santos, Nathaly Cardoso
   Bezerra Lemos Silva, Marilia Matos
   Vieira Rollemberg, Carla Virginia
   Ramalho de Amorim, Fabio Jorge
   Ueta, Marlene Tiduko
   de Melo, Claudia Moura
   Pacheco de Almeida, Jose Antonio
   Sierpe Jeraldo, Veronica de Lourdes
   de Jesus, Amelia Ribeiro
TI Biomphalaria species distribution and its effect on human Schistosoma
   mansoni infection in an irrigated area used for rice cultivation in
   northeast Brazil
SO GEOSPATIAL HEALTH
LA English
DT Article
DE Biomphalaria glabrata; Biomphalaria straminea; Schistosoma mansoni;
   geographical information system; irrigation; system; natural water
   sources; Brazil
ID INTERMEDIATE HOST SNAILS
AB The role of irrigated areas for the spread of schistosomiasis is of worldwide concern. The aim of the present study was to investigate the spatial distribution of the intermediate snail host Biomphalaria in an area highly endemic for schistosomiasis due to Schistosoma mansoni, evaluating the relationship between irrigation and types of natural water sources on one hand, and the influence of place and time of water exposure on the intensity of human infection on the other. A geographical information system (GIS) was used to map the distribution of the intermediate snail hosts in Ilha das Flores, Sergipe, Brazil, combined with a clinical/epidemiological survey. We observed a direct correlation between the intensity of human infection with S. mansoni and irrigation projects. Malacological studies to identify snail species and infection rates showed that B. glabrata is the main species responsible for human schistosomiasis in the municipality, but that B. straminea also plays a role. Our results provide evidence for a competitive selection between the two snail species in rice fields with a predominance of B. glabrata in irrigation systems and B. straminea in natural water sources.
C1 [Barboza, Delmany Moitinho; Vieira Rollemberg, Carla Virginia; Ramalho de Amorim, Fabio Jorge; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-49045100 Aracaju, Sergipe, Brazil.
   [Zhang, Cangjie; de Melo, Claudia Moura; Sierpe Jeraldo, Veronica de Lourdes] Univ Tiradentes UNIT, Inst Tecnol & Pesquisa, Aracaju, Sergipe, Brazil.
   [Santos, Nathaly Cardoso; Bezerra Lemos Silva, Marilia Matos; Pacheco de Almeida, Jose Antonio] Univ Fed Sergipe, Dept Geol Posgrad Geografia, BR-49045100 Aracaju, Sergipe, Brazil.
   [Ueta, Marlene Tiduko] Univ Estadual Campinas, Dept Biol Anim, Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Rua Claudio Batista,S-N Bairro Sanatorio, BR-49045100 Aracaju, Sergipe, Brazil.
EM jesus-amelia@uol.com.br
RI Jeraldo, Veronica VL/M-7033-2017; de Melo, Claudia Moura/I-7764-2014;
   Ueta, Marlene Tiduko/E-1914-2013
OI Jeraldo, Veronica VL/0000-0001-9813-7969; de Melo, Claudia
   Moura/0000-0001-9331-003X; 
FU MS /CNPq/FAPITEC/ SE (PPSUS); CAPESCAPES
FX We thank the health agents, Jorge Feitosa and Edmilson N. dos Santos and
   the Coordinator of the Endemic Disease Control Programme, Mario C.
   Silva, the students Debora D. Barreto, Karina M. S. C. Pessoa, Nayanna
   M. N. Lessa, Cybele M. B. Santos and Cynthia C. G. Andrade. Financial
   support was from MS /CNPq/FAPITEC/ SE (PPSUS) and CAPES.
CR Amin AM, 1976, PROBLEMS EFFECTS SCH
   Barbosa C S, 1993, Cad Saude Publica, V9, P170, DOI 10.1590/S0102-311X1993000200008
   Barbosa F, 1985, CAD SAUDE PUBLICA, V1, P153
   BARBOSA F S, 1973, Malacologia, V14, P401
   Barbosa FS, 1995, TOPICOS MALACOLOGIA
   Barreto ML, 1982, THESIS U FEDERAL BAH
   Brazil, 2009, GUIA VIG EP
   Carmo E H, 1994, Cad Saude Publica, V10, P425, DOI 10.1590/S0102-311X1994000400002
   COELHO MARCELLO VASCONCELLOS, 1954, PUBL AVULSAS INST AGGEU MAGALHAES, V3, P39
   DESLANDES NEWTON, 1951, REV SERV ESP SAUDE PUBL, V4, P371
   FIGUEIREDO CCSB, 1989, MEM I OSWALDO CRUZ, V84, P383, DOI 10.1590/S0074-02761989000300014
   Gazzinelli A, 2007, GEOSPATIAL HEALTH, V2, P51, DOI 10.4081/gh.2007.254
   GUYARD A, 1979, ANN PARASIT HUM COMP, V54, P193, DOI 10.1051/parasite/1979542193
   Guyard A, 1982, P 8 INT MAL C BUD HU
   HUANG YX, 1992, ACTA TROP, V51, P175, DOI 10.1016/0001-706X(92)90037-X
   Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397
   LIMA VLC, 1995, CAD SAUDE PUBLICA, V11, P45
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   Martins Jr. Davi Félix, 2003, Cad. Saúde Pública, V19, P383, DOI 10.1590/S0102-311X2003000200005
   Mello DA, 1969, GAZ MED TROP, V21, P246
   Michelson E.H., 1979, Revista do Instituto de Medicina Tropical de Sao Paulo, V21, P246
   MOBARAK AB, 1982, AM J TROP MED HYG, V31, P87, DOI 10.4269/ajtmh.1982.31.87
   Paraense W.L., 1975, ARQUIVO MUSEU NACL R, V55, P105
   PARAENSE W. LOBATO, 1961, REV BRASIL BIOL, V21, P163
   POINTIER JP, 1982, MALACOLOGIA, V22, P395
   POINTIER JP, 1983, SYMBIOSES, V15, P85
   Scholte RGC, 2012, GEOSPATIAL HEALTH, V6, pS95
   SMITH N., 1988, DESENVOLVIMENTO DESI
   SOUZA C.P., 1990, MOLUSCOS INTERESSE P
   Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159
   Rollemberg CVV, 2011, REV SOC BRAS MED TRO, V44
   WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.2307/3001968
   World Health Organization, 2011, SCHIST
NR 33
TC 19
Z9 22
U1 0
U2 5
PU UNIV NAPLES FEDERICO II
PI NAPLES
PA FAC VET MED, DEP PATHOLOGY & ANIMAL HEALTH, VET PARASITOLOGY, VIA DELLA
   VETERINARIA 1, NAPLES, 80137, ITALY
SN 1827-1987
EI 1970-7096
J9 GEOSPATIAL HEALTH
JI Geospatial Health
PD SEP
PY 2012
VL 6
IS 3
SI SI
BP S103
EP S109
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 011JC
UT WOS:000309159900014
PM 23032275
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Castellucci, L
   Jamieson, SE
   Almeida, L
   Oliveira, J
   Guimaraes, LH
   Lessa, M
   Fakiola, M
   de Jesus, AR
   Miller, EN
   Carvalho, EM
   Blackwell, JM
AF Castellucci, Lea
   Jamieson, Sarra E.
   Almeida, Lucas
   Oliveira, Joyce
   Guimaraes, Luiz Henrique
   Lessa, Marcus
   Fakiola, Michaela
   de Jesus, Amelia Ribeiro
   Miller, E. Nancy
   Carvalho, Edgar M.
   Blackwell, Jenefer M.
TI Wound healing genes and susceptibility to cutaneous leishmaniasis in
   Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Leishmaniasis; Wound healing; TGFB pathway; CTGF; SMADs; FLI1
ID TGF-BETA; POLYMORPHISM; EXPRESSION; FLI1; ASSOCIATION; REPRESSION;
   CYTOKINES; GENOTYPE; RECEPTOR; MUCOSAL
AB Leishmania braziliensis causes cutaneous (CL) and mucosal (ML) leishmaniasis. In the mouse, Fli1 was identified as a gene influencing enhanced wound healing and resistance to CL caused by Leishmania major. Polymorphism at FLI1 is associated with CL caused by L braziliensis in humans, with an inverse association observed for ML disease. Here we extend the analysis to look at other wound healing genes, including CTGF, TGFB1, TGFBR1/2, SMADS 2/3/4/7 and FLI1, all functionally linked along with FLI1 in the TGF beta pathway. Haplotype tagging single nucleotide polymorphisms (tag-SNPs) were genotyped using Taqman technology in 325 nuclear families (652 CL cases; 126 ML cases) from Brazil. Robust case-pseudocontrol (CPC) conditional logistic regression analysis showed associations between CL and SNPs at CTGF (SNP rs6918698; CC genotype; OR 1.67; 95%Cl 1.10-2.54; P = 0.016), TGFBR2 (rs1962859; OR 1.50; 95%Cl 1.12-1.99; P=0.005), SMAD2 (rs1792658; OR 1.57; 95%Cl 1.04-2.38; P = 0.03), SMAD7 (rs4464148; AA genotype; OR 2.80; 95%Cl 1.00-7.87; P=0.05) and FLI1 (rs2071242; OR 1.60; 95%Cl 1.14-2.24; P = 0.005), and between ML and SNPs at SMAD3 (rs1465841; OR 2.15; 95%Cl 1.13-4.07; P = 0.018) and SMAD7 (rs2337107; TT genotype; OR 3.70; 95%Cl 1.27-10.7; P = 0.016). Stepwise logistic regression analysis showed that all SNPs associated with CL at FLI1, CTGF, TGFBR2, and FLI1 showed independent effects from each other, but SNPs at SMAD2 and SMAD7 did not add independent effects to SNPs from other genes. These results suggest that TGF beta signalling via SMAD2 is important in directing events that contribute to CL whereas signalling via SMAD3 is important in ML Both are modulated by the inhibitory SMAD7 that acts upstream of SMAD2 and SMAD3 in this signalling pathway. Along with the published FLI1 association, these data further contribute to the hypothesis that wound healing processes are important determinants of pathology associated with cutaneous forms of leishmaniasis. (C) 2012 Elsevier By. All rights reserved.
C1 [Jamieson, Sarra E.; Fakiola, Michaela; Blackwell, Jenefer M.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Subiaco, WA, Australia.
   [Castellucci, Lea; Almeida, Lucas; Oliveira, Joyce; Guimaraes, Luiz Henrique; Lessa, Marcus; de Jesus, Amelia Ribeiro; Carvalho, Edgar M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Fakiola, Michaela; Miller, E. Nancy; Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge, England.
   [Fakiola, Michaela; Miller, E. Nancy; Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England.
   [de Jesus, Amelia Ribeiro] Inst Invest Imunol, Sao Paulo, Brazil.
   [de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Aracaju, Brazil.
RP Blackwell, JM (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Subiaco, WA, Australia.
EM leacastel@hotmail.com; sjamieson@ichr.uwa.edu.au;
   lucasfedrigo@hotmail.com; joycemouraoliveira@yahoo.com.br;
   luizhenriquesg@yahoo.com.br; lessamm@terra.com.br; mf300@cam.ac.uk;
   jesus-amelia@uol.com.br; nm7@sanger.ac.uk; edgar@ufba.br;
   jmb37@cam.ac.uk
RI DoenAas Tropicais, Inct/K-2308-2013; Blackwell, Jenefer M/H-3015-2015;
   Henrique, Luiz/ABA-2621-2020
OI Fakiola, Michaela/0000-0001-9071-4709
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI 30639]; Wellcome TrustWellcome
   Trust; NIH/FICUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [1 D43 TW007127-01]; NIH/FIC in BrazilUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1 D43 TW007127-0-1]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW007127, D43TW007127, D43TW007127, D43TW007127, D43TW007127,
   D43TW007127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI076233,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI076233, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI076233,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   R01AI076233, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639] Funding Source: NIH RePORTER
FX We acknowledge the support of NIH Grant AI 30639 for the field work in
   Brazil, and The Wellcome Trust for supporting the laboratory work and
   statistical analyses carried out in the UK. L.C. was supported by
   NIH/FIC 1 D43 TW007127-01 for her period of stay in UK. J.O. was also
   supported by NIH/FIC 1 D43 TW007127-0-1 in Brazil.
CR Asano Y, 2010, J DERMATOL, V37, P54, DOI 10.1111/j.1346-8138.2009.00758.x
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x
   Blackwell JM, 2009, PARASITE IMMUNOL, V31, P254, DOI 10.1111/j.1365-3024.2009.01102.x
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Castellucci L, 2011, GENES IMMUN, V12, P589, DOI 10.1038/gene.2011.37
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Castellucci L, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-10
   Castes M, 1993, Biol Res, V26, P233
   Clayton D, 1999, AM J HUM GENET, V65, P1161, DOI 10.1086/302566
   Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307
   da Silva L, 2011, BBA-MOL CELL RES, V1813, P1863, DOI 10.1016/j.bbamcr.2011.06.018
   De Franco M, 2007, MAMM GENOME, V18, P263, DOI 10.1007/s00335-007-9012-x
   El-Safi S, 2006, CR BIOL, V329, P863, DOI 10.1016/j.crvi.2006.07.007
   Fonseca C, 2007, NEW ENGL J MED, V357, P1210, DOI 10.1056/NEJMoa067655
   Galindo M, 2001, ARTHRITIS RHEUM-US, V44, P1382, DOI 10.1002/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T
   Gressner OA, 2011, WORLD J GASTROENTERO, V17, P151, DOI 10.3748/wjg.v17.i2.151
   Hahm KB, 1999, NAT GENET, V23, P222
   Jirmanus L, 2012, AM J TROP MED HYG, V86, P426, DOI 10.4269/ajtmh.2012.11-0378
   Klass BR, 2009, POSTGRAD MED J, V85, P9, DOI 10.1136/pgmj.2008.069831
   Knapp M, 1999, AM J HUM GENET, V64, P1177, DOI 10.1086/302334
   Kopecki Z, 2011, J PATHOL, V225, P401, DOI 10.1002/path.2973
   Lipoldova M, 2006, NAT REV GENET, V7, P294, DOI 10.1038/nrg1832
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Mori R, 2011, EUR J IMMUNOL, V41, P3230, DOI 10.1002/eji.201141640
   Nakerakanti SS, 2006, J BIOL CHEM, V281, P25259, DOI 10.1074/jbc.M600466200
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Pohlers D, 2009, BBA-MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004
   Pradhan L, 2011, J SURG RES, V167, P336, DOI 10.1016/j.jss.2009.09.012
   Ramasawmy R, 2010, INFECT GENET EVOL, V10, P607, DOI 10.1016/j.meegid.2010.04.006
   Sakthianandeswaren A, 2005, P NATL ACAD SCI USA, V102, P15551, DOI 10.1073/pnas.0505630102
   Sakthianandeswaren A, 2010, INFECT IMMUN, V78, P2734, DOI 10.1128/IAI.00126-10
   Sakthianandeswaren A, 2009, TRENDS PARASITOL, V25, P383, DOI 10.1016/j.pt.2009.05.004
   Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
   Sambrook J., 1989, MOL CLONING LAB MANU
   Santibanez JF, 2011, CLIN SCI, V121, P233, DOI 10.1042/CS20110086
   Schriefer A, 2009, EMERG INFECT DIS, V15, P871, DOI 10.3201/eid1506.080406
   Thaler R, 2011, J BIOL CHEM, V286, P5578, DOI 10.1074/jbc.M110.166181
   Thuraisingam T, 2006, J INVEST DERMATOL, V126, P890, DOI 10.1038/sj.jid.5700182
   Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948
   Zaja-Milatovic S, 2008, HISTOL HISTOPATHOL, V23, P1399, DOI 10.14670/HH-23.1399
NR 41
TC 22
Z9 22
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2012
VL 12
IS 5
BP 1102
EP 1110
DI 10.1016/j.meegid.2012.03.017
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 948RF
UT WOS:000304519600026
PM 22554650
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Santos, PL
   Costa, RV
   Braz, JM
   Santos, LFVC
   Batista, AC
   Vasconcelos, CRO
   Rangel, MR
   de Jesus, AR
   de Moura, TR
   Leopoldo, PTG
   Almeida, RP
AF Santos, P. L.
   Costa, R. V.
   Braz, J. M.
   Santos, L. F. V. C.
   Batista, A. C.
   Vasconcelos, C. R. O.
   Rangel, M. R.
   Ribeiro de Jesus, A.
   de Moura, T. R.
   Leopoldo, P. T. G.
   Almeida, R. P.
TI Leishmania chagasi naturally resistant to nitric oxide isolated from
   humans and dogs with visceral leishmaniasis in Brazil
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Leishmania chagasi; Viability; Sodium nitrite; SNAP; Infection; Visceral
   leishmaniasis
ID TEGUMENTARY LEISHMANIASIS; GENETIC SUSCEPTIBILITY; VIANNIA BRAZILIENSIS;
   CYTOTOXICITY; AMAZONENSIS; AMASTIGOTES; ASSOCIATION; ENDEMICITY;
   MECHANISMS; ANTIMONY
AB Nitric oxide (NO) plays an important role as a leishmanicidal agent in murine macrophages. NO resistant Escherichia coli and Mycobacterium tuberculosis have been associated with poor outcomes of their resulting diseases. NO resistant Leishmania braziliensis has also been identified and exacerbates the clinical course of human leishmaniasis. We report, for the first time, natural resistance of Leishmania chagasi promastigotes to NO. These parasites were isolated from humans and dogs with visceral leishmaniasis. We also demonstrate that this resistance profile was associated with a greater survival capacity and a greater parasite burden in murine macrophages, independent of activation and after activation by IFN-gamma and LPS. 2012 Elsevier Inc. All rights reserved.
C1 [Santos, P. L.; Costa, R. V.; Braz, J. M.; Santos, L. F. V. C.; Batista, A. C.; Vasconcelos, C. R. O.; Rangel, M. R.; Ribeiro de Jesus, A.; de Moura, T. R.; Leopoldo, P. T. G.; Almeida, R. P.] Univ Fed Sergipe Aracaju, Aracaju, Sergipe, Brazil.
   [Ribeiro de Jesus, A.; Almeida, R. P.] Inst Invest Imunol, Sao Paulo, Brazil.
RP Almeida, RP (corresponding author), Univ Hosp, Ctr Ciencias Biol & Saude, Rua Claudio Batista S-N, BR-49060100 Aracaju, Sergipe, Brazil.
EM roquepacheco@uol.com.br
RI almeida, roque/F-5609-2012; , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434
FU CNPq - FAPITEC/SE (Programa de Nucleos de Excelencia - PRO-NEX)
   [019.203.02712/2009-8]; CNPq UniversalNational Council for Scientific
   and Technological Development (CNPq) [476263/2010-7]; CAPES (Project
   "Formacao e incentivo a pesquisa em parasitologia")
FX CNPq - FAPITEC/SE (Programa de Nucleos de Excelencia - PRO-NEX), Process
   no 019.203.02712/2009-8. CNPq Universal, Process no 476263/2010-7 and
   CAPES (Project "Formacao e incentivo a pesquisa em parasitologia"). RPA
   and ARJ are CNPq Scientists.
CR Alexander J, 1999, J CELL SCI, V112, P2993
   ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Blackwell JM, 2004, TRENDS PARASITOL, V20, P268, DOI 10.1016/j.pt.2004.04.003
   Blackwell JM, 1996, PARASITOLOGY, V112, pS67, DOI 10.1017/S0031182000076678
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CUPOLILLO E, 1994, AM J TROP MED HYG, V50, P296, DOI 10.4269/ajtmh.1994.50.296
   Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473
   Giudice A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-7
   GRAMICCIA M, 1992, ANN TROP MED PARASIT, V86, P613, DOI 10.1080/00034983.1992.11812717
   Holzmuller P, 2006, INFECT GENET EVOL, V6, P187, DOI 10.1016/j.meegid.2005.03.003
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   Krauspenhar Cristina, 2007, Cienc. Rural, V37, P907, DOI 10.1590/S0103-84782007000300052
   Lage RS, 2007, VET IMMUNOL IMMUNOP, V115, P135, DOI 10.1016/j.vetimm.2006.10.001
   le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953, DOI 10.1128/JCM.37.6.1953-1957.1999
   Mauel J, 1997, EXP PARASITOL, V87, P98, DOI 10.1006/expr.1997.4205
   Mohamed HS, 2003, GENES IMMUN, V4, P351, DOI 10.1038/sj.gene.6363977
   Mosmann T., 1983, J IMMUNOL METHODS, V65, P55, DOI DOI 10.1016/0022-1759(83)90303-4
   Reis AB, 2006, CLIN EXP IMMUNOL, V146, P303, DOI 10.1111/j.1365-2249.2006.03206.x
   Ritter U, 2004, MICROBES INFECT, V6, P559, DOI 10.1016/j.micinf.2004.02.008
   Romao PRT, 2006, BRAZ J MED BIOL RES, V39, P355, DOI 10.1590/S0100-879X2006000300006
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
   Sharma MC, 2000, ACTA TROP, V76, P195, DOI 10.1016/S0001-706X(00)00068-1
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   Wanasen N, 2007, INFECT IMMUN, V75, P2802, DOI 10.1128/IAI.00026-07
NR 25
TC 17
Z9 17
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD JUN 30
PY 2012
VL 27
IS 1
BP 67
EP 71
DI 10.1016/j.niox.2012.04.004
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 961CK
UT WOS:000305441300009
PM 22580230
DA 2020-12-08
ER

PT J
AU Castellucci, L
   Jamieson, SE
   Miller, EN
   de Almeida, LF
   Oliveira, J
   Magalhaes, A
   Guimaraes, LH
   Lessa, M
   Lago, E
   de Jesus, AR
   Carvalho, EM
   Blackwell, JM
AF Castellucci, L.
   Jamieson, S. E.
   Miller, E. N.
   de Almeida, L. F.
   Oliveira, J.
   Magalhaes, A.
   Guimaraes, L. H.
   Lessa, M.
   Lago, E.
   de Jesus, A. R.
   Carvalho, E. M.
   Blackwell, J. M.
TI FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in
   Brazil
SO GENES AND IMMUNITY
LA English
DT Article
DE FLI1; cutaneous leishmaniasis; wound healing; genetic susceptibility
ID TRANSCRIPTION FACTOR FAMILY; MUCOSAL LEISHMANIASIS;
   TRANSMISSION/DISEQUILIBRIUM TEST; VISCERAL LEISHMANIASIS; MAJOR
   INFECTION; MICE; GENES; IDENTIFICATION; EXPRESSION; ASSOCIATION
AB Mapping murine genes controlling cutaneous leishmaniasis (CL) identified Fli1 as a candidate influencing resistance to L. major and enhanced wound healing. We examine FLI1 as a gene controlling CL and mucosal leishmaniasis (ML) caused by L. braziliensis in humans. Intron 1 single nucleotide polymorphisms tagging promoter and enhancer elements were analysed in 168 nuclear families (250 CL; 87 ML cases) and replicated in 157 families (402 CL; 39 ML cases). Robust case-pseudocontrol logistic regression analysis showed association between allele C (odds ratio (OR) 1.65; 95% confidence interval 1.18-2.29; P = 0.003) of FLI1_rs7930515 and CL in the primary sample that was confirmed (OR 1.60; 95% confidence interval 1.10-2.33; P = 0.014) in the replication set (combined P = 1.8 x 10(-4)). FLI1_rs7930515 is in linkage disequilibrium with the functional GAn microsatellite in the proximal promoter. Haplotype associations extended across the enhancer, which was not polymorphic. ML associated with inverse haplotypes compared with CL. Wound healing is therefore important in CL, providing potential for therapies modulating FLI1. Genes and Immunity (2011) 12, 589-594; doi:10.1038/gene.2011.37; published online 2 June 2011
C1 [Jamieson, S. E.; Blackwell, J. M.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Subiaco, WA 6008, Australia.
   [Castellucci, L.; de Almeida, L. F.; Oliveira, J.; Magalhaes, A.; Guimaraes, L. H.; Lessa, M.; Lago, E.; de Jesus, A. R.; Carvalho, E. M.] Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Castellucci, L.; Jamieson, S. E.; Miller, E. N.; Blackwell, J. M.] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge Inst Med Res, Cambridge, England.
   [de Jesus, A. R.] Univ Sao Paulo, Fac Med, Inst Invest Imunol, Sao Paulo, Brazil.
   [de Jesus, A. R.] Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
RP Blackwell, JM (corresponding author), Univ Western Australia, Inst Child Hlth Res, Ctr Child Hlth Res, 100 Roberts Rd, Subiaco, WA 6008, Australia.
EM jblackwell@ichr.uwa.edu.au
RI Blackwell, Jenefer M/H-3015-2015; Henrique, Luiz/ABA-2621-2020; DoenAas
   Tropicais, Inct/K-2308-2013
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI 30639]; NIH/FICUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [1 D43 TW007127-01]; NIH/FIC
   in BrazilUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1 D43 TW007127-01]; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW007127, D43TW007127, D43TW007127,
   D43TW007127, D43TW007127, D43TW007127] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI076233, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI076233, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI076233,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER
FX We acknowledge the support of NIH Grant AI 30639 for the field work in
   Brazil, and The Wellcome Trust for supporting the laboratory work and
   statistical analyses carried out in the UK. LC was supported by NIH/FIC
   1 D43 TW007127-01 for her period of stay in UK. JO and AM were also
   supported by NIH/FIC 1 D43 TW007127-01 in Brazil.
CR Asano Y, 2010, J DERMATOL SCI, V59, P153, DOI 10.1016/j.jdermsci.2010.06.008
   Asano Y, 2010, J DERMATOL, V37, P54, DOI 10.1111/j.1346-8138.2009.00758.x
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Beebe AM, 1997, IMMUNITY, V6, P551, DOI 10.1016/S1074-7613(00)80343-X
   Blackwell JM, 2009, PARASITE IMMUNOL, V31, P254, DOI 10.1111/j.1365-3024.2009.01102.x
   Boeva V, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq217
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Castellucci L, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-10
   Castes M, 1993, Biol Res, V26, P233
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307
   D'Oliveira Junior Argemiro, 2002, Rev. Soc. Bras. Med. Trop., V35, P7, DOI 10.1590/S0037-86822002000100002
   Donaldson IJ, 2005, HUM MOL GENET, V14, P595, DOI 10.1093/hmg/ddi056
   El-Safi S, 2006, CR BIOL, V329, P863, DOI 10.1016/j.crvi.2006.07.007
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Havelkova H, 2006, GENES IMMUN, V7, P220, DOI 10.1038/sj.gene.6364290
   Knapp M, 1999, AM J HUM GENET, V64, P1177, DOI 10.1086/302334
   KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Lipoldova M, 2006, NAT REV GENET, V7, P294, DOI 10.1038/nrg1832
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   MOCK B, 1993, EUR J IMMUNOGENET, V20, P335, DOI 10.1111/j.1744-313X.1993.tb00153.x
   Morris EE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3189
   *NCBI, 2010, ENTR SNP
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Ramasawmy R, 2010, INFECT GENET EVOL, V10, P607, DOI 10.1016/j.meegid.2010.04.006
   ROBERTS M, 1993, EUR J IMMUNOGENET, V20, P349, DOI 10.1111/j.1744-313X.1993.tb00154.x
   Sakthianandeswaren A, 2005, P NATL ACAD SCI USA, V102, P15551, DOI 10.1073/pnas.0505630102
   Sakthianandeswaren A, 2010, INFECT IMMUN, V78, P2734, DOI 10.1128/IAI.00126-10
   Sakthianandeswaren A, 2009, TRENDS PARASITOL, V25, P383, DOI 10.1016/j.pt.2009.05.004
   Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
   Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076
   Svenson JL, 2010, GENES IMMUN, V11, P161, DOI 10.1038/gene.2009.73
   Thaler R, 2011, J BIOL CHEM, V286, P5578, DOI 10.1074/jbc.M110.166181
   Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948
NR 36
TC 19
Z9 19
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
EI 1476-5470
J9 GENES IMMUN
JI Genes Immun.
PD OCT
PY 2011
VL 12
IS 7
BP 589
EP 594
DI 10.1038/gene.2011.37
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 838ZI
UT WOS:000296332900012
PM 21633373
OA Bronze, Green Accepted
DA 2020-12-08
ER

PT J
AU Simon, M
   Scherlock, J
   Duthie, MS
   de Jesus, AR
AF Simon, Marise
   Scherlock, Jonnia
   Duthie, Malcolm S.
   de Jesus, Amelia Ribeiro
TI Clinical, Immunological, and Genetic Aspects in Leprosy
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE leprosy; clinical; immunopathogenesis; immunogenetics
ID NERVE FUNCTION IMPAIRMENT; SINGLE-NUCLEOTIDE POLYMORPHISMS;
   TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-2; MONOCYTE CHEMOATTRACTANT
   PROTEIN-1; CELLULAR IMMUNE-RESPONSE; REGULATORY T-CELL;
   MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; LEPROMATOUS LEPROSY
AB Leprosy is a chronic infection caused by Mycobacterium leprae. It affects the skin and peripheral nerves and can cause irreversible chronic disabilities. The worldwide registered number of cases in 2009 was 213,036. This review discusses clinical aspects of the disease, including leprosy reactions and neuronal damage, as well as immunological and immunogenetic aspects influencing disease susceptibility and outcome. The cardinal signs of leprosy are skin lesions with altered sensation, thickened peripheral nerves, and presence of alcohol acid-resistant bacilli in skin biopsy or lymph. Confirmatory examinations include (1) bacteriological examination, which allows patients' classification into two operational groups, multibacillary (MB) and paucibacillary (PB); and (2) histopathological examination, which permits stratification in different clinical forms. These clinical forms differ not only by histopathology but also according to the host's immune response to M. leprae. These forms comprise the extremes of (1) tuberculoid leprosy (TT), with a specific Th1 response and control of M. leprae multiplication; (2) lepromatous leprosy (LL) without Th1 response and preserved Th2 response; and (3) the interpolar clinical forms, borderline tuberculoid (BT), borderline borderline (BB), borderline lepromatous (BL), and indeterminate form (IL). Appropriate treatment is based on smear examination or the number of lesions at diagnosis. In the evolution of leprosy, acute inflammation, known as reactions, may occur during or after treatment. These reactions are classified into two main types: the type I reaction or reversal reaction (RR), and the type II reaction or erythema nodosum leprosum (ENL). The role of innate immune response to control the infection is supported by immunological and genetic studies. Drug Dev Res 72:509-527, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Simon, Marise; Scherlock, Jonnia; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Lab Biol Mol, Univ Hosp, BR-49060100 Aracaju, Sergipe, Brazil.
   [Duthie, Malcolm S.] Infect Dis Res Inst, Seattle, WA 98104 USA.
   [de Jesus, Amelia Ribeiro] CNPq, Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, BR-05403000 Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Dept Med, Lab Biol Mol, Univ Hosp, Rua Claudio Batista S-N, BR-49060100 Aracaju, Sergipe, Brazil.
EM jesus-amelia@uol.com.br
OI do Vale Simon, Marise/0000-0002-7466-2002
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   UniversalNational Council for Scientific and Technological Development
   (CNPq) [477935/2009-5]; FAPITEC/SE FUNTEC/CNPq (Programa de Nucleos de
   Excelencia, PRONEX)National Council for Scientific and Technological
   Development (CNPq) [12/2009, 019.203.02712/2009-8]; CNPqNational Council
   for Scientific and Technological Development (CNPq)
FX Grant sponsor: Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) Universal; Grant number: (Processo no) 477935/2009-5;
   Grant sponsor: FAPITEC/SE FUNTEC/CNPq 12/2009 (Programa de Nucleos de
   Excelencia, PRONEX); Grant number: 019.203.02712/2009-8; Grant sponsor:
   American Leprosy Missions, ARJ is a Scientist sponsored by CNPq.
CR Abulafia J, 1999, INT J DERMATOL, V38, P321, DOI 10.1046/j.1365-4362.1999.00650.x
   Aguillon JC, 2006, IMMUNOBIOLOGY, V211, P75, DOI 10.1016/j.imbio.2005.09.005
   Alcais A, 2005, CURR OPIN IMMUNOL, V17, P44, DOI 10.1016/j.coi.2004.11.006
   Alcais A, 2000, J INFECT DIS, V181, P302, DOI 10.1086/315174
   Alcais A, 2007, NAT GENET, V39, P517, DOI 10.1038/ng2000
   Franceschi DSA, 2009, INT J INFECT DIS, V13, P493, DOI 10.1016/j.ijid.2008.08.019
   Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999
   Alter A, 2008, HUM GENET, V123, P227, DOI 10.1007/s00439-008-0474-z
   Alter A, 2011, MAMM GENOME, V22, P19, DOI 10.1007/s00335-010-9287-1
   Amim L, 2008, MOL BIOL REP, V35, P563, DOI 10.1007/s11033-007-9123-1
   Andersson AK, 2005, INFECT IMMUN, V73, P3725, DOI 10.1128/IAI.73.6.3725-3733.2005
   [Anonymous], 2004, INT J LEPROSY, V72, P166
   Attia EAS, 2010, INT J DERMATOL, V49, P1152, DOI 10.1111/j.1365-4632.2010.04535.x
   Bakker MI, 2006, LEPROSY REV, V77, P48
   Banham AH, 2006, EUR J IMMUNOL, V36, P2832, DOI 10.1002/eji.200636459
   Belgaumkar VA, 2007, LEPROSY REV, V78, P223
   Goulart IMB, 2008, ARCH DERMATOL RES, V300, P269, DOI 10.1007/s00403-008-0857-y
   Berrington WR, 2007, IMMUNOL REV, V219, P167, DOI 10.1111/j.1600-065X.2007.00545.x
   Beutler B, 2003, ANNU REV PHARMACOL, V43, P609, DOI 10.1146/annurev.pharmtox.43.100901.135729
   Blackwell JM, 1999, IMMUNOL LETT, V65, P73, DOI 10.1016/S0165-2478(98)00127-8
   BLACKWELL JM, 1994, IMMUNOL LETT, V43, P99, DOI 10.1016/0165-2478(94)00161-8
   Blackwell JM, 2001, TRENDS MOL MED, V7, P521, DOI 10.1016/S1471-4914(01)02169-4
   Blackwell JM, 2001, LEPROSY REV, V72, P352
   Bochud PY, 2003, J IMMUNOL, V170, P3451, DOI 10.4049/jimmunol.170.7.3451
   BRITTON WJ, 1993, T ROY SOC TROP MED H, V87, P508, DOI 10.1016/0035-9203(93)90066-Y
   Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7
   Britton WJ, 1998, LEPROSY REV, V69, P225
   Carr JA, 1997, J VIROL, V71, P7799, DOI 10.1128/JVI.71.10.7799-7803.1997
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851
   Clementi M, 2006, REPROD TOXICOL, V21, P345, DOI 10.1016/j.reprotox.2005.08.006
   COOMBS RRA, 1971, CLIN SCI, V41, pP1
   COOPER CL, 1989, J EXP MED, V169, P1565, DOI 10.1084/jem.169.5.1565
   Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800
   de Jong R, 1998, SCIENCE, V280, P1435
   Brito MDD, 2008, REV SOC BRAS MED TRO, V41, P67, DOI 10.1590/S0037-86822008000700014
   de Moura RS, 2008, REV SOC BRAS MED TRO, V41, P11, DOI 10.1590/S0037-86822008000700004
   Diniz LM, 2010, CLIN EXP IMMUNOL, V161, P142, DOI 10.1111/j.1365-2249.2010.04164.x
   Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1
   Fedele G, 2008, J IMMUNOL, V181, P208, DOI 10.4049/jimmunol.181.1.208
   Ferwerda G, 2005, PLOS PATHOG, V1, P279, DOI 10.1371/journal.ppat.0010034
   Feuth M, 2008, LEPROSY REV, V79, P254
   Flesch IEA, 1997, J IMMUNOL, V159, P7
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem.20050126
   FOSS NT, 1993, BRAZ J MED BIOL RES, V26, P43
   Gafa V, 2006, INFECT IMMUN, V74, P1480, DOI 10.1128/IAI.74.3.1480-1489.2006
   Teixeira MAG, 2010, REV SOC BRAS MED TRO, V43, P287, DOI 10.1590/S0037-86822010000300015
   Gell P G, 1967, Br Med Bull, V23, P1
   Geluk A, 2006, HUM IMMUNOL, V67, P439, DOI 10.1016/j.humimm.2006.03.009
   GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403
   Goulart LR, 2006, FEMS IMMUNOL MED MIC, V48, P91, DOI 10.1111/j.1574-695X.2006.00128.x
   Goulart L, 2009, ARCH DERMATOL RES, V301, P123, DOI 10.1007/s00403-008-0917-3
   GULIA A, 2010, NEW INSIGHTS PATHOGE, P1, DOI DOI 10.3410/M2-30
   Hagge DA, 2009, AM J PATHOL, V174, P1379, DOI 10.2353/ajpath.2009.080550
   Harboe M, 2005, LEPROSY REV, V76, P5
   Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517
   Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593
   HOTTAT F, 1988, MED MICROBIOL IMMUN, V177, P33
   Huber S, 2010, BLOOD, V116, P3311, DOI 10.1182/blood-2010-02-271981
   Jamieson SE, 2004, GENES IMMUN, V5, P46, DOI 10.1038/sj.gene.6364029
   Jardim MR, 2007, ARQ NEURO-PSIQUIAT, V65, P969, DOI 10.1590/S0004-282X2007000600009
   Kahawita IP, 2008, T ROY SOC TROP MED H, V102, P329, DOI 10.1016/j.trstmh.2008.01.004
   Kang TJ, 2004, IMMUNOLOGY, V112, P674, DOI 10.1111/j.1365-2567.2004.01926.x
   KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993
   KAPLAN G, 1989, J EXP MED, V169, P893, DOI 10.1084/jem.169.3.893
   Kar H K, 2009, Indian J Lepr, V81, P205
   Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758
   Khader SA, 2008, CYTOKINE, V41, P79, DOI 10.1016/j.cyto.2007.11.022
   Khan N, 2008, CELL MICROBIOL, V10, P1711, DOI 10.1111/j.1462-5822.2008.01161.x
   Kim J, 2001, J IMMUNOL, V167, P779, DOI 10.4049/jimmunol.167.2.779
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106
   Koelewijn LF, 2003, LEPROSY REV, V74, P42
   Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864
   LANCIONI CL, 2010, INFECT IMMUN
   LIENHARDT C, 1994, LEPROSY REV, V65, P9
   LOCKWOOD D, 2007, CLIN EVID
   Lockwood DNJ, 2007, LEPROSY REV, V78, P317
   Lockwood DNJ, 2004, INT J EPIDEMIOL, V33, P269, DOI 10.1093/ije/dyh115
   Malhotra D, 2005, HUM GENET, V118, P295, DOI 10.1007/s00439-005-0042-8
   Massone C, 2010, AM J DERMATOPATH, V32, P251, DOI 10.1097/DAD.0b013e3181b7fc56
   McNicholl JM, 2000, ANNU REV PUBL HEALTH, V21, P15, DOI 10.1146/annurev.publhealth.21.1.15
   Meima A, 2008, TROP MED INT HEALTH, V13, P241, DOI 10.1111/j.1365-3156.2007.01996.x
   Mendonca VA, 2008, REV SOC BRAS MED TRO, V41, P95, DOI 10.1590/S0037-86822008000700019
   Mira MT, 2004, NATURE, V427, P636, DOI 10.1038/nature02326
   Mochizuki M, 1998, J IMMUNOL, V160, P60
   MODLIN RL, 1986, J IMMUNOL, V136, P883
   Montoya D, 2009, CELL HOST MICROBE, V6, P343, DOI 10.1016/j.chom.2009.09.002
   Moschioni C, 2010, REV SOC BRAS MED TRO, V43, P19, DOI 10.1590/S0037-86822010000100005
   Motta Ana Carolina F., 2010, Braz. Dent. J., V21, P158, DOI 10.1590/S0103-64402010000200012
   Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875
   O'Neal SE, 2007, J INFECT DIS, V195, P142, DOI 10.1086/509808
   Ohyama H, 2005, J CLIN PATHOL, V58, P740, DOI 10.1136/jcp.2004.023903
   Ohyama H, 2008, J INTERF CYTOK RES, V28, P563, DOI 10.1089/jir.2008.0133
   Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011
   OTTENHOFF THM, 1986, J EXP MED, V164, P1923, DOI 10.1084/jem.164.6.1923
   Pace L, 2010, J IMMUNOL, V184, P5969, DOI 10.4049/jimmunol.0900526
   Pacheco AG, 2008, HUM GENET, V123, P477, DOI 10.1007/s00439-008-0497-5
   Partida-Sanchez S, 1998, INT ARCH ALLERGY IMM, V116, P60, DOI 10.1159/000023926
   Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200
   Penna GO, 2008, REV SOC BRAS MED TRO, V41, P575, DOI 10.1590/S0037-86822008000600006
   Pereira AC, 2009, GENES IMMUN, V10, P174, DOI 10.1038/gene.2008.97
   Pimentel MIF, 2004, LEPROSY REV, V75, P143
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Plancoulaine S, 2002, Rev Med Liege, V57, P165
   Powrie F, 2004, ANN NY ACAD SCI, V1029, P132, DOI 10.1196/annals.1309.030
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2010, INFECT GENET EVOL, V10, P607, DOI 10.1016/j.meegid.2010.04.006
   Ranque B, 2007, CLIN INFECT DIS, V44, P33, DOI 10.1086/509923
   Rao PSSS, 2006, LEPROSY REV, V77, P25
   Richardus JH, 2004, INT J EPIDEMIOL, V33, P337, DOI 10.1093/ije/dyg225
   Richardus JH, 2003, LEPROSY REV, V74, P311
   RIDEEY D. S., 1966, International Journal of Leprosy, V34, P255
   RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54
   RIGBY WFC, 1992, ARTHRITIS RHEUM, V35, P110, DOI 10.1002/art.1780350117
   RIGBY WFC, 1990, CELL IMMUNOL, V125, P396, DOI 10.1016/0008-8749(90)90094-8
   ROCHE PW, 1991, LANCET, V338, P654, DOI 10.1016/0140-6736(91)91232-J
   Roche PW, 1997, INT J LEPROSY, V65, P450
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Sales AM, 2007, BRAZ J MED BIOL RES, V40, P243, DOI 10.1590/S0100-879X2006005000070
   Sapkota BR, 2010, HUM IMMUNOL, V71, P992, DOI 10.1016/j.humimm.2010.07.001
   Sarno EN, 2000, LEPROSY REV, V71, pS154
   Saunderson P, 2000, LEPROSY REV, V71, P285
   Schuring RP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000283
   Scollard DM, 2006, CLIN INFECT DIS, V43, pE19, DOI 10.1086/505222
   Scollard DM, 2008, SOUTH MED J, V101, P583, DOI 10.1097/SMJ.0b013e318172e077
   Scollard DM, 2008, ANN ACAD MED SINGAP, V37, P1
   Scollard DM, 2008, LEPROSY REV, V79, P242
   SCOLLARD DM, 1994, INT J LEPROSY, V62, P559
   Scollard DM, 1996, INT J LEPROSY, V64, P146
   SCOLLARD DM, 1992, CLIN IMMUNOL IMMUNOP, V63, P230, DOI 10.1016/0090-1229(92)90227-F
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962
   Sha Wei, 2010, Zhonghua Jie He He Hu Xi Za Zhi, V33, P534
   Shen JP, 2009, LEPROSY REV, V80, P164
   Siddaraju N, 2009, DIAGN CYTOPATHOL, V37, P355, DOI 10.1002/dc.21035
   Siddiqui MR, 2002, J INFECT DIS, V186, P260, DOI 10.1086/341204
   Sieling PA, 2008, J IMMUNOL, V180, P5833, DOI 10.4049/jimmunol.180.9.5833
   Silva EA, 2007, TROP MED INT HEALTH, V12, P1450, DOI 10.1111/j.1365-3156.2007.01951.x
   Simmons DP, 2010, J IMMUNOL, V185, P2405, DOI 10.4049/jimmunol.0904005
   SKAMENE E, 1994, IMMUNOBIOLOGY, V191, P451, DOI 10.1016/S0171-2985(11)80451-1
   Smith WCS, 2004, BMJ-BRIT MED J, V328, P1459, DOI 10.1136/bmj.38107.645926.AE
   Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2
   Tadesse A, 2006, IMMUNOPHARM IMMUNOT, V28, P431, DOI 10.1080/08923970600928023
   Tato CM, 2006, NATURE, V441, P166, DOI 10.1038/441166a
   Teixeira AC, 2008, REV SOC BRAS MED TRO, V41, P48, DOI 10.1590/S0037-86822008000700011
   Thompson C, 2004, CURR OPIN PHARMACOL, V4, P408, DOI 10.1016/j.coph.2004.05.001
   Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004
   TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008
   Uhlig HH, 2006, J IMMUNOL, V177, P5852, DOI 10.4049/jimmunol.177.9.5852
   Uitterlinden AG, 2004, GENE, V338, P143, DOI 10.1016/j.gene.2004.05.014
   Van Veen NHJ, 2006, LEPROSY REV, V77, P356
   van Veen NHJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004548
   Van Veen NHJ, 2008, LEPROSY REV, V79, P361
   VANBRAKEL WH, 1994, LEPROSY REV, V65, P190
   Vanderborght PR, 2007, GENES IMMUN, V8, P320, DOI 10.1038/sj.gene.6364390
   Varkevisser CM, 2009, LEPROSY REV, V80, P65
   Vejbaesya Sasijit, 2007, Journal of the Medical Association of Thailand, V90, P1188
   Felix JSV, 2009, SALUD PUBLICA MEXICO, V51, P59, DOI 10.1590/s0036-36342009000100011
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   Villarroel MF, 2007, LEPROSY REV, V78, P110
   Villarroel MF, 2007, LEPROSY REV, V78, P102
   Walker SL, 2008, LEPROSY REV, V79, P372
   Walker SL, 2007, LEPROSY REV, V78, P197
   *WHO, 2009, INDIAN J LEPR, V81, P43
   *WHO, 2006, LEPROSY REV, V77, pR9
   *WHO, 2006, LEPROSY REV, V77, pR10
   Wong SH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000979
   World Health Organization, 2006, Indian J Lepr, V78, P7
   Yoshida A, 2009, ANTICANCER RES, V29, P907
   Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753
   Zhang FR, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-133
NR 178
TC 5
Z9 5
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD SEP
PY 2011
VL 72
IS 6
SI SI
BP 509
EP 527
DI 10.1002/ddr.20457
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 824CU
UT WOS:000295180100010
DA 2020-12-08
ER

PT J
AU Costa, DL
   Carregaro, V
   Lima, DS
   Silva, NM
   Milanezi, CM
   Cardoso, CR
   Giudice, A
   de Jesus, AR
   Carvalho, EM
   Almeida, RP
   Silva, JS
AF Costa, Diego L.
   Carregaro, Vanessa
   Lima-Junior, Djalma S.
   Silva, Neide M.
   Milanezi, Cristiane M.
   Cardoso, Cristina R.
   Giudice, Angela
   de Jesus, Amelia R.
   Carvalho, Edgar M.
   Almeida, Roque P.
   Silva, Joao S.
TI BALB/c Mice Infected with Antimony Treatment Refractory Isolate of
   Leishmania braziliensis Present Severe Lesions due to IL-4 Production
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID REGULATORY T-CELLS; AMERICAN CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSES;
   IN-VIVO; VIANNIA BRAZILIENSIS; DENDRITIC CELLS; NITRIC-OXIDE; MAJOR
   INFECTION; CLINICAL CURE; TNF-ALPHA
AB Background: Leishmania braziliensis is the main causative agent of cutaneous leishmaniasis in Brazil. Protection against infection is related to development of Th1 responses, but the mechanisms that mediate susceptibility are still poorly understood. Murine models have been the most important tools in understanding the immunopathogenesis of L. major infection and have shown that Th2 responses favor parasite survival. In contrast, L. braziliensis-infected mice develop strong Th1 responses and easily resolve the infection, thus making the study of factors affecting susceptibility to this parasite difficult.
   Methodology/Principal Findings: Here, we describe an experimental model for the evaluation of the mechanisms mediating susceptibility to L. braziliensis infection. BALB/c mice were inoculated with stationary phase promastigotes of L. braziliensis, isolates LTCP393(R) and LTCP15171(S), which are resistant and susceptible to antimony and nitric oxide (NO), respectively. Mice inoculated with LTCP393(R) presented larger lesions that healed more slowly and contained higher parasite loads than lesions caused by LTCP15171(S). Inflammatory infiltrates in the lesions and production of IFN-gamma, TNF-alpha, IL-10 and TGF-beta were similar in mice inoculated with either isolate, indicating that these factors did not contribute to the different disease manifestations observed. In contrast, IL-4 production was strongly increased in LTCP393(R)-inoculated animals and also arginase I (Arg I) expression. Moreover, anti-IL-4 monoclonal antibody (mAb) treatment resulted in decreased lesion thickness and parasite burden in animals inoculated with LTCP393(R), but not in those inoculated with LTCP15171(S).
   Conclusion/Significance: We conclude that the ability of L. braziliensis isolates to induce Th2 responses affects the susceptibility to infection with these isolates and contributes to the increased virulence and severity of disease associated with them. Since these data reflect what happens in human infection, this model could be useful to study the pathogenesis of the L. braziliensis infection, as well as to design new strategies of therapeutic intervention.
C1 [Costa, Diego L.; Carregaro, Vanessa; Lima-Junior, Djalma S.; Milanezi, Cristiane M.; Silva, Joao S.] Univ Sao Paulo, Dept Biochem & Immunol, Ribeirao Preto Med Sch, BR-14049 Ribeirao Preto, Brazil.
   [Silva, Neide M.] Univ Fed Uberlandia, Inst Biomed Sci, BR-38400 Uberlandia, MG, Brazil.
   [Cardoso, Cristina R.] Univ Fed Triangulo Mineiro, Dept Biol Sci, Uberaba, Brazil.
   [Giudice, Angela; Carvalho, Edgar M.] Univ Fed Bahia, Prof Edgar Santos Univ Hosp, Serv Immunol, Salvador, BA, Brazil.
   [de Jesus, Amelia R.; Almeida, Roque P.] Univ Fed Sergipe, Dept Internal Med & Pathol, Aracaju, Brazil.
RP Costa, DL (corresponding author), Univ Sao Paulo, Dept Biochem & Immunol, Ribeirao Preto Med Sch, BR-14049 Ribeirao Preto, Brazil.
EM jsdsilva@fmrp.usp.br
RI Lima-Junior, Djalma/H-4833-2013; almeida, roque/F-5609-2012; Silva,
   Neide/C-7813-2013; SILVA, NEIDE MARIA/AAQ-7995-2020; Silva, Joao
   S/A-4484-2008; de Barros Cardoso, Cristina Ribeiro/L-8396-2017; Costa,
   Diego Luis/F-7168-2019; Carregaro, Vanessa/D-2913-2012
OI Lima-Junior, Djalma/0000-0002-2092-8047; Silva,
   Neide/0000-0002-3615-1340; Silva, Joao S/0000-0002-3410-3927; de Barros
   Cardoso, Cristina Ribeiro/0000-0002-6156-3144; Costa, Diego
   Luis/0000-0002-9440-2814; Carregaro, Vanessa/0000-0002-8435-0766
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)
FX This study was supported by the Brazilian National Research Council
   (CNPq) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP). JSS, EMC, ARJ and RPA are investigators from the Brazilian
   National Research Council ( CNPq). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Anderson P, 2000, ANN RHEUM DIS, V59, P3
   Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557
   Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Belkaid Y, 2007, NAT REV IMMUNOL, V7, P875, DOI 10.1038/nri2189
   BIRON CA, 1995, CURR OPIN IMMUNOL, V7, P485, DOI 10.1016/0952-7915(95)80093-X
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9
   Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x
   Brandao SP, 1999, T ROY SOC TROP MED H, V93, P488, DOI 10.1016/S0035-9203(99)90346-2
   Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980
   CARVALHO EM, 1994, ACTA TROP, V56, P315, DOI 10.1016/0001-706X(94)90103-1
   CARVALHO EM, 1995, AM J TROP MED HYG, V53, P273, DOI 10.4269/ajtmh.1995.53.273
   Castellano LR, 2009, HUM IMMUNOL, V70, P383, DOI 10.1016/j.humimm.2009.01.007
   CHILDS GE, 1984, ANN TROP MED PARASIT, V78, P25, DOI 10.1080/00034983.1984.11811769
   de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   de Oliveira CI, 2004, MICROBES INFECT, V6, P977, DOI 10.1016/j.micinf.2004.05.009
   de Souza-Neto SM, 2004, MEM I OSWALDO CRUZ, V99, P289, DOI 10.1590/S0074-02762004000300009
   DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Gamboa D, 2008, PARASITOLOGY, V135, P319, DOI 10.1017/S0031182007003848
   Giudice A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-7
   Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135
   Kopf M, 1996, J EXP MED, V184, P1127, DOI 10.1084/jem.184.3.1127
   LIEW FY, 1990, IMMUNOLOGY, V69, P570
   Lopez-Bravo M, 2008, IMMUNITY, V29, P343, DOI 10.1016/j.immuni.2008.08.008
   Matthews DJ, 2000, J IMMUNOL, V164, P1458, DOI 10.4049/jimmunol.164.3.1458
   McSorley S, 1996, CLIN DERMATOL, V14, P451, DOI 10.1016/0738-081X(96)00037-5
   Pereira JCM, 2010, EUR J MED CHEM, V45, P4180, DOI 10.1016/j.ejmech.2010.06.010
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298
   Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135
   Mohrs M, 1999, J IMMUNOL, V162, P7302
   MOURA TR, 2007, PLOS NEGLECT TROP D, V28, pE84
   Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476-5381.2009.00291.x
   NAGASE H, 2007, LEISHMANIA, V179, P2435
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Ritter U, 2008, MED MICROBIOL IMMUN, V197, P29, DOI 10.1007/s00430-007-0056-z
   Ritter U, 2007, MED MICROBIOL IMMUN, V196, P51, DOI 10.1007/s00430-006-0023-0
   Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Salimuddin, 1999, AM J PHYSIOL-ENDOC M, V277, pE110, DOI 10.1152/ajpendo.1999.277.1.E110
   SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49
   Sassi A, 1999, CLIN EXP IMMUNOL, V116, P127
   Sonoki T, 1997, J BIOL CHEM, V272, P3689, DOI 10.1074/jbc.272.6.3689
   Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656
   Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Vargas-Inchaustegui DA, 2009, INFECT IMMUN, V77, P2948, DOI 10.1128/IAI.00154-09
   Von Stebut E, 2007, EUR J DERMATOL, V17, P115, DOI 10.1684/ejd.2007.0122
   Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503
   Yurchenko E, 2006, J EXP MED, V203, P2451, DOI 10.1084/jem.20060956
NR 64
TC 14
Z9 14
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2011
VL 5
IS 3
AR e965
DI 10.1371/journal.pntd.0000965
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 742KI
UT WOS:000288940800005
PM 21390155
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Rollemberg, CVV
   Santos, CMB
   Silva, MMBL
   Souza, AMB
   da Silva, AM
   de Almeida, JAP
   de Almeida, RP
   de Jesus, AR
AF Vieira Rollemberg, Carla Virginia
   Bomfim Santos, Cybele Maria
   Bezerra Lemos Silva, Marilia Matos
   Barros Souza, Acacia Maria
   da Silva, Angela Maria
   Pacheco de Almeida, Jose Antonio
   de Almeida, Roque Pacheco
   de Jesus, Amelia Ribeiro
TI Epidemiological characteristics and geographical distribution of
   schistosomiasis and geohelminths, in the State of Sergipe, according to
   data from the Schistosomiasis Control Program in Sergipe
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
DE Schistosomiasis; Schistosoma mansoni; Epidemiology; Morbidity;
   Geoprocessing
ID MANSONI; NORTHEAST
AB Introduction: Schistosomiasis is endemic in Brazil, with high prevalence in the State of Sergipe, despite the existence of the Schistosomiasis Control Program (PCE). Methods: The data from Sergipe's PCE between 2005 and 2008 were surveyed. From the raw information, a database was created on a spreadsheet using the Access software. The frequency and geographic distribution of infections due to Schistosoma mansoni and other intestinal parasites were analyzed. These data were exported to the Spring 5.0.5 software for georeferencing and preparation of thematic maps of the spatial and temporal distribution according to year of evaluation. Results: In 2005, 13.6% (14,471/106,287) of the tests were positive for S. mansoni, 11.2% (16,196/145,069) in 2006, 11.8% (10,220/86,824) in 2007 and 10.6% (8,329/78,859) in 2008. Analysis on the maps showed that there was high prevalence of the disease in Sergipe, and particularly in the municipalities of Ilha das Flores, Santa Rosa de Lima, Santa Luzia do Itanhi and Sao Cristovao. Furthermore, we evaluated the association between the frequencies of these parasitic diseases and social and developmental indicators in the different municipalities, according to data from the Brazilian Institute for Geography and Statistics (IBGE) and the Department of Water Resources (SRH). We found that municipalities with schistosomiasis prevalence higher than 15% had lower coverage of sewage systems (hygiene index) (p = 0.05). Additionally, municipalities with hookworm prevalence higher than 10% had lower educational HDI (p = 0.04). Conclusions: The importance of greater control over environmental risk and educational factors needs to be emphasized in attempts to reduce the prevalence of these parasitic diseases.
C1 [Vieira Rollemberg, Carla Virginia; Bomfim Santos, Cybele Maria; da Silva, Angela Maria; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Aracaju, SE, Brazil.
   [Bezerra Lemos Silva, Marilia Matos; Barros Souza, Acacia Maria; Pacheco de Almeida, Jose Antonio] Univ Fed Sergipe, Dept Geog, Aracaju, SE, Brazil.
   Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Invest Imunol, Inst Nacionais Ciencia Tecnol, Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Hosp Univ, Lab Biol Mol, DME, UFS, Rua Claudio Batista S-N, BR-49060100 Aracaju, SE, Brazil.
EM jesus-amelia@uol.com.br
RI almeida, roque/F-5609-2012
CR BUTTERWORTH AE, 1988, PHILOS T ROY SOC B, V321, P495, DOI 10.1098/rstb.1988.0105
   Campos MR, 2002, REV SAUDE PUBL, V36, P69, DOI 10.1590/s0034-89102002000100011
   CHEEVER AW, 1992, MEM I OSWALDO CRUZ, V87, P337, DOI 10.1590/S0074-02761992000800054
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   COURA JR, 1992, MEM I OSWALDO CRUZ, V87, P175, DOI 10.1590/S0074-02761992000800027
   Coura JR, 2004, MEM I OSWALDO CRUZ, V99, P13, DOI 10.1590/S0074-02762004000900003
   Coura-Filho, 1997, Cad Saude Publica, V13, P245, DOI 10.1590/S0102-311X1997000200014
   Coutinho A. D., 1992, Cadernos de Saude Publica, V8, P302, DOI 10.1590/S0102-311X1992000300009
   DEJESUS AMR, 1993, EUR J IMMUNOL, V23, P152, DOI 10.1002/eji.1830230125
   do Amaral RS, 2006, MEM I OSWALDO CRUZ, V101, P79, DOI 10.1590/S0074-02762006000900012
   Drummond SC, 2006, MEM I OSWALDO CRUZ, V101, P37, DOI 10.1590/S0074-02762006000900007
   Geiger SM, 2008, ACTA TROP, V108, P118, DOI 10.1016/j.actatropica.2008.05.012
   Guimaraes ICS, 2006, REV SOC BRAS MED TRO, V39, P451, DOI 10.1590/S0037-86822006000500006
   Instituto Brasileiro de Geografia e Estatistica, 2010, IBGE CID
   JESUS AR, 2004, INFECT IMMUN, V72, P3391
   Katz N, 2000, Rev Soc Bras Med Trop, V33, P303, DOI 10.1590/S0037-86822000000300009
   Lambertucci J, 2005, DINAMICA DOENCAS INF, P931
   *MIN SAUD, 1998, CONTR ESQ BRAS DIR T
   PROGRAMA DAS NACOES UNIDAS PARA O DESENVOLVIMENTO-PNUD, 2000, ATL DES HUM
   RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106
   Rollemberg CVV, 2008, REV FAPESE, V4, P63
   SLEIGH AC, 1985, LANCET, V2, P63
   WALDMAN EA, 2000, VELHOS NOVOS MALES S, P195
   World Health Organization, 1985, CONTR SCHIST
NR 24
TC 3
Z9 3
U1 1
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JAN-FEB
PY 2011
VL 44
IS 1
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 723VT
UT WOS:000287536100020
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Souza, AS
   Giudice, A
   Pereira, JMB
   Guimaraes, LH
   de Jesus, AR
   de Moura, TR
   Wilson, ME
   Carvalho, EM
   Almeida, RP
AF Souza, Anselmo S.
   Giudice, Angela
   Pereira, Julia M. B.
   Guimaraes, Luis H.
   de Jesus, Amelia R.
   de Moura, Tatiana R.
   Wilson, Mary E.
   Carvalho, Edgar M.
   Almeida, Roque P.
TI Resistance of Leishmania (Viannia) braziliensis to nitric oxide:
   correlation with antimony therapy and TNF-alpha production
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID DISSEMINATED CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSE; TEGUMENTARY
   LEISHMANIASIS; CHAGASI PROMASTIGOTES; SODIUM STIBOGLUCONATE; MURINE
   MACROPHAGES; NEW-WORLD; DONOVANI; AMASTIGOTES; AMAZONENSIS
AB Background: Nitric oxide (NO) produced in macrophages plays a pivotal role as a leishmanicidal agent. A previous study has demonstrated that 20% of the L. (V.) braziliensis isolated from initial cutaneous lesions of patients from the endemic area of Corte de Pedra, Bahia, Brazil, were NO resistant. Additionally, 5 to 11% of the patients did not respond to three or more antimony treatments" (refractory patients). The aim of this study is to investigate if there is an association between the resistance of L. (V.) braziliensis to NO and nonresponsiveness to antimony therapy and cytokine production.
   Methods: We evaluated the in vitro toxicity of NO against the promastigotes stages of L. (V.) braziliensis isolated from responsive and refractory patients, and the infectivity of the amastigote forms of these isolates against human macrophages. The supernatants from Leishmania infected macrophage were used to measure TNF-alpha and IL-10 levels.
   Results: Using NaNO(2) (pH 5.0) as the NO source, L. (V.) braziliensis isolated from refractory patients were more NO resistant (IC50 = 5.8 +/- 4.8) than L. (V.) braziliensis isolated from responsive patients (IC50 = 2.0 +/- 1.4). Four isolates were selected to infect human macrophages: NO-susceptible and NO-resistant L. (V.) braziliensis isolated from responsive and refractory patients. NO-resistant L. (V.) braziliensis isolated from refractory patients infected more macrophages stimulated with LPS and IFN-gamma at 120 hours than NO-susceptible L. (V.) braziliensis isolated from refractory patients. Also, lower levels of TNF-alpha were detected in supernatants of macrophages infected with NO-resistant L. (V.) braziliensis as compared to macrophages infected with NO-susceptible L. (V.) braziliensis (p < 0.05 at 2, 24 and 120 hours), while no differences were detected in IL-10 levels.
   Conclusion: These data suggest that NO resistance could be related to the nonresponsiveness to antimony therapy seen in American Tegumentary Leishmaniasis.
C1 [de Jesus, Amelia R.; de Moura, Tatiana R.; Almeida, Roque P.] Univ Fed Sergipe, Aracaju, Sergipe, Brazil.
   [Souza, Anselmo S.; Giudice, Angela; Pereira, Julia M. B.; Guimaraes, Luis H.; Carvalho, Edgar M.] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   [Wilson, Mary E.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
   [Wilson, Mary E.] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.
   [Wilson, Mary E.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
   [Wilson, Mary E.] VA Med Ctr, Iowa City, IA USA.
RP Almeida, RP (corresponding author), Univ Fed Sergipe, Aracaju, Sergipe, Brazil.
EM roquepacheco@uol.com.br
RI , Tatiana/AAN-1194-2020; Gollob, Kenneth J/C-1341-2008; almeida,
   roque/F-5609-2012; Henrique, Luiz/ABA-2621-2020; Souza,
   Anselmo/D-3570-2014
OI , Tatiana/0000-0002-7442-4434; Gollob, Kenneth J/0000-0003-4184-3867;
   Wilson, Mary/0000-0001-8680-7275
FU Instituto de Investigacao em Imunologia; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [D43
   TW007127-01]; US NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI045540, AI067874,
   AI059451, R21 AI080801, P50 AI30693]; Merit ReviewUS Department of
   Veterans Affairs; OEF-OIF; US Department of Veterans' AffairsUS
   Department of Veterans Affairs; CNPqNational Council for Scientific and
   Technological Development (CNPq); FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007127,
   D43TW007127, D43TW007127, D43TW007127, D43TW007127, D43TW007127] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [S15AI030693, R01AI045540, R01AI067874,
   R01AI067874, R01AI045540, R01AI059451, R01AI045540, R01AI045540,
   R01AI045540, R01AI045540, R01AI059451, R01AI059451, R01AI045540,
   R01AI045540, R01AI067874, R01AI067874, R01AI059451, R01AI059451,
   R01AI067874, R01AI045540, R21AI080801, R21AI080801] Funding Source: NIH
   RePORTER
FX We are grateful to Elbe Myrtes Silva and Lucia Reis for secretarial
   assistance. This work was supported by Instituto de Investigacao em
   Imunologia (iii), NIH Tropical grants D43 TW007127-01 (RPA), US NIH
   grants AI045540 (MEW), AI067874 (MEW), AI059451 (MEW), R21 AI080801
   (MEW), and P50 AI30693 (EMC, ARJ, RPA, MEW) and a Merit Review (MEW) and
   OEF-OIF grant (MEW) from the US Department of Veterans' Affairs and
   CNPq. AS, ARJ, EMC and RPA are funded by CNPq.
CR Alexander J, 1999, J CELL SCI, V112, P2993
   ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6
   Arevalo J, 2007, J INFECT DIS, V195, P1846, DOI 10.1086/518041
   ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1768-1797.2006, 10.1128/AAC.50.5.1788-1797.2006]
   BELLEY A, 1995, PARASITOL TODAY, V11, P327, DOI 10.1016/0169-4758(95)80185-5
   BERMAN JD, 1989, AM J TROP MED HYG, V40, P159, DOI 10.4269/ajtmh.1989.40.159
   BERMAN JD, 1985, ANTIMICROB AGENTS CH, V27, P916, DOI 10.1128/AAC.27.6.916
   BERMAN JD, 1987, BIOCHEM PHARMACOL, V36, P197, DOI 10.1016/0006-2952(87)90689-7
   Bogdan C, 1998, INT J PARASITOL, V28, P121, DOI 10.1016/S0020-7519(97)00169-0
   Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x
   Brandonisio O, 2002, CLIN EXP MED, V2, P125, DOI 10.1007/s102380200017
   Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515
   CARVALHO EM, 1994, ACTA TROP, V56, P315, DOI 10.1016/0001-706X(94)90103-1
   CARVALHO LP, 2005, GAZ MED BAHIA, V1, P57
   Castes M, 1993, Biol Res, V26, P233
   CHANNON JY, 1984, IMMUNOLOGY, V53, P345
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   CUPOLILLO E, 1994, AM J TROP MED HYG, V50, P296, DOI 10.4269/ajtmh.1994.50.296
   Ettinger NA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000252
   Gantt KR, 2003, J IMMUNOL, V170, P2613, DOI 10.4049/jimmunol.170.5.2613
   Gaur U, 2009, EXP PARASITOL, V122, P182, DOI 10.1016/j.exppara.2009.03.014
   Genestra M, 2006, ARCH MICROBIOL, V185, P348, DOI 10.1007/s00203-006-0105-9
   Giudice A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-7
   GREEN SJ, 1994, IMMUNOL LETT, V43, P87, DOI 10.1016/0165-2478(94)00158-8
   GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687
   Holzmuller P, 2005, ANTIMICROB AGENTS CH, V49, P4406, DOI 10.1128/AAC.49.10.4406-4409.2005
   Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x
   Iyer JP, 2008, MOL MICROBIOL, V68, P372, DOI 10.1111/j.1365-2958.2008.06154.x
   Lemesre JL, 1997, EXP PARASITOL, V86, P58, DOI 10.1006/expr.1997.4151
   LIEW FY, 1990, IMMUNOLOGY, V69, P570
   LIEW FY, 1993, ADV PARASIT, V32, P161, DOI 10.1016/S0065-308X(08)60208-0
   LIEW FY, 1991, EUR J IMMUNOL, V21, P3009, DOI 10.1002/eji.1830211216
   Liew FY, 1997, PHILOS T R SOC B, V352, P1311, DOI 10.1098/rstb.1997.0115
   Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   MAUEL J, 1987, EUR J IMMUNOL, V17, P203, DOI 10.1002/eji.1830170209
   MAUEL J, 1991, RES IMMUNOL, V142, P577, DOI 10.1016/0923-2494(91)90106-S
   MAUELS J, 1991, RES IMMUNOL, V142, P593
   Miller MA, 2000, J BIOL CHEM, V275, P33883, DOI 10.1074/jbc.M003671200
   MURRAY HW, 1982, J IMMUNOL, V129, P351
   NELSON BJ, 1991, J IMMUNOL, V146, P1849
   Olivier M, 2005, CLIN MICROBIOL REV, V18, P293, DOI 10.1128/CMR.18.2.293-305.2005
   Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705
   Rich EA, 1997, TUBERCLE LUNG DIS, V78, P247, DOI 10.1016/S0962-8479(97)90005-8
   Roberts SC, 2004, J BIOL CHEM, V279, P23668, DOI 10.1074/jbc.M402042200
   Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P2064, DOI 10.1128/AAC.45.7.2064-2069.2001
   STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783
   Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505
   WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994
   ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461
NR 53
TC 39
Z9 39
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 15
PY 2010
VL 10
AR 209
DI 10.1186/1471-2334-10-209
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 666RZ
UT WOS:000283138000002
PM 20633260
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ramasawmy, R
   Menezes, E
   Magalhaes, A
   Oliveira, J
   Castellucci, L
   Almeida, R
   Rosa, MEA
   Guimaraes, LH
   Lessa, M
   Noronha, E
   Wilson, ME
   Jamieson, SE
   Kalil, J
   Blackwell, JM
   Carvalho, EM
   de Jesus, AR
AF Ramasawmy, Rajendranath
   Menezes, Eliane
   Magalhaes, Andrea
   Oliveira, Joyce
   Castellucci, Lea
   Almeida, Roque
   Rosa, Maria Elisa A.
   Henrique Guimaraes, Luiz
   Lessa, Marcus
   Noronha, Elza
   Wilson, Mary E.
   Jamieson, Sarra E.
   Kalil, Jorge
   Blackwell, Jenefer M.
   Carvalho, Edgar M.
   Ribeiro de Jesus, Amelia
TI The-2518 bp promoter polymorphism at CCL2/MCP1 influences susceptibility
   to mucosal but not localized cutaneous leishmaniasis in Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Mucosal leishmaniasis; Genetic association; MCP-1; CCL2
ID PULMONARY TUBERCULOSIS; EXPRESSION; MCP-1; ASSOCIATION; INFECTION;
   RESPONSES; RECEPTOR; DISEASE; HUMANS; BAHIA
AB Mucosal leishmaniasis (ML) follows localized cutaneous leishmaniasis (CL) caused by Leishmania braziliensis. Proinflammatory responses mediate CL self-healing but are exaggerated in ML Proinflammatory monocyte chemoattractant protein 1 (MCP-1; encoded by CCL2) is associated with CL We explore its role in CL/ML through analysis of the regulatory CCL2 -2518 bp promoter polymorphism in CL/ML population samples and families from Brazil. Genotype frequencies were compared among ML/CL cases and control groups using logistic regression and the family-based association test (FBAT). MCP-1 was measured in plasma and macrophages. The GG recessive genotype at CCL2 -2518 bp was more common in patients with ML (N = 67) than in neighborhood control (NC; N = 60) subjects (OR 1.78; 95% Cl 1.01-3.14; P = 0.045), than in NC combined with leishmanin skin-test positive (N = 60) controls (OR 4.40; 95% CI 1.42-13.65; P = 0.010), and than in controls combined with CL (N = 60) patients (OR 2.78; 95% CI 1.13-6.85; P = 0.045). No associations were observed for CL compared to any groups. FBAT (91 ML and 223 CL cases in families) confirmed recessive association of ML with allele G (Z = 2.679; P = 0.007). Higher levels of MCP-1 occurred in plasma (P = 0.03) and macrophages (P < 0.0001) from GG compared to AA individuals. These results suggest that high MCP-1 increases risk of ML (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ramasawmy, Rajendranath; Menezes, Eliane; Magalhaes, Andrea; Oliveira, Joyce; Castellucci, Lea; Almeida, Roque; Rosa, Maria Elisa A.; Henrique Guimaraes, Luiz; Lessa, Marcus; Carvalho, Edgar M.; Ribeiro de Jesus, Amelia] Univ Fed Bahia, Salvador, BA, Brazil.
   [Ramasawmy, Rajendranath; Kalil, Jorge] Univ Sao Paulo, Lab Imunol InCor, BR-09500900 Sao Paulo, Brazil.
   [Ramasawmy, Rajendranath; Kalil, Jorge] Inst Invest Imunol, Sao Paulo, Brazil.
   [Almeida, Roque; Ribeiro de Jesus, Amelia] Univ Fed Sergipe, Aracaju, Brazil.
   [Noronha, Elza] Univ Fed Brasilia, Brasilia, DF, Brazil.
   [Wilson, Mary E.] Univ Iowa, Iowa City, IA USA.
   [Wilson, Mary E.] VA Med Ctr, Iowa City, IA USA.
   [Jamieson, Sarra E.; Blackwell, Jenefer M.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Subiaco, WA, Australia.
   [Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 0XY, England.
RP de Jesus, AR (corresponding author), HUPES, Serv Immunol, 5 Andar,Rua Joao das Botas S-N, Salvador, BA, Brazil.
EM jblackwell@ichr.uwa.edu.au; amelia.jesus@pq.cnpq.br
RI almeida, roque/F-5609-2012; Blackwell, Jenefer M/H-3015-2015; KALIL,
   JORGE/C-8029-2012; Ramasawmy, Rajendranath/V-4926-2019; Henrique,
   Luiz/ABA-2621-2020
OI KALIL, JORGE/0000-0001-8415-4274; Wilson, Mary/0000-0001-8680-7275
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P50 AI-30639, R03AI070909];
   NIH/FICUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [1 D43 TW007127-01, R01 AI076233, R01AI067874]; CNPqNational Council for
   Scientific and Technological Development (CNPq); VA Merit Review grantUS
   Department of Veterans Affairs; Wellcome TrustWellcome Trust; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW007127, D43TW007127, R03TW001369,
   D43TW007127, D43TW007127, D43TW007127, D43TW007127, R03TW001369,
   R03TW001369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI067874, R01AI048822,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, R03AI070909,
   R01AI067874, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI067874, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI048822, P50AI030639,
   P50AI030639, P50AI030639, R01AI048822, P50AI030639, P50AI030639,
   R01AI048822, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI067874, P50AI030639, R01AI076233,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, P50AI030639,
   R01AI076233, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI067874, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI048822, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R03AI070909, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI076233, P50AI030639] Funding
   Source: NIH RePORTER
FX We thank Ednaldo Lima do Lago and other staff at the Health Post of
   Corte de Pedra for helping with patient recruitment. We thank Paulo
   Machado and Albert Schriefer for help in diagnosis of patients. We thank
   Elbe M. Silva and Lucia Reis for secretarial assistance. This work was
   funded in part by NIH grants P50 AI-30639 and R03AI070909 (LC, EMC,
   MEW), NIH/FIC 1 D43 TW007127-01 (JO, AM), R01 AI076233 (JMB and MEW),
   R01AI067874 (JMB and MEW), CNPq (ARJ, RA, EMC), a VA Merit Review grant
   (MEW), and grants from The Wellcome Trust (JMB). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the NIAID or the National Institutes of Health.
CR Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   Antoniazi S, 2004, INFECT IMMUN, V72, P5168, DOI 10.1128/IAI.72.9.5168-5174.2004
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Bhattacharyya S, 2002, J INFECT DIS, V185, P1704, DOI 10.1086/340820
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007
   Cuba C. C., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P161, DOI 10.1590/S0037-86821984000400002
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem.20050126
   Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499
   Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D
   LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8
   Marsden PD, 1998, AM J TROP MED HYG, V59, P543, DOI 10.4269/ajtmh.1998.59.543
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ritter U, 2000, EUR J IMMUNOL, V30, P3111, DOI 10.1002/1521-4141(200011)30:11&lt;3111::AID-IMMU3111&gt;3.0.CO;2-O
   Ritter U, 1996, J INFECT DIS, V173, P699, DOI 10.1093/infdis/173.3.699
   ROSA AC, 1988, T ROY SOC TROP MED H, V82, P409, DOI 10.1016/0035-9203(88)90138-1
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
   Sambrook J, 1989, MOL CLONING LAB MANU
   Thye T, 2009, HUM MOL GENET, V18, P381, DOI 10.1093/hmg/ddn352
NR 29
TC 27
Z9 28
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2010
VL 10
IS 5
BP 607
EP 613
DI 10.1016/j.meegid.2010.04.006
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 614DP
UT WOS:000279035800003
PM 20430117
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Castellucci, L
   Jamieson, SE
   Miller, EN
   Menezes, E
   Oliveira, J
   Magalhaes, A
   Guimaraes, LH
   Lessa, M
   de Jesus, AR
   Carvalho, EM
   Blackwell, JM
AF Castellucci, Lea
   Jamieson, Sarra E.
   Miller, E. Nancy
   Menezes, Eliane
   Oliveira, Joyce
   Magalhaes, Andrea
   Guimaraes, Luiz Henrique
   Lessa, Marcus
   de Jesus, Amelia Ribeiro
   Carvalho, Edgar M.
   Blackwell, Jenefer M.
TI CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous
   leishmaniasis in Brazil: a case-control and family-based study
SO BMC MEDICAL GENETICS
LA English
DT Article
ID VISCERAL LEISHMANIASIS; FORMERLY NRAMP1; MUCOSAL LEISHMANIASIS;
   GENETIC-CONTROL; EXPRESSION; MICE; INFECTION; IDENTIFICATION;
   LOCALIZATION; ASSOCIATION
AB Background: L. braziliensis causes cutaneous (CL) and mucosal (ML) leishmaniasis. Wound healing neutrophil (PMN) and macrophage responses made following the bite of the vector sand fly contribute to disease progression in mice. To look at the interplay between PMN and macrophages in disease progression in humans we asked whether polymorphisms at genes that regulate their infiltration or function are associated with different clinical phenotypes. Specifically, CXCR1 (IL8RA) and CXCR2 (IL8RB) are receptors for chemokines that attract PMN to inflammatory sites. They lie 30-260 kb upstream of SLC11A1, a gene known primarily for its role in regulating macrophage activation, resistance to leishmaniasis, and wound healing responses in mice, but also known to be expressed in PMN, macrophages and dendritic cells.
   Methods: Polymorphic variants at CXCR1, CXCR2 and SLC11A1 were analysed using Taqman or ABI fragment separation technologies in cases (60 CL; 60 ML), unrelated controls (n = 120), and multicase families (104 nuclear families; 88 ML, 250 CL cases) from Brazil. Logistic regression analysis, family-based association testing (FBAT) and haplotype analysis (TRANSMIT) were performed.
   Results: Case-control analysis showed association between the common C allele (OR 2.38; 95% CI 1.23-4.57; P = 0.009) of CXCR1_rs2854386 and CL, supported by family-based (FBAT; Z score 2.002; P = 0.045) analysis (104 nuclear families; 88 ML, 250 CL cases). ML associated with the rarer G allele (Z score 1.999; P = 0.046). CL associated with a 3' insertion/deletion polymorphism at SLC11A1 (Z score 2.549; P = 0.011).
   Conclusions: The study supports roles for CXCR1 and SLC11A1 in the outcome of L. braziliensis infection in humans. Slc11a1 does not influence cutaneous lesion development following needle injection of Leishmania in mice, suggesting that its role here might relate to the action of PMN, macrophage and/or dendritic cells in the wound healing response to the sand fly bite. Together with the CXCR1 association, the data are consistent with hypotheses relating to the possible role of PMN in initiation of a lesion following the delivery of parasites via the sand fly bite. Association of ML with the rare derived G allele suggests that PMN also have an important positive role to play in preventing this form of the disease.
C1 [Castellucci, Lea; Jamieson, Sarra E.; Miller, E. Nancy; Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge, England.
   [Castellucci, Lea; Jamieson, Sarra E.; Miller, E. Nancy; Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England.
   [Castellucci, Lea; Menezes, Eliane; Oliveira, Joyce; Magalhaes, Andrea; Guimaraes, Luiz Henrique; Lessa, Marcus; de Jesus, Amelia Ribeiro; Carvalho, Edgar M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Jamieson, Sarra E.; Blackwell, Jenefer M.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Subiaco, WA, Australia.
   [de Jesus, Amelia Ribeiro] Inst Invest Imunol, Sao Paulo, Brazil.
   [de Jesus, Amelia Ribeiro] Univ Fed Sergipe Aracaju, Aracaju, SE, Brazil.
RP Blackwell, JM (corresponding author), Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge, England.
EM jmb37@cam.ac.uk
RI Blackwell, Jenefer M/H-3015-2015; Henrique, Luiz/ABA-2621-2020
FU NIH, BrazilUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI 30639, HC 1 D43 TW007127-01]; The
   Wellcome TrustWellcome Trust; FOGARTY INTERNATIONAL CENTERUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [D43TW007127, D43TW007127,
   D43TW007127, D43TW007127, D43TW007127, D43TW007127] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, R01AI076233, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI076233, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI076233,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639] Funding Source: NIH RePORTER
FX We acknowledge the support of NIH Grant AI 30639 for the field work in
   Brazil, and The Wellcome Trust for supporting the laboratory work and
   statistical analyses carried out in the UK. LC was supported by NIH/HC 1
   D43 TW007127-01 for her period of stay in UK. JO and AM were also
   supported by NIH/HC 1 D43 TW007127-01 in Brazil.
CR ALEXANDER J, 1986, LEISHMANIA TAXONOMIE, P185
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Blackwell JM, 2009, PARASITE IMMUNOL, V31, P254, DOI 10.1111/j.1365-3024.2009.01102.x
   Blackwell JM, 2001, CELL MICROBIOL, V3, P773, DOI 10.1046/j.1462-5822.2001.00150.x
   BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130
   Bucheton B, 2003, GENES IMMUN, V4, P104, DOI 10.1038/sj.gene.6363927
   Canonne-Hergaux F, 2002, BLOOD, V100, P268, DOI 10.1182/blood.V100.1.268
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Castes M, 1993, Biol Res, V26, P233
   Clayton D, 1999, AM J HUM GENET, V65, P1161, DOI 10.1086/302566
   El-Safi S, 2006, CR BIOL, V329, P863, DOI 10.1016/j.crvi.2006.07.007
   Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625
   Knapp M, 1999, AM J HUM GENET, V64, P1177, DOI 10.1086/302334
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D
   LIU J, 1995, AM J HUM GENET, V56, P845
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Mohamed HS, 2004, EUR J HUM GENET, V12, P66, DOI 10.1038/sj.ejhg.5201089
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Peters NC, 2009, CELL MICROBIOL, V11, P1290, DOI 10.1111/j.1462-5822.2009.01348.x
   ROBERTS M, 1989, INFECT IMMUN, V57, P875, DOI 10.1128/IAI.57.3.875-881.1989
   Sakthianandeswaren A, 2009, TRENDS PARASITOL, V25, P383, DOI 10.1016/j.pt.2009.05.004
   Sanchez-Robert E, 2005, J HERED, V96, P755, DOI 10.1093/jhered/esi111
   Sanchez-Robert E, 2008, VET RES, V39, DOI 10.1051/vetres:2008013
   Searle S, 1998, J CELL SCI, V111, P2855
   Stober CB, 2007, INFECT IMMUN, V75, P5059, DOI 10.1128/IAI.00153-07
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   Teixeira MJ, 2006, TRENDS PARASITOL, V22, P32, DOI 10.1016/j.pt.2005.11.010
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   Thuraisingam T, 2006, J INVEST DERMATOL, V126, P890, DOI 10.1038/sj.jid.5700182
   Weindl G, 2007, J CLIN INVEST, V117, P3664, DOI 10.1172/JCI28115
NR 32
TC 37
Z9 39
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JAN 20
PY 2010
VL 11
AR 10
DI 10.1186/1471-2350-11-10
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 557OT
UT WOS:000274679600001
PM 20089160
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   Menezes, EP
   Ramaswmy, R
   Fae, KC
   Borba, SC
   Oliveira, J
   Magalhaes, A
   Castellucci, L
   Guimaraes, LH
   Lessa, M
   Noronha, E
   Wilson, ME
   Jamieson, SE
   Bales, A
   Kalil, J
   Blackwell, JM
   Carvalho, EM
AF Jesus, Amelia R. de
   Menezes, Eliane P.
   Ramaswmy, Rajendranath
   Fae, Kellen C.
   Borba, Susan C.
   Oliveira, Joyce
   Magalhaes, Andrea
   Castellucci, Lea
   Guimaraes, Luiz H.
   Lessa, Marcus
   Noronha, Elza
   Wilson, Mary E.
   Jamieson, Sarra E.
   Bales, Ashlee
   Kalil, Jorge
   Blackwell, Jenefer M.
   Carvalho, Edgar M.
TI FUNCTIONAL VARIATIONS IN CANDIDATE GENES FROM INNATE IMMUNE RESPONSE
   (MCP-1 AND MBL2 GENES) ARE ASSOCIATED WITH MUCOSAL LEISHMANIASIS OUTCOME
   IN CORTE DE PEDRA, BAHIA, BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Jesus, Amelia R. de] Univ Fed Sergipe, Aracaju, SE, Brazil.
   [Menezes, Eliane P.; Ramaswmy, Rajendranath; Oliveira, Joyce; Magalhaes, Andrea; Castellucci, Lea; Guimaraes, Luiz H.; Lessa, Marcus; Carvalho, Edgar M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Fae, Kellen C.; Borba, Susan C.; Kalil, Jorge] State Univ Sao Paulo, Sao Paulo, Brazil.
   [Noronha, Elza] Fed Univ Brasilia, Brasilia, DF, Brazil.
   [Wilson, Mary E.; Bales, Ashlee] Univ Iowa, Iowa City, IA USA.
   [Wilson, Mary E.; Bales, Ashlee] VA Med Ctr, Iowa City, IA USA.
   [Jamieson, Sarra E.; Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Cambridge, England.
RI KALIL, JORGE/C-8029-2012; Henrique, Luiz/ABA-2621-2020
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 161
BP 48
EP 48
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644600162
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   Luna, T
   de Almeida, RP
   Machado, PRL
   Carvalho, EM
AF de Jesus, Amelia Ribeiro
   Luna, Tania
   de Almeida, Roque Pacheco
   Machado, Paulo Roberto Lima
   Carvalho, Edgar M.
TI Pentoxifylline down modulate in vitro T cell responses and attenuate
   pathology in Leishmania and HTLV-1 infections
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT 13th International Congress of Immunology
CY AUG 21-25, 2007
CL Rio de Janeiro, BRAZIL
DE pentoxifylline; HTLV-1; leishmaniasis; cutaneous leishmaniasis; mucosal
   leishmaniasis; immunotherapy
ID VIRUS TYPE-I; COLONY-STIMULATING FACTOR; AMERICAN CUTANEOUS
   LEISHMANIASIS; NF-KAPPA-B; GRANULOCYTE-MACROPHAGE; DOUBLE-BLIND; MUCOSAL
   LEISHMANIASIS; INTERFERON-ALPHA; VISCERAL LEISHMANIASIS; PENTAVALENT
   ANTIMONY
AB Tumor necrosis factor-alpha (TNF-alpha) is known to have numerous biological properties relating to inflammation. This cytokine participates in the tissue damage of chronic inflammatory, autoimmune and infectious diseases. Pentoxifylline is a methylxanthine that inhibits phosphodiesterase IV, which inhibits the degradation of the cAMP and prostanoids. The increased intracellular concentration of the cAMP leads to a negative regulation of NF-kappa B and NF-AT transcription factors and suppresses TNF-alpha production. This review describes studies that support evidences that TNF-alpha is involved in the pathogenesis of HTLV-1 associated myelopathy and of cutaneous and mucosal leishmaniasis. Additionally, it demonstrates the effect of pentoxifylline in vitro in inhibiting TNF-alpha. and IFN-gamma spontaneous production in PBMC from HTLV-1-infected patients, as well as its in vivo effect in inhibiting TNF-a in sera from mucosal leishmaniasis patients. Moreover, we review the results of clinical studies from the last 10 years using pentoxifylline to treat HTLV-1 associated myelopathy and cutaneous and mucosal leishmaniasis. (c) 2008 Elsevier B.V. All rights reserved.
C1 [de Jesus, Amelia Ribeiro; Luna, Tania; de Almeida, Roque Pacheco; Machado, Paulo Roberto Lima; Carvalho, Edgar M.] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, Aracaju, SE, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, 5 Andar,Rua Joao Botas S-No, BR-40110160 Salvador, BA, Brazil.
EM edgar@ufba.br
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; KALIL, JORGE/C-8029-2012;
   almeida, roque/F-5609-2012
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; KALIL,
   JORGE/0000-0001-8415-4274; 
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   Almeida RP, 2005, AM J TROP MED HYG, V73, P79, DOI 10.4269/ajtmh.2005.73.79
   AMVROSIEVA TV, 1993, VOP VIRUSOL+, V38, P230
   ANTONELLI LR, 2005, IMMUNOL LETT, V2
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Araujo A. Q.-C., 1993, Acta Neurologica Scandinavica, V88, P59
   ARAUJO AD, 1995, J NEUROL SCI, V129, P147
   ARDIZZOIA A, 1993, SUPPORT CARE CANCER, V1, P331, DOI 10.1007/BF00364972
   Azimi N, 2001, P NATL ACAD SCI USA, V98, P14559, DOI 10.1073/pnas.251540598
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Bafica A, 2003, INT J DERMATOL, V42, P203, DOI 10.1046/j.1365-4362.2003.01868.x
   Becker I, 1999, PARASITOL RES, V85, P165, DOI 10.1007/s004360050529
   Ben Salah A, 2005, J INFECT DIS, V192, P1981, DOI 10.1086/498042
   BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Blackwell JM, 1997, PHILOS T R SOC B, V352, P1331, DOI 10.1098/rstb.1997.0118
   Blam ME, 2001, AM J GASTROENTEROL, V96, P1977, DOI 10.1016/S0002-9270(01)02494-7
   Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Cabrera-Gomez JA, 1999, REV NEUROLOGIA, V29, P1225, DOI 10.33588/rn.2912.98318
   Carod-Artal FJ, 2000, REV NEUROLOGIA, V31, P32, DOI 10.33588/rn.3101.2000004
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Castes Marianella, 1998, Acta Cientifica Venezolana, V49, P42
   Castro Neviton M., 2007, Int. braz j urol., V33, P238, DOI 10.1590/S1677-55382007000200016
   Castro NM, 2007, UROLOGY, V69, P813, DOI 10.1016/j.urology.2007.01.052
   Clerici M, 1997, J INFECT DIS, V175, P1210, DOI 10.1086/593570
   Cupolillo E, 1997, ANN TROP MED PARASIT, V91, P617, DOI 10.1080/00034989760716
   daCosta RM, 1997, AM J SURG, V173, P165, DOI 10.1016/S0002-9610(97)89589-X
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Desjeux P., 1992, World Health Statistics Quarterly, V45, P267
   Edlich Richard F, 2003, J Long Term Eff Med Implants, V13, P127, DOI 10.1615/JLongTermEffMedImplants.v13.i2.70
   Eigler A, 1997, IMMUNOL TODAY, V18, P487, DOI 10.1016/S0167-5699(97)01118-3
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Follador I, 1999, Rev Soc Bras Med Trop, V32, P497, DOI 10.1590/S0037-86821999000500005
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   FRANKE ED, 1990, ANN INTERN MED, V113, P934, DOI 10.7326/0003-4819-113-12-934
   Fujimoto T, 1999, INTERNAL MED, V38, P717, DOI 10.2169/internalmedicine.38.717
   GESSAIN A, 1985, LANCET, V2, P407
   GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993
   Guerreiro JB, 2006, CLIN EXP IMMUNOL, V145, P296, DOI 10.1111/j.1365-2249.2006.03150.x
   HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427
   Kollias G, 1999, ANN RHEUM DIS, V58, P32, DOI 10.1136/ard.58.2008.i32
   Kunkel S L, 1988, Methods Achiev Exp Pathol, V13, P240
   KURODA Y, 1992, ACTA NEUROL SCAND, V86, P82, DOI 10.1111/j.1600-0404.1992.tb08059.x
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   Machado P, 2002, EUR J DERMATOL, V12, P449
   Machado PRL, 2007, CLIN INFECT DIS, V44, P788, DOI 10.1086/511643
   Machuca A, 2001, VIRUS RES, V78, P93, DOI 10.1016/S0168-1702(01)00287-8
   Martin JA, 2003, AEROSPACE AM, V41, P6
   Nagai M, 2003, J NEUROVIROL, V9, P228, DOI 10.1080/13550280390194028
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nagai M, 2001, J INFECT DIS, V183, P197, DOI 10.1086/317932
   Nakagawa M, 1996, J NEUROVIROL, V2, P345, DOI 10.3109/13550289609146899
   Narikawa K, 2005, J NEUROIMMUNOL, V159, P177, DOI 10.1016/j.jneuroim.2004.10.011
   Navarro J, 1996, AIDS, V10, P469, DOI 10.1097/00002030-199605000-00004
   Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998
   Neuner P, 1997, IMMUNOLOGY, V90, P435, DOI 10.1111/j.1365-2567.1997.00435.x
   Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280260422668
   OSAME M, 1986, LANCET, V1, P1031
   Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Reilly MP, 2007, J INVEST MED, V55, P26, DOI 10.2310/6650.2007.06013
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   ROBSON M, 1994, EUR J CLIN MICROBIOL, V13, pS41, DOI 10.1007/BF01973601
   Rozieres A, 2006, ANN DERMATOL VENER, V133, P174, DOI 10.1016/S0151-9638(06)70873-0
   RYFFEL B, 1991, IMMUNOLOGY, V74, P446
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sadeghian G, 2006, INT J DERMATOL, V45, P819, DOI 10.1111/j.1365-4632.2006.02867.x
   Saito M, 2004, J INFECT DIS, V189, P29, DOI 10.1086/380101
   Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P1592, DOI 10.1053/gast.2002.33426
   Santos JB, 2004, J INFECT DIS, V190, P1793, DOI 10.1086/424848
   Santos SB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-7
   Santos SB, 2006, NEUROIMMUNOMODULAT, V13, P145, DOI 10.1159/000097259
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
   SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x
   Shirabe S, 1997, J NEUROL SCI, V151, P97, DOI 10.1016/S0022-510X(97)00074-9
   Staak K, 1997, BLOOD, V89, P3682, DOI 10.1182/blood.V89.10.3682.3682_3682_3690
   Suryaprasad AG, 2003, AUTOIMMUN REV, V2, P346, DOI 10.1016/S1568-9972(03)00048-X
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
   WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436
   Witkamp R, 2000, VET QUART, V22, P11, DOI 10.1080/01652176.2000.9695016
NR 96
TC 16
Z9 16
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2008
VL 8
IS 10
SI SI
BP 1344
EP 1353
DI 10.1016/j.intimp.2008.03.020
PG 10
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 350XC
UT WOS:000259385900007
DA 2020-12-08
ER

PT J
AU de Oliveira, EJ
   Kanamura, H
   Takei, K
   Hirata, RDC
   Valli, LCP
   Nguyen, NY
   Rodrigues, IDC
   de Jesus, AR
   Hirata, MH
AF de Oliveira, Edward Jose
   Kanamura, HerminiaYohko
   Kioko Takei
   Hirata, Rosario Dominguez Crespo
   Valli, Luiz Carlos Pedrosa
   Nguyen, Nga Yen
   Rodrigues, Izabel de Carvalho
   de Jesus, Amelia Ribeiro
   Hirata, Mario Hiroyuki
TI Synthetic peptides as an antigenic base in an ELISA for laboratory
   diagnosts of schistosomiasis mansoni
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Schistosoma mansoni; diagnosis; SeroLogy; ELISA; synthetic peptides;
   sensitivity and specificity
ID ANTIBODIES; INFECTION; SM31; CYSTICERCOSIS; PROTEINS; CHAGAS; SERA
AB A pool of five synthetic peptides was used as an antigenic base in an ELISA (ELISA-Pp) for laboratory diagnosis of Schistosoma mansoni. Serum samples were obtained from individuals with acute (n = 23) and chronic (n = 30) schistosomiasis, with other parasitoses (n = 39) or without parasitic infections (n = 100). ELISA-Pp was compared with other immunoenzymatic methods for detection of IgM (IgM-ELISA) or IgG (IgG-ELISA) as well as an immunofluorescence test for detection of IgM antibodies (IgM-IFT). The sensitivity and specificity of ELISA-Pp was 86.8% and 94.2% when tested on the schistosomiasis group and the non-schistosomiasis group, respectively. Comparison of ELISA-Pp with other serological methods resulted in K concordance indices varying from 0.59 to 0.75. Evaluation of anti-peptide IgG antibodies showed higher Levels in patients with acute compared with chronic schistosomiasis (P = 0.001). ELISA-Pp showed satisfactory sensitivity and high specificity and may constitute a potentially useful method for laboratory diagnosis of schistosomiasis mansoni. (c) 2007 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 [de Oliveira, Edward Jose; Kanamura, HerminiaYohko; Kioko Takei; Hirata, Rosario Dominguez Crespo; Hirata, Mario Hiroyuki] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin, BR-05508900 Sao Paulo, SP, Brazil.
   [Kanamura, HerminiaYohko] Univ Taubate, Inst Basico Biociencias, Taubate, SP, Brazil.
   [Valli, Luiz Carlos Pedrosa] Curso Farm, Fac Brasileira, Vitoria, ES, Brazil.
   [Nguyen, Nga Yen] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA.
   [Rodrigues, Izabel de Carvalho] Inst Evandro Chagas, Secretaria Vigilancia Saude MS, Belem, Para, Brazil.
   [de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Univ Hosp, Mol Biol Lab, Sergipe, Brazil.
RP de Oliveira, EJ (corresponding author), Avenida Lime,1715 Barro Preto, BR-30190002 Belo Horizonte, MG, Brazil.
EM edwardjo@cpqrr.fiocruz.br
RI Hirata, Mario Hiroyuki/C-9718-2013; Hirata, Rosario D C/A-7284-2011;
   Hirata, Mario/D-3593-2012
OI Hirata, Mario Hiroyuki/0000-0002-9521-7979; Hirata, Rosario D
   C/0000-0003-3073-5967; 
CR CARLIER Y, 1980, J IMMUNOL, V124, P2442
   da Silva RM, 1998, MEM I OSWALDO CRUZ, V93, P279, DOI 10.1590/S0074-02761998000700054
   de Jesus AR, 2002, J INFECT DIS, V185, P98, DOI 10.1086/324668
   de Oliveira EJ, 2006, MEM I OSWALDO CRUZ, V101, P355, DOI 10.1590/S0074-02762006000900058
   Oliveira Edward José de, 2003, Cad. Saúde Pública, V19, P255
   de Oliveira EJ, 2005, MEM I OSWALDO CRUZ, V100, P421, DOI 10.1590/S0074-02762005000400013
   Dean AG, 1995, EPI INFO VERSION 6
   DEELDER AM, 1980, Z PARASITENKD, V64, P65, DOI 10.1007/BF00927057
   El-Sayed LH, 1998, TROP MED INT HEALTH, V3, P721, DOI 10.1046/j.1365-3156.1998.00298.x
   Engels D, 1996, AM J TROP MED HYG, V54, P319, DOI 10.4269/ajtmh.1996.54.319
   Ferreira AW, 2001, J CLIN MICROBIOL, V39, P4390, DOI 10.1128/JCM.39.12.4390-4395.2001
   Ferrer E, 2003, VET PARASITOL, V111, P83, DOI 10.1016/S0304-4017(02)00327-8
   FLEISS AR, 1985, ARCHITECTURE CLIN RE, P185
   Hernandez M, 2000, IMMUNOL LETT, V71, P13, DOI 10.1016/S0165-2478(99)00166-2
   HOFFMANN WA, 1939, PUERTO RICO J PUBL H, V9, P281
   Kanamura Herminia Yohko, 1998, Revista do Instituto de Medicina Tropical de Sao Paulo, V40, P85, DOI 10.1590/S0036-46651998000200004
   KANAMURA HY, 1979, AM J TROP MED HYG, V28, P242, DOI 10.4269/ajtmh.1979.28.242
   KLINKERT MQ, 1991, TROP MED PARASITOL, V42, P319
   KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X
   Kongs A, 2001, TROP MED INT HEALTH, V6, P163, DOI 10.1046/j.1365-3156.2001.00687.x
   Noya O, 2001, PARASITE IMMUNOL, V23, P567, DOI 10.1046/j.1365-3024.2001.00414.x
   Valli Luiz Carlos Pedrosa, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P187, DOI 10.1590/S0036-46652007000300009
   Rabello A, 1999, MEM I OSWALDO CRUZ, V94, P77, DOI 10.1590/S0074-02761999000100016
   RUPPEL A, 1985, CLIN EXP IMMUNOL, V62, P499
   SILVA RM, 1992, REV BRAS PAT CLIN, V28, P39
   Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2
   Valli LCP, 1997, AM J TROP MED HYG, V57, P358, DOI 10.4269/ajtmh.1997.57.358
NR 27
TC 16
Z9 17
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD APR
PY 2008
VL 102
IS 4
BP 360
EP 366
DI 10.1016/j.trstmh.2007.11.008
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 289GR
UT WOS:000255043500013
PM 18314149
DA 2020-12-08
ER

PT J
AU Carvalho, EM
   Nascimento, MC
   Castro, N
   Muniz, ALA
   de Jesus, AR
   Porto, AF
   Siqueira, I
   Santos, SB
AF Carvalho, Edgar M.
   Nascimento, Marcia C.
   Castro, Neviton
   Muniz, Andre Luiz A.
   de Jesus, Amelia R.
   Porto, Aurelia F.
   Siqueira, Isadora
   Santos, Silvane B.
TI Immunological response and proviral load as factors influencing disease
   expression in HTLV-1
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Carvalho, Edgar M.; Nascimento, Marcia C.; Castro, Neviton; Muniz, Andre Luiz A.; de Jesus, Amelia R.; Porto, Aurelia F.; Siqueira, Isadora; Santos, Silvane B.] Univ Fed Bahia, Salvador, BA, Brazil.
RI de Siqueira, Isadora Cristina/R-9953-2016
OI de Siqueira, Isadora Cristina/0000-0002-2520-4099
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 283
BP 80
EP 80
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758200282
DA 2020-12-08
ER

PT J
AU Carvalho, LP
   Passos, S
   Bacellar, O
   Lessa, M
   Almeida, RP
   Magalhaes, A
   Dutra, WO
   Gollob, KJ
   Machado, P
   de Jesus, AR
AF Carvalho, L. P.
   Passos, S.
   Bacellar, O.
   Lessa, M.
   Almeida, R. P.
   Magalhaes, A.
   Dutra, W. O.
   Gollob, K. J.
   Machado, P.
   de Jesus, A. Ribeiro
TI Differential immune regulation of activated T cells between cutaneous
   and mucosal leishmaniasis as a model for pathogenesis
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE activated T cells; cutaneous leishmaniasis; cytokines; human
   leishmaniasis; mucosal leishmaniasis
ID IN-SITU EXPRESSION; VISCERAL LEISHMANIASIS; RESPONSE CHARACTERISTICS;
   CYTOTOXIC RESPONSES; IMMUNOREGULATION; INTERLEUKIN-10; IMMUNOTHERAPY;
   INTERFERON; CYTOKINES; RECEPTOR
AB Cutaneous (CL) and mucosal leishmaniasis (ML) are characterized by a predominant type 1 immune response (IFN-gamma and TNF-alpha production) and strong inflammatory response in the lesions with few parasites. This exacerbated type 1 response is more evident in ML as compared to CL. Our main hypothesis is that a differential immune regulation of T cell activation leads to over reactive T cells in ML. In the present study, we investigated immunological factors that could explain the mechanisms behind it by comparing some immune regulatory mechanisms between ML and CL patients: frequency of cells expressing co-stimulatory molecules, apoptotic markers, T cell activation markers; and ability of neutralizing antibodies to IL-2, IL-12 and IL-15 do down-regulate IFN-gamma production in leishmania antigen-stimulated peripheral blood mononuclear cells (PBMC). Interestingly, in CL anti-IL-2 and anti-IL-15 significantly suppressed antigen-specific IFN-gamma production, while in ML only anti-IL-2 suppressed IFN-gamma production. Finally, higher frequency of CD4+ T cells expressing CD28-, CD69+ and CD62L(low) were observed in ML as compared to CL. These data indicate that an exacerbated type 1 response in ML is differentially regulated and not appropriately down modulated, with increased frequencies of activated effectors T cells, maintaining the persistent inflammatory response and tissue damage observed in ML.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Immunol, Salvador, BA, Brazil.
   Univ Fed Minas Gerais, Dept Morphol, ICB, Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Dept Imunol & Bioquim, ICB, Belo Horizonte, MG, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Immunol, 5 Andar,Rua Joao Botas S-N,Canela 40110-160, Salvador, BA, Brazil.
EM amelia@ufba.br
RI Gollob, Kenneth J/C-1341-2008; almeida, roque/F-5609-2012; Carvalho,
   Lucas/J-6734-2012; Carvalho, Lucas/AAP-1844-2020; MACHADO, PAULO ROBERTO
   LIMA/AAP-2642-2020
OI Gollob, Kenneth J/0000-0003-4184-3867; MACHADO, PAULO ROBERTO
   LIMA/0000-0003-1894-6171
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW 007127, D43 TW007127-04, 1D43 TW 007127-01, D43 TW007127]
   Funding Source: Medline; NIAID NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P50 AI030639, AI
   30639, P50 AI030639-15] Funding Source: Medline; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW007127, D43TW007127, D43TW007127, D43TW007127, D43TW007127,
   D43TW007127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639] Funding Source: NIH RePORTER
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Azimi N, 1999, J IMMUNOL, V163, P4064
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Bottrel RLA, 2001, INFECT IMMUN, V69, P3232, DOI 10.1128/IAI.69.5.3232-3239.2001
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CONVIT J, 1989, J INFECT DIS, V160, P104, DOI 10.1093/infdis/160.1.104
   DaCruz AM, 1996, MEM I OSWALDO CRUZ, V91, P225, DOI 10.1590/S0074-02761996000200019
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Hasan MS, 2000, J INTERF CYTOK RES, V20, P119, DOI 10.1089/107999000312513
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   Lazarevic V, 2005, INFECT IMMUN, V73, P2910, DOI 10.1128/IAI.73.5.2910-2922.2005
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Louzir H, 1998, J INFECT DIS, V177, P1687, DOI 10.1086/515297
   Machado P, 2002, EUR J DERMATOL, V12, P449
   MELBY PC, 1994, INFECT IMMUN, V62, P837, DOI 10.1128/IAI.62.3.837-842.1994
   Melby PC, 1996, FEMS IMMUNOL MED MIC, V15, P101, DOI 10.1016/0928-8244(96)00047-8
   Murphy ML, 1998, J IMMUNOL, V161, P4153
   Murray HW, 2003, INFECT IMMUN, V71, P6453, DOI 10.1128/IAI.71.11.6453-6462.2003
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   Rocha PN, 1999, J INFECT DIS, V180, P1731, DOI 10.1086/315071
   Santos SB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-7
   SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675
   SCOTT P, 1989, IMMUNOL REV, V112, P161, DOI 10.1111/j.1600-065X.1989.tb00557.x
   SCOTT P, 1994, ANN NY ACAD SCI, V730, P84, DOI 10.1111/j.1749-6632.1994.tb44241.x
   Sestak K, 2003, INFECT IMMUN, V71, P4079, DOI 10.1128/IAI.71.7.4079-4086.2003
   Stuyt RJL, 2003, CYTOKINE, V21, P65, DOI 10.1016/S1043-4666(02)00501-X
   Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6
NR 32
TC 62
Z9 63
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD MAY
PY 2007
VL 29
IS 5
BP 251
EP 258
DI 10.1111/j.1365-3024.2007.00940.x
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 156JP
UT WOS:000245644300003
PM 17430548
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Giudice, A
   Camada, I
   Leopoldo, PTG
   Pereira, JMB
   Riley, LW
   Wilson, ME
   Ho, JL
   de Jesus, AR
   Carvalho, EM
   Almeida, RP
AF Giudice, Angela
   Camada, Ilza
   Leopoldo, Paulo T. G.
   Pereira, Julia M. B.
   Riley, Lee W.
   Wilson, Mary E.
   Ho, John L.
   Ribeiro de Jesus, Amelia
   Carvalho, Edgar M.
   Almeida, Roque P.
TI Resistance of Leishmania (Leishmania) amazonensis and Leishmania
   (Viannia) braziliensis to nitric oxide correlates with disease severity
   in Tegumentary Leishmaniasis
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID MURINE PERITONEAL-MACROPHAGES; NEW-WORLD LEISHMANIA; CUTANEOUS
   LEISHMANIASIS; VISCERAL LEISHMANIASIS; ALVEOLAR MACROPHAGES;
   SUPEROXIDE-DISMUTASE; REACTIVE NITROGEN; IN-VIVO; SYNTHASE; CHAGASI
AB Background: Nitric oxide (NO center dot) plays a pivotal role as a leishmanicidal agent in mouse macrophages. NO center dot resistant Escherichia coli and Mycobacterium tuberculosis have been associated with a severe outcome of these diseases.
   Methods: In this study we evaluated the in vitro toxicity of nitric oxide for the promastigote stages of Leishmania ( Viannia) braziliensis and Leishmania ( Leishmania) amazonensis parasites, and the infectivity of the amastigote stage for human macrophages. Parasites were isolated from patients with cutaneous, mucosal or disseminated leishmaniasis, and NO center dot resistance was correlated with clinical presentation.
   Results: Seventeen isolates of L. ( L.) amazonensis or L. ( V.) braziliensis promastigotes were killed by up to 8 mM of more of NaNO2 ( pH 5.0) and therefore were defined as nitric oxide-susceptible. In contrast, eleven isolates that survived exposure to 16 mM NaNO2 were defined as nitric oxide-resistant. Patients infected with nitric oxide-resistant Leishmania had significantly larger lesions than patients infected with nitric oxide-susceptible isolates. Furthermore, nitric oxide-resistant L. ( L.) amazonensis and L. ( V.) braziliensis multiplied significantly better in human macrophages than nitric oxide-susceptible isolates.
   Conclusion: These data suggest that nitric oxide-resistance of Leishmania isolates confers a survival benefit for the parasites inside the macrophage, and possibly exacerbates the clinical course of human leishmaniasis.
C1 Univ Fed Bahia, Inst Invest Imunol 3, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   Univ Fed Sergipe, Dept Fisiol, Aracaju, Sergipe, Brazil.
   Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA.
   Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.
   Cornell Univ, Weill Med Coll, Dept Med, Div Infect Dis & Internal Med, New York, NY USA.
RP Giudice, A (corresponding author), Univ Fed Bahia, Inst Invest Imunol 3, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
EM agiudice@ufba.br; imuno@ufba.br; pauloleopoldo@bol.com.br;
   juliambp@yahoo.com.br; lwriley@berkeley.edu; mary-wilson@uiowa.edu;
   jlho@med.cornell.ed; amelia@ufba.br; edgar@ufba.br; roque@ufba.br
RI almeida, roque/F-5609-2012
OI Wilson, Mary/0000-0001-8680-7275
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   R01AI032135, P50AI030639, P50AI030639, P50AI030639, R01AI032135,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI048822, P50AI030639, R01AI032135, P50AI030639,
   P50AI030639, R01AI045540, P50AI030639, P50AI030639, R01AI032135,
   P50AI030639, P50AI030639, R01AI032135, P50AI030639, P50AI030639,
   P50AI030639, R01AI045540, P50AI030639, R01AI045540, P50AI030639,
   R21AI032135, P50AI030639, R01AI045540, R01AI045540, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI032135, R01AI048822, R01AI045540,
   P50AI030639, P50AI030639, P50AI030639, R01AI032135, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI032135, P50AI030639, R01AI048822,
   P50AI030639, P50AI030639, R01AI032135, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI048822,
   R01AI032135, P50AI030639, R01AI045540, P50AI030639, P50AI030639,
   R01AI045540, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   R01AI048822, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI045540] Funding
   Source: NIH RePORTER; FIC NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R03 TW001369, TW01369] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50 AI030639, R01 AI045540,
   P50 AI-30639, AI30639, AI32135, AI45540, R01 AI032135, AI48822, R21
   AI032135, R01 AI048822] Funding Source: Medline
CR Alexander J, 1999, J CELL SCI, V112, P2993
   ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6
   ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328
   Balestieri FMP, 2002, MICROBES INFECT, V4, P23, DOI 10.1016/S1286-4579(01)01505-2
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Basu NK, 1997, FEMS MICROBIOL LETT, V156, P43, DOI 10.1016/S0378-1097(97)00401-1
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549
   Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9
   Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907
   Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x
   Castes M, 1993, Biol Res, V26, P233
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   CUPOLILLO E, 1994, AM J TROP MED HYG, V50, P296, DOI 10.4269/ajtmh.1994.50.296
   Cupolillo E, 1998, MEM I OSWALDO CRUZ, V93, P663, DOI 10.1590/S0074-02761998000500018
   Cupolilo SMN, 2003, HISTOL HISTOPATHOL, V18, P1059, DOI 10.14670/HH-18.1059
   Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4
   EVANS TG, 1993, J IMMUNOL, V151, P907
   Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Genestra M, 2006, ARCH MED RES, V37, P328, DOI 10.1016/j.arcmed.2005.07.011
   Genestra M, 2006, ARCH MICROBIOL, V185, P348, DOI 10.1007/s00203-006-0105-9
   GREEN SJ, 1990, J IMMUNOL, V145, P4290
   HANANO R, 1995, IMMUNOL LETT, V45, P23, DOI 10.1016/0165-2478(94)00193-U
   JARDIM A, 1995, BIOCHEM J, V305, P307, DOI 10.1042/bj3050307
   Kawakami K, 1997, CELL IMMUNOL, V180, P47, DOI 10.1006/cimm.1997.1166
   Kumar P, 2002, J MED MICROBIOL, V51, P832, DOI 10.1099/0022-1317-51-10-832
   Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4
   LIEW FY, 1990, IMMUNOLOGY, V69, P570
   LIEW FY, 1993, ADV PARASIT, V32, P161, DOI 10.1016/S0065-308X(08)60208-0
   Liew FY, 1997, PHILOS T R SOC B, V352, P1311, DOI 10.1098/rstb.1997.0115
   Louzir H, 1998, J INFECT DIS, V177, P1687, DOI 10.1086/515297
   Marsden P D, 1994, Rev Soc Bras Med Trop, V27, P93, DOI 10.1590/S0037-86821994000200007
   Mauel J, 1997, EXP PARASITOL, V87, P98, DOI 10.1006/expr.1997.4205
   MESHNICK SR, 1981, BIOCHEM BIOPH RES CO, V102, P970, DOI 10.1016/0006-291X(81)91633-8
   Miller MA, 2000, J BIOL CHEM, V275, P33883, DOI 10.1074/jbc.M003671200
   MURRAY HW, 1992, J INFECT DIS, V165, P513, DOI 10.1093/infdis/165.3.513
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293
   PAKIANATHAN DR, 1994, J PARASITOL, V80, P432, DOI 10.2307/3283414
   Paramchuk WJ, 1997, MOL BIOCHEM PARASIT, V90, P203, DOI 10.1016/S0166-6851(97)00141-2
   REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7
   Rockett KA, 1998, INFECT IMMUN, V66, P5314, DOI 10.1128/IAI.66.11.5314-5321.1998
   Romao PRT, 2006, BRAZ J MED BIOL RES, V39, P355, DOI 10.1590/S0100-879X2006000300006
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
   Scott P, 2003, IMMUNOL RES, V27, P489, DOI 10.1385/IR:27:2-3:489
   SCOTT P, 1991, J IMMUNOL, V147, P3149
   Vickers TJ, 2004, J BIOL CHEM, V279, P49003, DOI 10.1074/jbc.M407958200
   Vouldoukis I, 1997, EUR J IMMUNOL, V27, P860, DOI 10.1002/eji.1830270409
   VOULDOUKIS I, 1995, P NATL ACAD SCI USA, V92, P7804, DOI 10.1073/pnas.92.17.7804
   WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994
   Wilson ME, 2005, MICROB PATHOGENESIS, V38, P147, DOI 10.1016/j.micpath.2004.11.002
   Wilson ME, 1998, J IMMUNOL, V161, P6148
NR 54
TC 46
Z9 46
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD FEB 22
PY 2007
VL 7
AR 7
DI 10.1186/1471-2334-7-7
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA 142OS
UT WOS:000244660000001
PM 17316450
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT B
AU Menezes, E
   Oliveira, J
   Magalhaes, A
   Ramasawmy, R
   Castellucci, L
   Jamielsen, S
   Blackwell, JM
   Almeida, R
   Lessa, M
   Kalil, J
   Carvalho, EM
   de Jesus, AR
AF Menezes, E.
   Oliveira, J.
   Magalhaes, A.
   Ramasawmy, R.
   Castellucci, L.
   Jamielsen, S.
   Blackwell, J. M.
   Almeida, R.
   Lessa, M.
   Kalil, J.
   Carvalho, E. M.
   de Jesus, A. Ribeiro
BE Kalil, J
   CunhaNeto, E
   Rizzo, LV
TI Association between polymorphisms in genes that influences the immune
   response with cutaneous and mucosal leishmaniasis
SO 13TH INTERNATIONAL CONGRESS OF IMMUNOLOGY
LA English
DT Proceedings Paper
CT 13th International Congress of Immunology
CY AUG 21-25, 2007
CL Rio de Janeiro, BRAZIL
ID MUCOCUTANEOUS LEISHMANIASIS; PROMOTER POLYMORPHISM;
   RHEUMATOID-ARTHRITIS; CHAGASI INFECTION; SUSCEPTIBILITY; BRAZIL; IL-6;
   RESISTANCE; LEPROSY; REGION
AB We examined the association of candidate genes (IL-6, Lymphotoxin-a, and MCP-1) with leishmaniasis outcome using a case-control design and family-based association test (FBAT). The C allele of the IL-6 -174 G/C was more common in mucosal leishmaniasis (NIL) as compared to cutaneous leishmaniasis (CL) cases, leishmanin skin-test positive or neighbourhood controls (NC). FBAT analysis confirmed association between allele C and ML under both additive and dominant models. Lower IL-6 was measured in un-stimulated macrophages from CC compared to GG individuals, and after stimulation with soluble leishmania antigen. Higher frequency of allele G of MCP1-2518 A/G was found in NIL as compared to NC. The FBAT confirmed the association of G allele of MCP-1 with NIL under recessive model. This studies demonstrated associations of polymorphisms in genes that induce high inflammatory response with NIL, suggesting that they might influence leishmaniasis clinical outcome.
C1 [Menezes, E.; Oliveira, J.; Magalhaes, A.; Castellucci, L.; Almeida, R.; Lessa, M.; Carvalho, E. M.; de Jesus, A. Ribeiro] Univ Fed Bahia, Serv Imunol, Salvador, BA, Brazil.
   [Ramasawmy, R.; Kalil, J.] Univ Sao Paulo, InCor, Lab Imunol, Sao Paulo, Brazil.
   [Ramasawmy, R.; Kalil, J.; Carvalho, E. M.; de Jesus, A. Ribeiro] III, Sao Paulo, Brazil.
   [Jamielsen, S.; Blackwell, J. M.] Univ Cambridge, Sch Clin Med, Cambridge, England.
RP Menezes, E (corresponding author), Univ Fed Bahia, Serv Imunol, Salvador, BA, Brazil.
RI Ramasawmy, Rajendranath/V-4926-2019; almeida, roque/F-5609-2012; KALIL,
   JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU NIH-TMRCUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI-30639, AI-48822]; FAPESB;
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [1D43TW007127-01-NIH]
FX We thank Ednaldo Lima do Lago and other people from the Health Post of
   Corte de Pedra for helping patients recruitment. We thank Paulo Machado
   and Albert Schriefer that helped diagnosing the patients. We thank Elbe
   M. Silva and Lucia Reis for secretarial assistance. Financial Support:
   NIH-TMRC AI-30639 and AI-48822, FAPESB, CNPq, TGrant1D43TW007127-01-NIH.
CR Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Blackwell JM, 1999, PARASITOL TODAY, V15, P73, DOI 10.1016/S0169-4758(98)01355-6
   Blackwell JM, 1998, INT J PARASITOL, V28, P21, DOI 10.1016/S0020-7519(97)00175-6
   BLACKWELL JM, 1997, STUDY PHILOS T R S B, V352, P1331
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2005, SCAND J IMMUNOL, V61, P337, DOI 10.1111/j.1365-3083.2005.01581.x
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   FLORESVILLANUEV.PO, 2005, JEXP MED, V202, P1
   Hajeer AH, 1998, SCAND J RHEUMATOL, V27, P142
   Jeronimo SMB, 2000, CLIN INFECT DIS, V30, P608, DOI 10.1086/313697
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Pawlik A, 2005, SCAND J RHEUMATOL, V34, P109, DOI 10.1080/03009740510026373
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282
   Sambrook J., 1989, MOL CLONING LAB MANU, V2
   Sawczenko A, 2005, P NATL ACAD SCI USA, V102, P13260, DOI 10.1073/pnas.0503589102
   TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788
   Testa R, 2006, DIABETES RES CLIN PR, V71, P299, DOI 10.1016/j.diabres.2005.07.007
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
NR 23
TC 0
Z9 0
U1 0
U2 3
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 978-88-7587-379-0
PY 2007
BP 423
EP +
PG 3
WC Immunology
SC Immunology
GA BGZ88
UT WOS:000251729100076
DA 2020-12-08
ER

PT J
AU Carvalho, EM
   Bacellar, O
   Carvalho, LP
   Gollob, KJ
   Passos, ST
   Dutra, WO
   de Jesus, AR
AF Carvalho, Edgar M.
   Bacellar, Olivia
   Carvalho, Lucas P.
   Gollob, Kenneth J.
   Passos, Sara T.
   Dutra, Walderez O.
   de Jesus, Amelia R.
TI Impaired ability to down modulate the immune response
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RI Carvalho, Lucas/AAP-1844-2020
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2006
VL 75
IS 5
SU S
MA 451
BP 132
EP 132
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 109XW
UT WOS:000242343900452
DA 2020-12-08
ER

PT J
AU Castellucci, L
   Menezes, E
   Oliveira, J
   Magalhaes, A
   Guimaraes, LH
   Lessa, M
   Ribeiro, S
   Reale, J
   Noronha, EF
   Wilson, ME
   Duggal, P
   Beaty, TH
   Jeronimo, S
   Jamieson, SE
   Bales, A
   Blackwell, JM
   de Jesus, AR
   Carvalho, EM
AF Castellucci, Lea
   Menezes, Eliane
   Oliveira, Joyce
   Magalhaes, Andrea
   Guimaraes, Luiz Henrique
   Lessa, Marcus
   Ribeiro, Silvana
   Reale, Jeancarlo
   Noronha, Elza Ferreira
   Wilson, Mary E.
   Duggal, Priya
   Beaty, Terri H.
   Jeronimo, Selma
   Jamieson, Sarra E.
   Bales, Ashlee
   Blackwell, Jenefer M.
   Ribeiro de Jesus, Amelia
   Carvalho, Edgar M.
TI IL6-174 G/C promoter polymorphism influences susceptibility to mucosal
   but not localized cutaneous leishmaniasis in Brazil
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID REGULATORY T-CELLS; TRES-BRACOS; IL-6; GENOTYPE; DIFFERENTIATION;
   IDENTIFICATION; ASSOCIATION; DISEASE; ALPHA; BAHIA
AB Background. Mucosal leishmaniasis (ML) is associated with exaggerated tumor necrosis factor-alpha and interferon-gamma responses and tissue destruction. ML follows localized cutaneous leishmaniasis (CL) caused by Leishmania braziliensis infection. Interleukin (IL)-6 down-regulates T helper (Th) cell type 1 differentiation and drives Th2 cell differentiation. The IL6 -174 G/C polymorphism is associated with proinflammatory diseases and IL-6 regulation.
   Methods. The -174 G/C polymorphism was genotyped in population samples and families with CL and ML from Brazil. Genotype frequencies were compared among patients with ML, patients with CL, and 2 control groups by logistic regression and family-based association test (FBAT) analysis. IL-6 levels were measured in macrophages.
   Results. The C allele was more common in patients with ML than in patients with CL (odds ratio [OR], 2.55 [95% confidence interval {CI}, 1.32-4.91]; P = .005), than in patients who were leishmanin skin-test positive (OR, 2.23 [95% CI, 1.23-4.05]; P = .009), and than in neighborhood control subjects (OR, 2.47 [95% CI, 1.24-4.90]; P = .01). FBAT analysis confirmed an association between allele C and ML under both additive (P = .000017) and dominant (z = 4.325; P = .000015) models. Significantly lower levels of IL-6 were measured in unstimulated macrophages from CC individuals than from GG individuals (P = .003) as well as after stimulation with soluble leishmania antigen (P = .009).
   Conclusions. IL-6 may regulate type 1 proinflammatory responses, putting individuals with low macrophage IL-6 levels at increased risk for ML.
C1 Univ Fed Bahia, HUPES, Serv Imunol, Salvador, BA, Brazil.
   Univ Fed Rio Grande do Norte, Dept Bioquim, Ctr Biociencias, BR-59072970 Natal, RN, Brazil.
   Univ Brasilia, BR-70910900 Brasilia, DF, Brazil.
   Univ Iowa, Iowa City, IA 52242 USA.
   Vet Affairs Med Ctr, Iowa City, IA 52242 USA.
   NHGRI, Inherited Dis Res Branch, NIH, Baltimore, MD USA.
   Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
   Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 1TN, England.
RP de Jesus, AR (corresponding author), Univ Fed Bahia, HUPES, Serv Imunol, 5o Andar,Rua Joao Botas S-N, Salvador, BA, Brazil.
EM imuno@ufba.br
RI Blackwell, Jenefer M/H-3015-2015; Jeronimo, Selma/AAY-4033-2020;
   Henrique, Luiz/ABA-2621-2020
OI Jeronimo, Selma/0000-0002-4784-9904; Wilson, Mary/0000-0001-8680-7275
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [1 D43 TW007127-01] Funding Source: Medline; Intramural NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-48822, AI-30639, R01 AI048822] Funding Source: Medline; Wellcome
   TrustWellcome Trust Funding Source: Medline; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW007127, D43TW007127, D43TW007127, D43TW007127, D43TW007127,
   D43TW007127] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [Z01HG200327, Z01HG200327,
   Z01HG200327, Z01HG200327] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI048822,
   P50AI030639, P50AI030639, P50AI030639, R01AI048822, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, R01AI048822,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI048822, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI048822, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER
CR Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   BERMUDEZ LE, 1992, INFECT IMMUN, V60, P4245, DOI 10.1128/IAI.60.10.4245-4252.1992
   Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645
   Bittar MN, 2005, HEART SURG FORUM, V8, pE140, DOI 10.1532/HSF98.20041120
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2005, SCAND J IMMUNOL, V61, P337, DOI 10.1111/j.1365-3083.2005.01581.x
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   CASTES M, 1984, CLIN EXP IMMUNOL, V57, P279
   Castes M, 1993, Biol Res, V26, P233
   CUBA CAC, 1984, T ROY SOC TROP MED H, V78, P708, DOI 10.1016/0035-9203(84)90256-6
   de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128
   Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026
   Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Fife MS, 2005, GENES IMMUN, V6, P367, DOI 10.1038/sj.gene.6364186
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Grady WM, 2005, CLIN CANCER RES, V11, P3151, DOI 10.1158/1078-0432.CCR-05-0414
   HATZIGEORGIOU DE, 1993, J IMMUNOL, V151, P3682
   Herbert A, 2005, DIABETOLOGIA, V48, P1492, DOI 10.1007/s00125-005-1830-3
   Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Marsden PD, 1998, AM J TROP MED HYG, V59, P543, DOI 10.4269/ajtmh.1998.59.543
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Pawlik A, 2005, SCAND J RHEUMATOL, V34, P109, DOI 10.1080/03009740510026373
   REIN T, 1995, J BIOL CHEM, V270, P19643, DOI 10.1074/jbc.270.33.19643
   Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461
   ROSA AC, 1988, T ROY SOC TROP MED H, V82, P409, DOI 10.1016/0035-9203(88)90138-1
   SAMBROOK J, 1989, MOL CLONING LAB MAN, V2
   Sawczenko A, 2005, P NATL ACAD SCI USA, V102, P13260, DOI 10.1073/pnas.0503589102
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200
   Testa R, 2006, DIABETES RES CLIN PR, V71, P299, DOI 10.1016/j.diabres.2005.07.007
   VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253
   Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200
NR 38
TC 70
Z9 71
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 15
PY 2006
VL 194
IS 4
BP 519
EP 527
DI 10.1086/505504
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 064WO
UT WOS:000239121000016
PM 16845637
DA 2020-12-08
ER

PT J
AU Muniz, AL
   Rodrigues, W
   Santos, SB
   de Jesus, AR
   Porto, AF
   Castro, N
   Oliveira, J
   Almeida, JP
   Moreno-Carvalho, O
   Carvalho, EM
AF Muniz, Andre Luiz
   Rodrigues, Waldyr, Jr.
   Santos, Silvane B.
   de Jesus, Amelia R.
   Porto, Aurelia F.
   Castro, Neviton
   Oliveira, Jamary, Jr.
   Almeida, Juliana Passos
   Moreno-Carvalho, Otavio
   Carvalho, Edgar M.
TI Association of cytokines, neurological disability, and disease duration
   in HAM/TSP patients
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE human T-lymphotropic virus 1; nervous system diseases; cytokines;
   neurological disability
ID I-ASSOCIATED MYELOPATHY; VIRUS TYPE-I; CEREBROSPINAL-FLUID;
   IMMUNE-RESPONSES; INTERLEUKIN-6; INFECTION; CARRIERS
AB Objective: To identify clinical and immunological markers associated with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Method: 237 HTLV-1 infected individuals were clinically assessed. They were classified according to the Expanded Disability Status Scale (EDSS) and Osame's Motor Disability Score (OMDS). Cytokine levels were determined in HTLV-1 seropositive individuals. Results: 37 patients had HAM/TSP. There was a correlation between the degrees of disability assessed by both scales. There was also a correlation between the duration of HAM/TSP and the severity of disability assessed by either EDSS or OMDS. Higher levels of IFN-gamma were detected in unstimulated peripheral blood mononuclear cells (PBMC) from HAM/TSP patients as compared with HTLV-1 carriers. Conclusion: This study shows the validity of the neurological scales to classify the degree of neurological disability in HTLV-1 carriers and suggests a progressive behavior of HAM/TSP This study also shows that IFN-gamma in PBMC supernatants are markers of HAM/TSP.
C1 Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, BR-40110160 Salvador, BA, Brazil.
   SIMPEL, Lab Liquorol, Salvador, BA, Brazil.
RP Muniz, AL (corresponding author), Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, 5 Andar,Rua Joao Botas S-N, BR-40110160 Salvador, BA, Brazil.
EM muniz.a@uol.com.br
RI Oliveira-Filho, Jamary/B-6441-2016
OI Oliveira-Filho, Jamary/0000-0003-1915-0423
CR AndradaSerpa MJ, 1996, J NEUROL SCI, V139, P7, DOI 10.1016/S0022-510X(96)00025-1
   ARAUJO AD, 1995, J NEUROL SCI, V129, P147
   Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001
   CARVALHO EM, 1995, INTERLEUKIN 10, P91
   Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Hanon E, 2001, BLOOD, V98, P721, DOI 10.1182/blood.V98.3.721
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   Jacobson S, 1996, J ACQ IMMUN DEF SYND, V13, pS100, DOI 10.1097/00042560-199600001-00017
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Nagai M, 2001, CURR OPIN NEUROL, V14, P381, DOI 10.1097/00019052-200106000-00019
   NISHIMOTO N, 1990, J NEUROL SCI, V97, P183, DOI 10.1016/0022-510X(90)90217-B
   OHBO K, 1991, NEUROLOGY, V41, P594, DOI 10.1212/WNL.41.4.594
   OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191
   Porto AF, 2005, J INFECT DIS, V191, P612, DOI 10.1086/427560
   Porto AF, 2001, PARASITE IMMUNOL, V23, P503, DOI 10.1046/j.1365-3024.2001.00407.x
   Porto Maria Aurélia F., 2002, Rev. Soc. Bras. Med. Trop., V35, P641, DOI 10.1590/S0037-86822002000600016
   PuccioniSohler M, 1997, ARQ NEURO-PSIQUIAT, V55, P144, DOI 10.1590/S0004-282X1997000100024
   Santos SB, 2004, MEM I OSWALDO CRUZ, V99, P121, DOI 10.1590/S0074-02762004000900022
   Santos SB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-7
   Strle K, 2001, CRIT REV IMMUNOL, V21, P427
   ZANINOVIC V, 1987, LANCET, V2, P280
NR 23
TC 11
Z9 11
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2006
VL 64
IS 2A
BP 217
EP 221
DI 10.1590/S0004-282X2006000200009
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 050UC
UT WOS:000238113200009
PM 16791359
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Leopoldo, PTG
   Machado, PRL
   Almeida, RP
   Schriefer, A
   Giudice, A
   de Jesus, AR
   Ho, JL
   Guimaraes, LH
   Bacellar, O
   Carvalho, EM
AF Leopoldo, Paulo T. G.
   Machado, Paulo R. L.
   Almeida, Roque P.
   Schriefer, Albert
   Giudice, Angela
   de Jesus, Amelia Ribeiro
   Ho, John L.
   Guimaraes, Luiz Henrique
   Bacellar, Olivia
   Carvalho, Edgar M.
TI Differential effects of antigens from L-braziliensis isolates from
   disseminated and cutaneous leishmaniasis on in vitro cytokine production
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID VISCERAL LEISHMANIASIS; INTERFERON-GAMMA; VIANNIA; LYMPHOCYTES; DIFFUSE;
   FORM
AB Background: Disseminated leishmaniasis is an emerging infectious disease, mostly due to L. braziliensis, which has clinical and histopathological features distinct from cutaneous leishmaniasis.
   Methods: In the current study we evaluated the in vitro production of the cytokines IFN-gamma, TNF-alpha, IL-5 and IL-10 by peripheral blood mononuclear cells (PBMC) from 15 disseminated leishmaniasis and 24 cutaneous leishmaniasis patients upon stimulation with L. braziliensis antigens genotyped as disseminated leishmaniasis or cutaneous leishmaniasis isolates.
   Results: Regardless of the source of L. braziliensis antigens, PBMC from cutaneous leishmaniasis patients produced significantly higher IFN-gamma than PBMC from disseminated leishmaniasis patients. Levels of TNF-alpha by PBMC from cutaneous leishmaniasis patients were significantly higher than disseminated leishmaniasis patients only when stimulated by genotyped cutaneous leishmaniasis antigens. The levels of IL-5 and IL-10 production by PBMC were very low and similar in PBMCs from both disseminated leishmaniasis and cutaneous leishmaniasis patients. The immune response of each patient evaluated by the two L. braziliensis antigens was assessed in a paired analysis in which we showed that L. braziliensis genotyped as disseminated leishmaniasis isolate was more potent than L. braziliensis genotyped as cutaneous leishmaniasis isolate in triggering IFN-gamma and TNF-alpha production in both diseases and IL-5 only in cutaneous leishmaniasis patients.
   Conclusion: This study provides evidence that antigens prepared from genotypically distinct strains of L. braziliensis induce different degrees of immune response. It also indicates that both parasite and host play a role in the outcome of L. braziliensis infection.
C1 Univ Fed Bahia, Inst Invest Imunol, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   Univ Fed Sergipe, Dept Fisiol, Aracaju, Sergipe, Brazil.
   Univ Fed Bahia, Inst Ciencias Saude, Dept Biointeracao, Salvador, BA, Brazil.
   Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, New York, NY USA.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Inst Invest Imunol, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
EM pauloleopoldo@bol.com.br; prlmachado@uol.com.br; roque@ufba.br;
   aschriefer@hupes.ufba.br; agiudice@ufba.br; amelia@ufba.br;
   jlhjlho@med.cornell.edu; luizhenrique@ig.com.br; olivinha@ufba.br;
   edgar@ufba.br
RI Henrique, Luiz/ABA-2621-2020; almeida, roque/F-5609-2012; Schriefer,
   Albert/AAP-2765-2020; MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020
OI Schriefer, Albert/0000-0002-5496-6789; MACHADO, PAULO ROBERTO
   LIMA/0000-0003-1894-6171
CR AKUFFO JH, 1987, SCAND J IMMUNOL, V26, P717, DOI 10.1111/j.1365-3083.1987.tb02308.x
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1994, ACTA TROP, V56, P315, DOI 10.1016/0001-706X(94)90103-1
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CARVALHO EM, 1985, CYTOKINE, V12, P1228
   Castes Marianella, 1998, Acta Cientifica Venezolana, V49, P42
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   Cupolillo E, 2003, J CLIN MICROBIOL, V41, P3126, DOI 10.1128/JCM.41.7.3126-3132.2003
   Cupolillo E, 1997, ANN TROP MED PARASIT, V91, P617, DOI 10.1080/00034989760716
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Galvao C E, 1993, Rev Soc Bras Med Trop, V26, P121, DOI 10.1590/S0037-86821993000200008
   GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270
   HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1
   Saravia NG, 2002, AM J TROP MED HYG, V66, P738, DOI 10.4269/ajtmh.2002.66.738
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
   Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
   Vieira MGS, 2002, MEM I OSWALDO CRUZ, V97, P979, DOI 10.1590/S0074-02762002000700009
NR 25
TC 23
Z9 23
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 25
PY 2006
VL 6
AR 75
DI 10.1186/1471-2334-6-75
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 060UC
UT WOS:000238826100001
PM 16638143
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gaze, ST
   Dutra, WO
   Lessa, M
   Lessa, H
   Guimaraes, LH
   de Jesus, AR
   Carvalho, LP
   Machado, P
   Carvalho, EM
   Gollob, KJ
AF Gaze, ST
   Dutra, WO
   Lessa, M
   Lessa, H
   Guimaraes, LH
   de Jesus, AR
   Carvalho, LP
   Machado, P
   Carvalho, EM
   Gollob, KJ
TI Mucosal leishmaniasis patients display an activated inflammatory T-cell
   phenotype associated with a nonbalanced monocyte population
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CUTANEOUS LEISHMANIASIS; CHAGASIC PATIENTS; INTERFERON-GAMMA;
   IMMUNE-RESPONSES; ANTIGEN; INTERLEUKIN-10; MECHANISMS; EXPRESSION;
   RECEPTOR; DONOVANI
AB Leishmania braziliensis is a parasite that can induce at least two clinical forms of leishmaniasis in humans: cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML). In humans, the specific mechanisms that determine which form will develop following infection are not well established. In this study, peripheral blood mononuclear cells from 17 CL and 9 ML patients were compared both ex vivo and after culture with soluble leishmania antigen (SLA). Patients with ML presented a higher frequency of activated T cells as measured by ex vivo frequencies of CD4(+)CD69(+), CD4(+)CD28(-), CD4(+)CD62L(-) and CD8(+)CD69(+) than those with CL. Moreover, after stimulation with SLA, patients with ML presented a higher frequency of TNF-alpha-producing CD4(+) and CD14(+) cells than CL individuals. While CL patients displayed a positive correlation between the frequency of IL-10 and TNF-alpha-producing monocytes, the ML patients did not. This lack of a positive correlation between IL-10-producing and TNF-alpha-producing monocytes in ML patients could lead to a less controlled inflammatory response in vivo. These results corroborate with a model of an exacerbated, unregulated, immune response in ML patients and point to key immunomodulatory leucocyte populations and cytokine networks that may be involved in the development of immunopathology in ML patients.
C1 UFMG ICB, Dept Biochem Immunol, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Belo Horizonte, MG, Brazil.
   Univ Fed Bahia, Prof Edgard Santos Univ Hosp, Serv Immunol, Salvador, BA, Brazil.
RP Gollob, KJ (corresponding author), UFMG ICB, Dept Biochem Immunol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM kjgollob@icb.ufmg.br
RI Gollob, Kenneth J/C-1341-2008; Carvalho, Lucas/AAP-1844-2020; MACHADO,
   PAULO ROBERTO LIMA/AAP-2642-2020; Carvalho, Lucas/J-6734-2012; Gaze,
   Soraya/B-9419-2013; Gaze, Soraya T/B-3085-2013; Henrique,
   Luiz/ABA-2621-2020
OI Gollob, Kenneth J/0000-0003-4184-3867; MACHADO, PAULO ROBERTO
   LIMA/0000-0003-1894-6171; Gaze, Soraya/0000-0001-8600-2389; Gaze, Soraya
   T/0000-0001-8600-2389; 
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [1 D43 TW007127-01] Funding Source: Medline; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW007127, D43TW007127, D43TW007127, D43TW007127, D43TW007127,
   D43TW007127] Funding Source: NIH RePORTER
CR Amato VS, 2003, AM J TROP MED HYG, V68, P527, DOI 10.4269/ajtmh.2003.68.527
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BARRAL A, 1995, INT J DERMATOL, V34, P474, DOI 10.1111/j.1365-4362.1995.tb00613.x
   Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629
   Bottrel RLA, 2001, INFECT IMMUN, V69, P3232, DOI 10.1128/IAI.69.5.3232-3239.2001
   Bourreau E, 2003, SCAND J IMMUNOL, V58, P201, DOI 10.1046/j.1365-3083.2003.01280.x
   Bourreau E, 2002, EUR J IMMUNOL, V32, P510, DOI 10.1002/1521-4141(200202)32:2<510::AID-IMMU510>3.0.CO;2-4
   CASTES M, 1984, CLIN EXP IMMUNOL, V57, P279
   CHATELAIN R, 1992, J IMMUNOL, V148, P1182
   CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T
   Costa RP, 2003, IMMUNOL LETT, V90, P155, DOI 10.1016/j.imlet.2003.09.001
   Da-Cruz AM, 2002, CLIN DIAGN LAB IMMUN, V9, P251, DOI 10.1128/CDLI.9.2.251-256.2002
   Dutra WO, 1996, SCAND J IMMUNOL, V43, P88, DOI 10.1046/j.1365-3083.1996.d01-9.x
   Kemp K, 1999, SCAND J IMMUNOL, V49, P655
   Liew FY, 1999, IMMUNOL LETT, V65, P101, DOI 10.1016/S0165-2478(98)00131-X
   Menezes CAS, 2004, CLIN EXP IMMUNOL, V137, P129, DOI 10.1111/j.1365-2249.2004.02479.x
   MOCCI S, 1995, J IMMUNOL, V154, P3779
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   MURRAY HW, 1983, J CLIN INVEST, V72, P32, DOI 10.1172/JCI110972
   PEARSON RD, 1981, INFECT IMMUN, V32, P1249, DOI 10.1128/IAI.32.3.1249-1253.1981
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473
   TEDDER TF, 1990, EUR J IMMUNOL, V20, P1351, DOI 10.1002/eji.1830200622
   Weiss E, 2004, J AM ACAD DERMATOL, V50, P657, DOI 10.1016/j.jaad.2003.11.075
   Weyand CM, 2003, EXP GERONTOL, V38, P833, DOI 10.1016/S0531-5565(03)00090-1
NR 28
TC 54
Z9 54
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JAN
PY 2006
VL 63
IS 1
BP 70
EP 78
DI 10.1111/j.1365-3083.2005.01707.x
PG 9
WC Immunology
SC Immunology
GA 996LS
UT WOS:000234176000009
PM 16398703
OA Bronze
DA 2020-12-08
ER

PT J
AU Faria, DR
   Gollob, KJ
   Barbosa, J
   Schriefer, A
   Machado, PRL
   Lessa, H
   Carvalho, LP
   Romano-Silva, MA
   de Jesus, AR
   Carvalho, EM
   Dutra, WO
AF Faria, DR
   Gollob, KJ
   Barbosa, J
   Schriefer, A
   Machado, PRL
   Lessa, H
   Carvalho, LP
   Romano-Silva, MA
   de Jesus, AR
   Carvalho, EM
   Dutra, WO
TI Decreased in situ expression of interleukin-10 receptor is correlated
   with the exacerbated inflammatory and cytotoxic responses observed in
   mucosal leishmaniasis
SO INFECTION AND IMMUNITY
LA English
DT Article
ID AMERICAN CUTANEOUS LEISHMANIASIS; POLYMERASE CHAIN-REACTION;
   NITRIC-OXIDE; T-CELLS; IFN-GAMMA; MUCOCUTANEOUS LEISHMANIASIS; CYTOKINE
   PROFILE; UP-REGULATION; TNF-ALPHA; LESIONS
AB Human infection with Leishmania braziliensis can lead to cutaneous leishmaniasis (CL) or mucosal leishmaniasis (ML). We hypothesize that the intense tissue destruction observed in ML is a consequence of an uncontrolled exacerbated inflammatory immune response, with cytotoxic activity. For the first time, this work identifies the cellular sources of inflammatory and antiinflammatory cytokines, the expression of effector molecules, and the expression of interleukin-10 (IL-10) receptor in ML and CL lesions by using confocal microscopy. ML lesions displayed a higher number of gamma interferon (IFN-gamma)-producing cells than did CL lesions. In both ML and CL, CD4(+) cells represented the majority of IFN-gamma-producing cells, followed by CD8(+) cells and CD4(-) CD8(-) cells. The numbers of tumor necrosis factor alpha-positive cells, as well as those of IL-10-producing cells, were similar in ML and CL lesions. The effector molecule granzyme A showed greater expression in ML than in CL lesions, while inducible nitric oxide synthase did not. Finally, the expression of IL-10 receptor was lower in ML than in CL lesions. Thus, our data identified distinct cytokine and cell population profiles for CL versus ML patients and provide a possible mechanism for the development of ML disease through the demonstration that low expression of IL-10 receptor is present in conjunction with a cytotoxic and inflammatory profile in ML.
C1 Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morfol, Inst Ciencias Biol, BR-13270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Dept Biochem Immunol, BR-13270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Dept Pharmacol, Inst Biol Sci, BR-13270901 Belo Horizonte, MG, Brazil.
   Educ Community Fdn Formiga, Sch Hlth Sci, Formiga, MG, Brazil.
   Univ Fed Bahia, HUPES, Serv Immunol, Salvador, BA, Brazil.
RP Dutra, WO (corresponding author), Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morfol, Inst Ciencias Biol, Bloco N3,Sala 302,Av Antonio Carlos,6627, BR-13270901 Belo Horizonte, MG, Brazil.
EM waldutra@mono.icb.ufmg.br
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; Romano-Silva, Marco
   Aurelio/T-8321-2019; Schriefer, Albert/AAP-2765-2020; Carvalho,
   Lucas/J-6734-2012; Gollob, Kenneth J/C-1341-2008; Carvalho,
   Lucas/AAP-1844-2020; Romano-Silva, Marco Aurelio/A-1790-2008
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; Schriefer,
   Albert/0000-0002-5496-6789; Gollob, Kenneth J/0000-0003-4184-3867;
   Romano-Silva, Marco Aurelio/0000-0002-6558-4639
CR Amato VS, 2003, AM J TROP MED HYG, V68, P527, DOI 10.4269/ajtmh.2003.68.527
   ANDERSON P, 1990, J IMMUNOL, V144, P574
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   AZULAY RD, 1995, INT J DERMATOL, V34, P303, DOI 10.1111/j.1365-4362.1995.tb03608.x
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BARRALNETTO M, 1995, PARASITE IMMUNOL, V17, P21, DOI 10.1111/j.1365-3024.1995.tb00962.x
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Bottrel RLA, 2001, INFECT IMMUN, V69, P3232, DOI 10.1128/IAI.69.5.3232-3239.2001
   Bourreau E, 2001, J INFECT DIS, V183, P953, DOI 10.1086/319249
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CASTES M, 1984, CLIN EXP IMMUNOL, V57, P279
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   ESTERRE P, 1994, PARASITE, V1, P305, DOI 10.1051/parasite/1994014305
   FRISCHHOLZ S, 1994, IMMUNOLOGY, V82, P255
   Grisham MB, 2002, J INVEST MED, V50, P272, DOI 10.2310/6650.2002.33281
   Joyce DA, 1996, J INTERF CYTOK RES, V16, P511, DOI 10.1089/jir.1996.16.511
   Lee Samuel A., 2003, International Journal of Infectious Diseases, V7, P86, DOI 10.1016/S1201-9712(03)90002-6
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   LIEW FY, 1995, CURR OPIN IMMUNOL, V7, P396, DOI 10.1016/0952-7915(95)80116-2
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   Machado P, 2002, EUR J DERMATOL, V12, P449
   MELBY PC, 1993, J IMMUNOL METHODS, V159, P235, DOI 10.1016/0022-1759(93)90162-Z
   MELBY PC, 1994, INFECT IMMUN, V62, P837, DOI 10.1128/IAI.62.3.837-842.1994
   Michel G, 1997, J IMMUNOL, V159, P6291
   MOSMANN TR, 1991, IMMUNOL TODAY, V12, P49
   Napoli C, 2002, J CARDIAC SURG, V17, P355
   NETTO EM, 1990, T ROY SOC TROP MED H, V84, P367, DOI 10.1016/0035-9203(90)90321-5
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   PIRMEZ C, 1990, J IMMUNOL, V145, P3100
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sasiain MD, 1998, CLIN EXP IMMUNOL, V114, P196
   TANNENBAUM CS, 1993, J IMMUNOL, V151, P6833
   Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911
NR 36
TC 144
Z9 146
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2005
VL 73
IS 12
BP 7853
EP 7859
DI 10.1128/IAI.73.12.7853-7859.2005
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 986WK
UT WOS:000233480200008
PM 16299275
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Castellucci, LA
   Cheng, LH
   Araujo, C
   Guimaraes, LH
   Lessa, H
   Machado, P
   Almeida, MF
   Oliveira, A
   Ko, A
   Johnson, WD
   Wilson, ME
   Carvalho, EM
   De Jesus, AR
AF Castellucci, LA
   Cheng, LH
   Araujo, C
   Guimaraes, LH
   Lessa, H
   Machado, P
   Almeida, MF
   Oliveira, A
   Ko, A
   Johnson, WD
   Wilson, ME
   Carvalho, EM
   De Jesus, AR
TI Familial aggregation of mucosal leishmaniasis in Northeast Brazil
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID REGULATORY T-CELLS; MUCOCUTANEOUS LEISHMANIASIS; TEGUMENTARY
   LEISHMANIASIS; CHAGASI INFECTION; NEW-WORLD; SUSCEPTIBILITY;
   EPIDEMIOLOGY; POPULATION; MICE
AB To evaluate whether familial clustering occurs in mucosal leishmaniasis (ML), patients with ML (index cases) were randomly selected from medical records at a health post in an endemic area for Leishmania braziliensis infection. Control individuals (index controls) matched by age, gender, and place of residence to index cases were selected. Family members of index cases and controls were compared with respect to environmental factors and the incidence of cutaneous leishmaniasis (CL) and ML. Delayed type hypersensitivity test (DTH) to Leishmania antigen was tested in selected families. Among 289 members of 46 families enrolled, significant differences were found in the frequencies of CL (37% versus 20%) and ML (5% versus 0) in case versus control families, respectively. Families with 2 cases of ML had a higher frequency (29.6%) of DTH-positive individuals than control families (9.4%). These data demonstrate familial clustering of CL, ML, and positive DTH skin tests in an area endemic for L. braziliensis infection.
C1 Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, BR-40110160 Salvador, BA, Brazil.
   Fdn Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   Cornell Univ, Div Int Med & Infect Dis, Weill Med Coll, New York, NY USA.
   Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.
RP De Jesus, AR (corresponding author), Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, 5 Andar,Rua Joao Botas S-N, BR-40110160 Salvador, BA, Brazil.
EM imuno@ufba.br; aik2001@med.cornell.edu; wdjohnso@med.cornell.edu;
   mary-wilson@uiowa.edu; imuno@ufba.br
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; Ko, Albert
   Icksang/P-2343-2015; Henrique, Luiz/ABA-2621-2020
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; Ko, Albert
   Icksang/0000-0001-9023-2339; Wilson, Mary/0000-0001-8680-7275
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639-11A, AI048822] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI048822, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI048822, P50AI030639, P50AI030639, P50AI030639,
   R01AI048822, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   R01AI048822, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   R01AI048822, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639] Funding Source: NIH RePORTER
CR Alcais A, 1997, AM J HUM GENET, V61, P968, DOI 10.1086/514882
   Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Belkaid Y, 2003, EXPERT OPIN BIOL TH, V3, P875, DOI 10.1517/14712598.3.6.875
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Blackwell JM, 1997, PHILOS T R SOC B, V352, P1331, DOI 10.1098/rstb.1997.0118
   BRETSCHER PA, 1997, BEHRING I MITT, V98, P153
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Coffman RL, 1998, ADV EXP MED BIOL, V452, P61
   CONCEICAOSILVA F, 1990, CLIN EXP IMMUNOL, V79, P221, DOI 10.1111/j.1365-2249.1990.tb05182.x
   Cupolillo E, 1997, ANN TROP MED PARASIT, V91, P617, DOI 10.1080/00034989760716
   Desjeux P., 1992, World Health Statistics Quarterly, V45, P267
   DYE C, 1992, PARASITOLOGY, V104, pS7, DOI 10.1017/S0031182000075211
   Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x
   GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993
   GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687
   Jeronimo SMB, 2000, CLIN INFECT DIS, V30, P608, DOI 10.1086/313697
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   SARAVIA NG, 1989, J INFECT DIS, V159, P725, DOI 10.1093/infdis/159.4.725
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
NR 23
TC 21
Z9 22
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2005
VL 73
IS 1
BP 69
EP 73
DI 10.4269/ajtmh.2005.73.69
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 944TH
UT WOS:000230451900015
PM 16014836
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Almeida, RP
   Brito, J
   Machado, PL
   De Jesus, AR
   Schriefer, AR
   Guimaraes, LH
   Carvalho, EM
AF Almeida, RP
   Brito, J
   Machado, PL
   De Jesus, AR
   Schriefer, AR
   Guimaraes, LH
   Carvalho, EM
TI Successful treatment of refractory cutaneous leishmaniasis with GM-CSF
   and antimonials
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE; KERATINOCYTE GROWTH;
   VENOUS ULCERS; DOUBLE-BLIND
AB Therapeutic failure in the treatment of cutaneous leishmaniasis (CL) occurs in 5% of patients infected by Leishmania braziliensis. This study evaluates the use of topically applied granulocyte macrophage colony-stimulating factor (GM-CSF) combined with the standard dose of antimony to treat refractory cases of CL. Five patients who had received three courses or more of antimony were enrolled in an open-label clinical trial. One to 2 mL of the GM-CSF solution (10 mu g/mL in 0.9% saline) was reapplied topically, and dressings were changed three times per week for 3 weeks, associated with standard parenteral antimony (20 mg kg(-1) day(-1) for 20 days). All the patients healed their CL ulcers; 3 healed within 50 days (21, 27, and 44 days) and 2 in 118 and 120 days after beginning therapy. There were no side effects. This study shows that combined topically applied GM-CSF and antimony can be effective and well tolerated in the treatment of relapsed CL.
C1 Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, BR-40110160 Canela, BA, Brazil.
   Inst Invest Imunol, Sao Paulo, Brazil.
   CNPq, Sao Paulo, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgard Santos, Rua Joao Botas S-N, BR-40110160 Canela, BA, Brazil.
EM roque@utba.br; imuno@ufba.br; imuno@ufba.br; amelia@ufba.br;
   umuno@ufba.br; edgar@ufba.br
RI Henrique, Luiz/ABA-2621-2020; almeida, roque/F-5609-2012; Machado, Pedro
   L. O. A./H-2826-2013
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   AlZamel F, 1996, ZBL BAKT-INT J MED M, V285, P92, DOI 10.1016/S0934-8840(96)80027-2
   Barral-Netto M, 1997, CURRENT OPINION DERM, V4, P51
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   DACOSTA RM, 1994, LANCET, V344, P481
   DOHERTY TM, 1993, J IMMUNOL, V150, P5476
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   Jaschke E, 1999, INT J DERMATOL, V38, P380, DOI 10.1046/j.1365-4362.1999.00665.x
   Jones TC, 1996, MED ONCOL, V13, P141, DOI 10.1007/BF02990842
   JONES TC, 1993, EJC SUPPL, V29, P10
   KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717
   KOFF AB, 1994, J AM ACAD DERMATOL, V31, P693, DOI 10.1016/S0190-9622(94)70229-2
   KUCUKCELEBI A, 1992, WOUNDS, V4, P241
   KURZROCK R, 1992, AM J MED, V93, P41, DOI 10.1016/0002-9343(92)90678-5
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99
   Modabber F., 1987, Tropical disease research: a global partnership. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases 8th Programme Report: the first ten years, with highlights of the 1985-86 biennium.., P99
   ROBSON M, 1994, EUR J CLIN MICROB S2, V13, P41
   Robson MC, 2001, WOUND REPAIR REGEN, V9, P347, DOI 10.1046/j.1524-475x.2001.00347.x
   SAMPAIO S A P, 1971, International Journal of Dermatology, V10, P179, DOI 10.1111/j.1365-4362.1971.tb01694.x
   Santos JB, 2004, J INFECT DIS, V190, P1793, DOI 10.1086/424848
   SOTOMANCIPE J, 1993, CLIN INFECT DIS, V16, P417, DOI 10.1093/clind/16.3.417
NR 22
TC 35
Z9 36
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2005
VL 73
IS 1
BP 79
EP 81
DI 10.4269/ajtmh.2005.73.79
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 944TH
UT WOS:000230451900017
PM 16014838
OA Bronze
DA 2020-12-08
ER

PT J
AU Carvalho, LP
   Passos, S
   Dutra, WO
   Soto, M
   Alonso, C
   Gollob, KJ
   Carvalho, EM
   de Jesus, AR
AF Carvalho, LP
   Passos, S
   Dutra, WO
   Soto, M
   Alonso, C
   Gollob, KJ
   Carvalho, EM
   de Jesus, AR
TI Effect of LACK and KMP11 on IFN-gamma production by peripheral blood
   mononuclear cells from cutaneous and mucosal leishmaniasis patients
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CD4(+) T-CELLS; IMMUNE-RESPONSES; CYTOKINE PROFILE; ANTIGEN;
   IMMUNOREGULATION; BRAZILIENSIS; INFECTION; PROTEINS; LEVEL
AB The immune modulatory properties of recombinant antigens Kinetoplasmid membrane protein-11 (KMP11) and Leishmania homologue of receptors for activated C kinase (LACK) in cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) patients were evaluated. The mean levels of interferon-gamma (IFN-gamma) in soluble leishmania antigen (SLA) stimulated peripheral blood mononuclear cells (PBMC) of ML and CL patients were 5625 +/- 2333 pg/ml and 4422 +/- 3665 pg/ml, respectively. IFN-gamma was not detected in Cultures stimulated with KMP11 or LACK. Interletikin-10 (IL-10) concentration in SLA, KMP1 I and LACK-stimulated PBMC of ML patients was 13 +/- 12 pg/ml, 285 +/- 388 pg/ml and 802 +/- 483 pg/ml, respectively. Addition of KMP11 or LACK to SLA-stimulated PBMC of CL and ML patients enhanced IL-10 production (P< 0.05). Addition of KMP11 decreased IFN-gamma levels by 52% in CL patients and by 19% in ML patients. Addition of LACK to SLA-stimulated cultures decreased IFN-gamma levels by 58% in CL patients and by 30% in ML patients. Neutralization of IL-10 abrogated the downregulatory effect of LACK and KMP11. The modulatory properties of LACK and KMP11 are due to induction of IL-10 production and may be helpful for attenuating chronic inflammatory diseases. However, in some clinical conditions, as demonstrated for ML, these molecules are not able to suppress the IFN-gamma response, even inducing IL-10 production.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Immunol, BR-40110160 Salvador, BA, Brazil.
   Univ Fed Minas Gerais, Dept Morfol, Belo Horizonte, MG, Brazil.
   Univ Madrid, Ctr Biol Mol, Madrid, Spain.
   Univ Fed Minas Gerais, Dept Bioquim Imunol, Belo Horizonte, MG, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Immunol, 5 Andar,Rua Joao das Botas,S-N Canela, BR-40110160 Salvador, BA, Brazil.
EM amelia@ufba.br
RI Carvalho, Lucas/J-6734-2012; Carvalho, Lucas/AAP-1844-2020; Alvarez,
   Manuel Soto/Q-5234-2018; Gollob, Kenneth J/C-1341-2008
OI Alvarez, Manuel Soto/0000-0001-6825-841X; Gollob, Kenneth
   J/0000-0003-4184-3867
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-30639] Funding
   Source: Medline
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Bottrel RLA, 2001, INFECT IMMUN, V69, P3232, DOI 10.1128/IAI.69.5.3232-3239.2001
   Bourreau E, 2003, SCAND J IMMUNOL, V58, P201, DOI 10.1046/j.1365-3083.2003.01280.x
   Bourreau E, 2002, EUR J IMMUNOL, V32, P510, DOI 10.1002/1521-4141(200202)32:2<510::AID-IMMU510>3.0.CO;2-4
   BURNS JM, 1991, J IMMUNOL, V146, P742
   CARVALHO EM, 1994, ACTA TROP, V56, P315, DOI 10.1016/0001-706X(94)90103-1
   CARVALHO EM, 1995, AM J TROP MED HYG, V53, P273, DOI 10.4269/ajtmh.1995.53.273
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   D'Oliveira Junior Argemiro, 2002, Rev. Soc. Bras. Med. Trop., V35, P7, DOI 10.1590/S0037-86822002000100002
   de Carvalho LP, 2003, MICROBES INFECT, V5, P7, DOI 10.1016/S1286-4579(02)00051-5
   Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   Machado P, 2002, EUR J DERMATOL, V12, P449
   Malherbe L, 2000, IMMUNITY, V13, P771, DOI 10.1016/S1074-7613(00)00075-3
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   RUSSO DM, 1991, J IMMUNOL, V147, P3575
   SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675
   SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995
   Skeiky YAW, 1998, J IMMUNOL, V161, P6171
   Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473
   Thomas MC, 2000, DNA CELL BIOL, V19, P47, DOI 10.1089/104454900314708
NR 30
TC 27
Z9 28
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD APR
PY 2005
VL 61
IS 4
BP 337
EP 342
DI 10.1111/j.1365-3083.2005.01581.x
PG 6
WC Immunology
SC Immunology
GA 922KD
UT WOS:000228835900006
PM 15853916
DA 2020-12-08
ER

PT J
AU Santos, JB
   de Jesus, AR
   Machado, PR
   Magalhaes, A
   Salgado, K
   Carvalho, EM
   Almeida, RP
AF Santos, JB
   de Jesus, AR
   Machado, PR
   Magalhaes, A
   Salgado, K
   Carvalho, EM
   Almeida, RP
TI Antimony plus recombinant human granulocyte-macrophage
   colony-stimulating factor applied topically in low doses enhances
   healing of cutaneous leishmaniasis ulcers: A randomized, double-blind,
   placebo-controlled study
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 52nd Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 03-07, 2003
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
ID VENOUS ULCERS; CSF
AB Cutaneous leishmaniasis (CL) requires 2-6 months to heal. In an effort to reduce this healing time, we studied topically applied granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to antimonial therapy. Ten patients received antimony plus topical GM-CSF, and 10 patients received antimony plus placebo (saline). GM-CSF was diluted for topical use and was applied 3 times weekly for 3 weeks (1-2 mug/cm(2)/lesion). The mean +/-SD healing time was 43 +/-14 days in the GM-CSF group and was days in 104 +/- 79 the placebo group (P = .043). Ten (100%) of 10 patients in the GM-CSF group healed within 60 days, compared with 5 (50%) of 10 patients in the placebo group. Two of the patients in the placebo group required retreatment with antimony. In conclusion, topically applied GM-CSF is effective in the management of CL.
C1 Univ Fed Bahia, Hosp Univ Professor Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   Inst Invest Imunol, Inst Milenio, Rio De Janeiro, Brazil.
RP Almeida, RP (corresponding author), UFBA, Rua Joao Das Botas S-N, RA-40110160 Canela, BA, Brazil.
EM roque@ufba.br
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; almeida, roque/F-5609-2012
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; 
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   Jaschke E, 1999, INT J DERMATOL, V38, P380, DOI 10.1046/j.1365-4362.1999.00665.x
   JONES TC, 1993, EUR J CANCER, V29A, pS10, DOI 10.1016/0959-8049(93)90625-P
   KURZROCK R, 1992, AM J MED, V93, P41, DOI 10.1016/0002-9343(92)90678-5
   Lehmann MH, 1998, MOL IMMUNOL, V35, P479, DOI 10.1016/S0161-5890(98)00043-1
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99
   Marsden P D, 1994, Rev Soc Bras Med Trop, V27, P93, DOI 10.1590/S0037-86821994000200007
   MODABBER F, 1987, 8 TDR WHO, P99
   PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538
   Robson MC, 2001, WOUND REPAIR REGEN, V9, P347, DOI 10.1046/j.1524-475x.2001.00347.x
   SAMPAIO SA, 1971, INT J DERMATOL, V10, P19
NR 15
TC 32
Z9 32
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2004
VL 190
IS 10
BP 1793
EP 1796
DI 10.1086/424848
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 865KG
UT WOS:000224700800011
PM 15499535
OA Bronze
DA 2020-12-08
ER

PT J
AU Santos, SB
   Porto, AF
   Muniz, AL
   de Jesus, AR
   Magalhaes, E
   Melo, A
   Dutra, WO
   Gollob, KJ
   Carvalho, EM
AF Santos, SB
   Porto, AF
   Muniz, AL
   de Jesus, AR
   Magalhaes, E
   Melo, A
   Dutra, WO
   Gollob, KJ
   Carvalho, EM
TI Exacerbated inflammatory cellular immune response characteristics of
   HAM/TSP is observed in a large proportion of HTLV-I asymptomatic
   carriers
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; CYTOTOXIC T-LYMPHOCYTES;
   NEUROLOGIC DISEASE; PERIPHERAL-BLOOD; PROVIRAL LOAD; MYELOPATHY;
   LEUKEMIA; EXPRESSION; CELLS
AB Background: A small fraction of Human T cell Leukemia Virus type-1 (HTLV-I) infected subjects develop a severe form of myelopathy. It has been established that patients with HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) show an exaggerated immune response when compared with the immunological response observed in HTLV-I asymptomatic carriers. In this study the immunological responses in HAM/TSP patients and in HTLV-I asymptomatic carriers were compared using several immunological assays to identify immunological markers associated with progression from infection to disease.
   Methods: Immunoproliferation assays, cytokine levels of unstimulated cultures, and flow cytometry analysis were used to evaluate the studied groups. Nonparametric tests (Mann-Whitney U test and Wilcoxon matched-pairs signed ranks) were used to compare the difference between the groups.
   Results: Although both groups showed great variability, HAM/TSP patients had higher spontaneous lymphoproliferation as well as higher IFN-gamma levels in unstimulated supernatants when compared with asymptomatic carriers. Flow cytometry studies demonstrated a high frequency of inflammatory cytokine (IFN-gamma and TNF-alpha) producing lymphocytes in HAM/TSP as compared to the asymptomatic group. This difference was accounted for mainly by an increase in CD8 cell production of these cytokines. Moreover, the HAM/TSP patients also expressed an increased frequency of CD28-/CD8+ T cells. Since forty percent of the asymptomatic carriers had spontaneous lymphoproliferation and IFN-gamma production similar to HAM/TSP patients, IFN-gamma levels were measured eight months after the first evaluation in some of these patients to observe if this was a transient or a persistent situation. No significant difference was observed between the means of IFN-gamma levels in the first and second evaluation.
   Conclusions: The finding that a large proportion of HTLV-I carriers present similar immunological responses to those observed in HAM/TSP, strongly argues for further studies to evaluate these parameters as markers of HAM/TSP progression.
C1 Univ Fed Bahia, HUPES, Serv Imunol, Salvador, BA, Brazil.
   Univ Fed Bahia, HUPES, Serv Neurol, Salvador, BA, Brazil.
   Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   Inst Invest Imunol, Sao Paulo, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, HUPES, Serv Imunol, Salvador, BA, Brazil.
EM silvane@ufba.br; porto@ufba.br; muniz.a@terra.com.br; amelia@ufba.br;
   imuno@ufba.br; imuno@ufba.br; waldutra@mono.icb.ufmg.br;
   kjgollob@terra.com.br; edgar@ufba.br
RI Gollob, Kenneth J/C-1341-2008
OI Gollob, Kenneth J/0000-0003-4184-3867
CR Azimi N, 2000, AIDS RES HUM RETROV, V16, P1717, DOI 10.1089/08892220050193209
   AZUMA M, 1993, J IMMUNOL, V150, P1147
   Biddison WE, 1997, J IMMUNOL, V159, P2018
   Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001
   Dutra WO, 1996, SCAND J IMMUNOL, V43, P88, DOI 10.1046/j.1365-3083.1996.d01-9.x
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   GESSAIN A, 1985, LANCET, V2, P407
   Giguere JF, 2002, J IMMUNOL, V169, P2762, DOI 10.4049/jimmunol.169.5.2762
   Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   Jacobson S, 1996, J ACQ IMMUN DEF SYND, V13, pS100, DOI 10.1097/00042560-199600001-00017
   JACOBSON S, 1990, ANN NEUROL, V27, P149, DOI 10.1002/ana.410270209
   KRAMER A, 1995, AM J EPIDEMIOL, V142, P1212
   Kubota R, 1998, J IMMUNOL, V161, P482
   Kubota R, 2000, J NEUROIMMUNOL, V102, P208, DOI 10.1016/S0165-5728(99)00175-7
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nagai M, 2001, CURR OPIN NEUROL, V14, P381, DOI 10.1097/00019052-200106000-00019
   NISHIMOTO N, 1990, J NEUROL SCI, V97, P183, DOI 10.1016/0022-510X(90)90217-B
   Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280260422668
   OSAME M, 1986, LANCET, V1, P1031
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402
   PRINCE H, 1990, J ACQ IMMUN DEF SYND, V3, P1199
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Sakai JA, 2001, BLOOD, V98, P1506, DOI 10.1182/blood.V98.5.1506
   Taylor GP, 1999, J ACQ IMMUN DEF SYND, V22, P92, DOI 10.1097/00042560-199909010-00012
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009
   Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x
NR 31
TC 69
Z9 73
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAR 2
PY 2004
VL 4
AR 7
DI 10.1186/1471-2334-4-7
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 812MY
UT WOS:000220844800001
PM 15070424
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Schriefer, A
   Schriefer, ALF
   Goes-Neto, A
   Guimaraes, LH
   Carvalho, LP
   Almeida, RP
   Machado, PR
   Lessa, HA
   de Jesus, AR
   Riley, LW
   Carvalho, EM
AF Schriefer, A
   Schriefer, ALF
   Goes-Neto, A
   Guimaraes, LH
   Carvalho, LP
   Almeida, RP
   Machado, PR
   Lessa, HA
   de Jesus, AR
   Riley, LW
   Carvalho, EM
TI Multiclonal Leishmania braziliensis population structure and its
   clinical implication in a region of endemicity for American tegumentary
   leishmaniasis
SO INFECTION AND IMMUNITY
LA English
DT Article
ID DISSEMINATED CUTANEOUS LEISHMANIASIS; GENETIC-HETEROGENEITY;
   EVOLUTIONARY GENETICS; PHYLOGENETIC TAXONOMY; VIANNIA BRAZILIENSIS;
   PARASITES; DONOVANI; DNA; TRYPANOSOMA; DIVERSITY
AB In Corte de Pedra (CP), northeastern Brazil, Leishmania braziliensis causes three distinct forms of American tegumentary leishmaniasis (ATL). To test the hypothesis that strain polymorphism may be involved in this disease spectrum and accurately characterize the parasite population structure in CP, we compared one L. major, two non-CP L. braziliensis, one CP L. amazonensis, and 45 CP L. braziliensis isolates, obtained over a 10-year period from localized cutaneous, mucosal, and disseminated leishmaniasis patients, with randomly amplified polymorphic DNA (RAPD). Electrophoretic profiles were mostly unique across species. All typing protocols revealed polymorphism among the 45 CP L. braziliensis isolates, which displayed eight different RAPD patterns and greater than 80% overall fingerprint identity, attesting to the adequacy of the tools to assess strain variability in CP's geographically limited population of parasites. The dendrogram based on the sum of RAPD profiles of each isolate unveiled nine discrete typing units clustered into five clades. Global positioning showed extensive overlap of these clades in CP, precluding geographic sequestration as the mechanism of the observed structuralization. Finally, all forms of ATL presented a statistically significant difference in their frequencies among the clades, suggesting that L. braziliensis genotypes may be accompanied by specific disease manifestation after infection.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   Univ Calif Berkeley, Div Infect Dis, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Schriefer, A (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Rua Joao Botas S-N,5o Andar,Canela, BR-40110160 Salvador, BA, Brazil.
RI Carvalho, Lucas/AAP-1844-2020; MACHADO, PAULO ROBERTO
   LIMA/AAP-2642-2020; Schriefer, Albert/AAP-2765-2020; Henrique,
   Luiz/ABA-2621-2020; almeida, roque/F-5609-2012; Carvalho,
   Lucas/J-6734-2012; Goes-Neto, Aristoteles/A-6955-2013
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; Schriefer,
   Albert/0000-0002-5496-6789; Goes-Neto, Aristoteles/0000-0002-7692-6243
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639, P50 AI030639] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639] Funding Source: NIH RePORTER
CR AZULAY RD, 1995, INT J DERMATOL, V34, P303, DOI 10.1111/j.1365-4362.1995.tb03608.x
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Banuls AL, 1999, INT J PARASITOL, V29, P1137, DOI 10.1016/S0020-7519(99)00083-1
   BELLI AA, 1994, PARASITOLOGY, V109, P435, DOI 10.1017/S0031182000080689
   CARVALHO EM, 1994, ACTA TROP, V56, P315, DOI 10.1016/0001-706X(94)90103-1
   Chouicha N, 1997, PARASITOLOGY, V115, P343, DOI 10.1017/S0031182097001376
   COSTA JML, 1986, J TROP MED HYG, V89, P319
   Cupolillo E, 1997, ANN TROP MED PARASIT, V91, P617, DOI 10.1080/00034989760716
   Desjeux P., 1992, World Health Statistics Quarterly, V45, P267
   DUJARDIN JC, 1995, ACTA TROP, V59, P293, DOI 10.1016/0001-706X(95)00094-U
   El Tai NO, 2001, EXP PARASITOL, V97, P35, DOI 10.1006/expr.2001.4592
   Evans D.A., 1987, Parassitologia (Rome), V29, P165
   GOMES RF, 1995, EXP PARASITOL, V80, P681, DOI 10.1006/expr.1995.1084
   Hide M, 2001, PARASITOLOGY, V123, P425, DOI 10.1017/S003118200100871X
   IBRAHIM ME, 1994, ACTA TROP, V57, P327, DOI 10.1016/0001-706X(94)90078-7
   Ishikawa EA, 2002, T R SOC TROP MED HYG, V96, P111
   KREUTZER RD, 1994, AM J TROP MED HYG, V51, P301, DOI 10.4269/ajtmh.1994.51.301
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Marsden PD, 1985, CLIN MANIFESTATIONS
   Mauricio IL, 1999, PARASITOLOGY, V119, P237, DOI 10.1017/S0031182099004710
   MEBRAHTU YB, 1991, AM J TROP MED HYG, V45, P290, DOI 10.4269/ajtmh.1991.45.290
   MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L
   Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902
   REINER NE, 1989, AM J TROP MED HYG, V41, P416, DOI 10.4269/ajtmh.1989.41.416
   Saravia NG, 1998, AM J TROP MED HYG, V59, P86, DOI 10.4269/ajtmh.1998.59.86
   Saravia NG, 2002, AM J TROP MED HYG, V66, P738, DOI 10.4269/ajtmh.2002.66.738
   Schonian G, 2001, T ROY SOC TROP MED H, V95, P217, DOI 10.1016/S0035-9203(01)90173-7
   SHAW JJ, 1987, LEISHMANIASIS BIOL M
   SILVEIRA FT, 1984, REV INST MED TROP SP, V26, P272, DOI 10.1590/S0036-46651984000500008
   THOMAZSOCCOL V, 1993, ANN PARASIT HUM COMP, V68, P107
   THOMAZSOCCOL V, 1993, ANN PARASIT HUM COMP, V68, P104
   TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414
   Tibayrenc M, 1999, MICROBES INFECT, V1, P465, DOI 10.1016/S1286-4579(99)80050-1
   Toledo A, 2002, MOL BIOCHEM PARASIT, V119, P257, DOI 10.1016/S0166-6851(01)00424-8
   Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
   Youssef Magda Y. M., 1997, Journal of the Egyptian Society of Parasitology, V27, P651
NR 36
TC 76
Z9 77
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JAN
PY 2004
VL 72
IS 1
BP 508
EP 514
DI 10.1128/IAI.72.1.508-514.2004
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 758JR
UT WOS:000187631600059
PM 14688132
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Magalhaes, A
   Miranda, DG
   Miranda, RG
   Araujo, MI
   de Jesus, AA
   Silva, A
   Santana, LB
   Pearce, E
   Carvalho, EM
   de Jesus, AR
AF Magalhaes, A
   Miranda, DG
   Miranda, RG
   Araujo, MI
   de Jesus, AA
   Silva, A
   Santana, LB
   Pearce, E
   Carvalho, EM
   de Jesus, AR
TI Cytokine profile associated with human chronic schistosomiasis mansoni
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT 9th international Symposium on Schistosomiasis
CY NOV 02-05, 2003
CL Salvador, BRAZIL
DE schistosomiasis; hepatic fibrosis; interleukin-5; interieukin-13
ID IFN-GAMMA; PERIPORTAL FIBROSIS; IMMUNE-RESPONSES; TNF-ALPHA;
   PATHOPHYSIOLOGY; ULTRASOUND; INFECTION; IL-10
AB This study objective was to evaluate the cytokines associated with early events of hepatic fibrosis in schistosomiasis mansoni. Hepatic fibrosis was classified by ultrasonography in 94 patients. Immunological evaluation was performed by measurement of secreted cytokines (interleukin IL-5, IL-10, IL-13, interferon-gamma tumor necrosis factor-alpha and transforming growth factors-beta) in peripherl blood mononuclear cells stimulated by Schistosoma mansoni antigens. Significantly, higher levels of IL-5, IL-10 and IL-13 were found in supernatants of SEA-stimulated PBMC from subjects with degree III hepatic fibrosis as compared to patients with degree I or II fibrosis, Significant increases in IL-5 and IL-13 levels were also observed in some of the subjects who remained untreated for one year following initial assessment and developed more serious fibrosis during this period. The data suggests a role for type 2 cytokines in early stages of hepatic fibrosis in human schistosomiasis mansoni.
C1 Univ Fed Bahia, Hosp Univ Professor Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   Clin Gonzalez Miranda Ltda, Salvador, BA, Brazil.
   Univ Fed Sergipe, Dept Doencas Infecciosas, Aracaju, SE, Brazil.
   Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Professor Edgard Santos, Serv Imunol, Rua Joao Botas S-N, BR-40110160 Salvador, BA, Brazil.
EM imuno@ufba.br
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER
CR ABDELWAHAB MF, 1992, J UROLOGY, V148, P346, DOI 10.1016/S0022-5347(17)36590-4
   Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633
   Bica I, 2000, INFECT DIS CLIN N AM, V14, P583, DOI 10.1016/S0891-5520(05)70122-7
   Booth M, 2004, J IMMUNOL, V172, P1295, DOI 10.4049/jimmunol.172.2.1295
   BOROS DL, 1992, MEM I OSWALDO CRUZ, V87, P75, DOI 10.1590/S0074-02761992000800010
   CHEEVER AW, 1994, J IMMUNOL, V153, P753
   Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325
   Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903
   Chiaramonte MG, 2001, HEPATOLOGY, V34, P273, DOI 10.1053/jhep.2001.26376
   Clark IA, 2003, PHARMACOL THERAPEUT, V99, P221, DOI 10.1016/S0163-7258(03)00060-3
   de Jesus AR, 2002, J INFECT DIS, V185, P98, DOI 10.1086/324668
   De Jesus AR, 2000, AM J TROP MED HYG, V63, P1
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   DEWALLMALEFYT HR, 1993, J EXP MED, V174, P915
   Doumenge JP, 1987, ATLAS GLOBAL DISTRIB
   Falcao PL, 1998, PARASITE IMMUNOL, V20, P447, DOI 10.1046/j.1365-3024.1998.00166.x
   Henri S, 2002, J IMMUNOL, V169, P929, DOI 10.4049/jimmunol.169.2.929
   Mwatha JK, 1998, J IMMUNOL, V160, P1992
   Naus CWA, 2003, J INFECT DIS, V187, P1272, DOI 10.1086/368361
   PEARCE EJ, 1986, J IMMUNOL, V137, P3593
   PESSOA SB, 1978, PARASITOLOGIA MED
   Ribeiro De Jesus Amelia, 1993, European Journal of Immunology, V23, P152, DOI 10.1002/eji.1830230125
   Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269
   WARREN KS, 1968, B NEW YORK ACAD MED, V44, P280
   WARREN WD, 1967, ANN SURG, V165, P999, DOI 10.1097/00000658-196706000-00015
NR 25
TC 12
Z9 13
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2004
VL 99
IS 5
SU S
BP 21
EP 26
DI 10.1590/S0074-02762004000900004
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 853VS
UT WOS:000223857600004
PM 15486630
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bacellar, O
   Lessa, H
   Schriefer, A
   Machado, P
   de Jesus, AR
   Dutra, WO
   Gollob, KJ
   Carvalho, EM
AF Bacellar, O
   Lessa, H
   Schriefer, A
   Machado, P
   de Jesus, AR
   Dutra, WO
   Gollob, KJ
   Carvalho, EM
TI Up-regulation of Th1-type responses in mucosal leishmaniasis patients
SO INFECTION AND IMMUNITY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; AMERICAN CUTANEOUS LEISHMANIASIS;
   GROWTH-FACTOR-BETA; VISCERAL LEISHMANIASIS; CYTOKINE PROFILE;
   FACTOR-ALPHA; TEGUMENTARY LEISHMANIASIS; IFN-GAMMA; RECEPTORS; ANTIGEN
AB The cytokine profile produced by peripheral blood mononuclear cells (PBMC) in response to leishmania antigens and the ability of interleukin-10 (IL-10) and transforming growth factor beta (TGF-beta) to modulate the immune response were evaluated in 21 mucosal leishmaniasis patients. Patients with mucosal disease exhibited increased gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) secretion and decreased IL-10 secretion compared to patients with classical cutaneous leishmaniasis. CD4(+) Th1 cells were the main source of IFN-gamma and TNF-alpha production in mucosal leishmaniasis patients. Evaluation of cytokine gene expression in PBMC of these patients showed that there was strong up-regulation of IFN-gamma transcripts upon stimulation with leishmania antigen, in contrast to the baseline levels of IL-10 mRNA. IL-10 suppressed IFN-gamma production by 48% in cell cultures from cutaneous leishmaniasis patients and by 86% in cell cultures from healthy subjects stimulated with purified protein derivative, whereas in similar conditions IL-10 suppressed IFN-gamma production by 19% in cell cultures from mucosal leishmaniasis patients stimulated with leishmania antigen. TGF-beta suppressed IFN-gamma levels to a greater extent in healthy subjects than in mucosal leishmaniasis and cutaneous leishmaniasis patients. These data indicate that a poorly modulated T-cell response in mucosal leishmaniasis patients leads to production of high levels of proinflammatory cytokines, such as IFN-gamma and TNF-alpha, as well as a decreased ability of IL-10 and TGF-beta to modulate this response. These abnormalities may be the basis for the pathological findings observed in this disease.
C1 Univ Fed Bahia, HUPES, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   Univ Fed Minas Gerais, ICB, Dept Bioquim Imunol, Dept Morfol, Belo Horizonte, MG, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, HUPES, Serv Imunol, Rua Joao Botas SN, BR-40110160 Salvador, BA, Brazil.
RI Gollob, Kenneth J/C-1341-2008; MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020
OI Gollob, Kenneth J/0000-0003-4184-3867; MACHADO, PAULO ROBERTO
   LIMA/0000-0003-1894-6171
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-30639, P50
   AI030639] Funding Source: Medline
CR AZULAY RD, 1995, INT J DERMATOL, V34, P303, DOI 10.1111/j.1365-4362.1995.tb03608.x
   Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   BARRAL A, 1993, P NATL ACAD SCI USA, V90, P3442, DOI 10.1073/pnas.90.8.3442
   BARRALNETTO M, 1995, PARASITE IMMUNOL, V17, P21, DOI 10.1111/j.1365-3024.1995.tb00962.x
   BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Bottrel RLA, 2001, INFECT IMMUN, V69, P3232, DOI 10.1128/IAI.69.5.3232-3239.2001
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1994, J IMMUNOL, V152, P5949
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CASTES M, 1984, CLIN EXP IMMUNOL, V57, P279
   Castes M, 1993, Biol Res, V26, P233
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   CUBA CAC, 1984, T ROY SOC TROP MED H, V78, P708, DOI 10.1016/0035-9203(84)90256-6
   DaCruz AM, 1996, MEM I OSWALDO CRUZ, V91, P225, DOI 10.1590/S0074-02761996000200019
   DOHERTY GM, 1991, SURGERY, V110, P192
   GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x
   HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   LIU Y, 1994, J IMMUNOL, V152, P1821
   Marsden PD, 1985, CLIN MANIFESTATIONS
   Michel G, 1997, J IMMUNOL, V159, P6291
   Othieno C, 1999, INFECT IMMUN, V67, P5730, DOI 10.1128/IAI.67.11.5730-5735.1999
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   REED SG, 1992, J ACQ IMMUN DEF SYND, V5, P666
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   Rocha PN, 1999, J INFECT DIS, V180, P1731, DOI 10.1086/315071
   Russo D M, 1993, Prog Clin Parasitol, V3, P119
   SARNO EN, 1991, CLIN EXP IMMUNOL, V84, P103
   Schubach A, 1998, AM J TROP MED HYG, V58, P824, DOI 10.4269/ajtmh.1998.58.824
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995
   Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473
   STEIN M, 1991, EUR J IMMUNOL, V21, P431, DOI 10.1002/eji.1830210227
NR 37
TC 212
Z9 217
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2002
VL 70
IS 12
BP 6734
EP 6740
DI 10.1128/IAI.70.12.6734-6740.2002
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 617TU
UT WOS:000179377600030
PM 12438348
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   Silva, A
   Santana, LB
   Magalhaes, A
   de Jesus, AA
   de Almeida, RP
   Rego, MAV
   Burattini, MN
   Pearce, EJ
   Carvalho, EM
AF de Jesus, AR
   Silva, A
   Santana, LB
   Magalhaes, A
   de Jesus, AA
   de Almeida, RP
   Rego, MAV
   Burattini, MN
   Pearce, EJ
   Carvalho, EM
TI Clinical and immunologic evaluation of 31 patients with acute
   schistosomiasis mansoni
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 49th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY OCT 29-NOV 02, 2000
CL HOUSTON, TEXAS
SP Amer Soc Trop Med & Hyg
ID CIRCULATING IMMUNE-COMPLEXES; MURINE SCHISTOSOMIASIS; CYTOKINE
   PRODUCTION; RESPONSES; ANTIGENS; INFECTION; DISEASE; GAMMA; TYPE-1;
   IL-10
AB Thirty-one patients with acute schistosomiasis were evaluated clinically and immunologically. Cytokine levels were determined in peripheral blood mononuclear cell (PBMC) supernatants. Levels of total and antigen-specific IgE, tumor necrosis factor (TNF)-alpha, and immune complexes were measured in serum samples. Clinical findings included general symptoms, liver damage, pulmonary involvement, and pericarditis. All patients had eosinophilia. Immune complexes were detected in 55% of the patients (mean +/- SD, 7.8 +/- 7.6 mug Eq/mL) and were associated with cough, dyspnea, and abnormal chest radiographic findings. Levels (mean +/- SD) of TNF-alpha (1349.3 +/- 767.6 pg/mL), interleukin (IL)-1 (2683 +/- 1270 mug/mL), and IL-6 (382 +/- 52.3 pg/mL) were elevated in PBMC. Serum TNF-alpha levels were elevated in 87% of the patients and were associated with abdominal pain. Higher interferon-gamma levels were detected in PBMC of patients with acute disease than in those of patients with chronic schistosomiasis; IL-5 levels were higher in those with chronic disease. Low IL-5 levels were associated with weight loss. Proinflammatory cytokines and immune complexes with low Th2 responses might explain the immunopathogenesis of acute schistosomiasis.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, Brazil.
   Univ Fed Sergipe, Dept Doencas Infecciosas, Sergipe, Brazil.
   Univ Fed Sao Paulo, Serv Doencas Infecciosas, Sao Paulo, Brazil.
   Cornell Univ, Coll Vet Med, Dept Microbiol Immunol & Parasitol, Ithaca, NY 14853 USA.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, Brazil.
RI almeida, roque/F-5609-2012; Burattini, Marcelo Nascimento/J-9272-2014
OI Burattini, Marcelo Nascimento/0000-0002-5407-6890
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-30639] Funding
   Source: Medline
CR ABDELWAHAB MF, 1992, AM J TROP MED HYG, V46, P403, DOI 10.4269/ajtmh.1992.46.403
   Angstwurm K, 1998, NEUROSCIENCE, V86, P627, DOI 10.1016/S0306-4522(98)00032-3
   Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633
   ARAUJO MI, 1994, BRAZ J MED BIOL RES, V27, P1619
   BACH JF, 1997, LANCET, V350, P11
   BahiaOliveira LMG, 1996, PARASITE IMMUNOL, V18, P53, DOI 10.1046/j.1365-3024.1996.d01-49.x
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Bina J. C., 1981, Revista de Patologia Tropical, V10, P221
   BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488
   Brunet LR, 1997, J IMMUNOL, V159, P777
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   DEJESUS AMR, 1993, EUR J IMMUNOL, V23, P152, DOI 10.1002/eji.1830230125
   Dinarello CA, 2000, NEW ENGL J MED, V343, P732, DOI 10.1056/NEJM200009073431011
   Doumenge JP, 1987, ATLAS GLOBAL DISTRIB
   Fallon PG, 2000, EUR J IMMUNOL, V30, P470, DOI 10.1002/1521-4141(200002)30:2&lt;470::AID-IMMU470&gt;3.0.CO;2-T
   FARID Z, 1989, TROP GEOGR MED, V41, P172
   GAZZINELLI G, 1985, J IMMUNOL, V135, P2121
   GAZZINELLI RT, 1988, AM J TROP MED HYG, V39, P288, DOI 10.4269/ajtmh.1988.39.288
   GELFAND V, 1981, CENT AFR J MED, V27, P219
   Gryzch JM, 1991, J IMMUNOL, V146, P1322
   HIATT RA, 1979, J INFECT DIS, V139, P659, DOI 10.1093/infdis/139.6.659
   HIATT RA, 1980, J INFECT DIS, V142, P665, DOI 10.1093/infdis/142.5.665
   Hoffmann KF, 2000, J IMMUNOL, V164, P6406, DOI 10.4049/jimmunol.164.12.6406
   KATZ N, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P295
   KATZ N, 1970, J PARASITOL, V56, P1032, DOI 10.2307/3277532
   KATZ N, 1966, J PARASITOL, V52, P917, DOI 10.2307/3276534
   KEMENY DM, 1991, PRACTICAL GUIDE ELIS
   Kox WJ, 2000, INTENS CARE MED, V26, pS124, DOI 10.1007/s001340051129
   Kubler-Kielb J, 2000, Postepy Hig Med Dosw, V54, P119
   LAMBERTUCCI J, 1989, T R SOC MED HYG, V83, P76
   Lambertucci J. R., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P399, DOI 10.1590/S0036-46651993000500003
   Lambertucci JR, 1997, MEM I OSWALDO CRUZ, V92, P631, DOI 10.1590/S0074-02761997000500013
   LAWLEY TJ, 1979, CLIN EXP IMMUNOL, V37, P221
   Montenegro SML, 1999, J INFECT DIS, V179, P1502, DOI 10.1086/314748
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Mwatha JK, 1998, J IMMUNOL, V160, P1992
   Pearce EJ, 1996, EXP PARASITOL, V84, P295, DOI 10.1006/expr.1996.0116
   PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159
   PESSOA SB, 1977, PARASITOLOGIA MED, P399
   RABELLO A, 1995, MEM I OSWALDO CRUZ, V90, P277, DOI 10.1590/S0074-02761995000200026
   Rabello ALT, 1997, CLIN INFECT DIS, V24, P304, DOI 10.1093/clinids/24.3.304
   Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269
   VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433
   *WHO, 1985, REP WHO EXP COMM CON
   *WHO, 1995, WHO UNICEF JOINT PRO
   World Health Organization, 1993, WHO TECHN REP SER, V830
   Wynn TA, 1998, J IMMUNOL, V160, P4473
NR 48
TC 112
Z9 115
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2002
VL 185
IS 1
BP 98
EP 105
DI 10.1086/324668
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 502AZ
UT WOS:000172722600013
PM 11756987
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU De Jesus, AR
   Miranda, DG
   Miranda, RG
   Araujo, I
   Magalhaes, A
   Bacellar, M
   Carvalho, EM
AF De Jesus, AR
   Miranda, DG
   Miranda, RG
   Araujo, I
   Magalhaes, A
   Bacellar, M
   Carvalho, EM
TI Morbidity associated with Schistosoma mansoni infection determined by
   ultrasound in an endemic area of Brazil, Caatinga do Moura
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PERIPORTAL FIBROSIS; NORTHEAST BRAZIL; ULTRASONOGRAPHY; IMMUNOPATHOLOGY;
   DIAGNOSIS
AB Morbidity in schistosomiasis is caused by a granulomatous response to Schistosoma mansoni eggs deposited in peripheral portal veins. Ultrasonography has been useful to assess the impact of control programs on the prevalence of hepatic fibrosis. In the present study, ultrasonographic criteria proposed by the World Health Organization were used to classify the degree of hepatic fibrosis in 164 schistosomiasis patients from an endemic area of Brazil. The majority of subjects (89%) had degree I or II hepatic fibrosis. Periportal tract thickness, portal vein diameter, splenic vein diameter, and spleen size were positively correlated (P < 0.01). Ultrasonography was repeated on 21 patients one year later and hepatic fibrosis had progressed in 17. Ultrasonography was performed after treatment on 39 subjects and periportal fibrosis had regressed in 27.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   Clin Delfin Gonzalez Miranda LTDA, Salvador, BA, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
CR ABDELWAHAB MF, 1992, AM J TROP MED HYG, V46, P403, DOI 10.4269/ajtmh.1992.46.403
   Andrade Z A, 1983, Mem Inst Oswaldo Cruz, V78, P285, DOI 10.1590/S0074-02761983000300007
   Bina J. C., 1981, Revista de Patologia Tropical, V10, P221
   Bina J. C., 1997, Revista de Patologia Tropical, V26, P69
   BINA JC, 1990, EVOLUCAO NATURAL ESQ
   BOROS DL, 1989, CLIN MICROBIOL REV, V2, P250, DOI 10.1128/CMR.2.3.250-269.1989
   CHEEVER AW, 1985, PARASITE IMMUNOL, V7, P399, DOI 10.1111/j.1365-3024.1985.tb00086.x
   DOEHRINGSCHWERDTFEGER E, 1995, MEM I OSWALDO CRUZ, V90, P141, DOI 10.1590/S0074-02761995000200003
   DOEHRINGSCHWERDTFEGER E, 1992, AM J TROP MED HYG, V46, P409, DOI 10.4269/ajtmh.1992.46.409
   DOMINGUES ALC, 1993, T ROY SOC TROP MED H, V87, P555, DOI 10.1016/0035-9203(93)90087-7
   HOMEIDA M, 1988, AM J TROP MED HYG, V38, P86, DOI 10.4269/ajtmh.1988.38.86
   HOMEIDA MA, 1988, LANCET, V2, P437
   Homeida MMA, 1996, AM J TROP MED HYG, V54, P140, DOI 10.4269/ajtmh.1996.54.140
   KATZ N, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P295
   KATZ N, 1970, J PARASITOL, V56, P1032, DOI 10.2307/3277532
   Katz N, 1980, Rev Inst Med Trop Sao Paulo, V22, P8
   KATZ N, 1975, BRAS MED, V11, P55
   NOOMAN ZM, 1995, MEM I OSWALDO CRUZ, V90, P147, DOI 10.1590/S0074-02761995000200004
   Pinto-Silva Rogerio Augusto, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P355, DOI 10.1590/S0036-46651994000400008
   SLEIGH AC, 1986, LANCET, V1, P635
   SLEIGH AC, 1985, LANCET, V2, P63
   Thomas AK, 1997, ACTA TROP, V68, P347, DOI 10.1016/S0001-706X(97)00112-5
   WAHAB MFA, 1992, MEM I OSWALDO CRUZ, V87, P143, DOI 10.1590/S0074-02761992000800021
NR 23
TC 16
Z9 19
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL-AUG
PY 2000
VL 63
IS 1-2
BP 1
EP 4
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 431JZ
UT WOS:000168629200001
PM 11357987
DA 2020-12-08
ER

PT J
AU Rocha, PN
   Almeida, RP
   Bacellar, O
   de Jesus, AR
   Correia, D
   Cruz, A
   Barral, A
   Coffman, RL
   Carvalho, EM
AF Rocha, PN
   Almeida, RP
   Bacellar, O
   de Jesus, AR
   Correia, D
   Cruz, A
   Barral, A
   Coffman, RL
   Carvalho, EM
TI Down-regulation of Th1 type of response in early human American
   cutaneous leishmaniasis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CYTOKINE PATTERNS; INTERFERON-GAMMA; SUSCEPTIBILITY; INTERLEUKIN-4;
   EXPRESSION; INFECTION; DONOVANI
AB This study examined the T cell responses in the early phase of Leishmania braziliensis infection. Cytokine profiles, lymphoproliferative responses, and skin test results in 25 patients with early cutaneous leishmaniasis (ECL; illness duration <60 days) were compared with those in persons with late cutaneous leishmaniasis (LCL; illness duration >2 months). Absent or low lymphoproliferative responses were observed in 8 (32%) of 25 patients and an absence of interferon (IFN)-gamma production in 9 (41%) of 22 patients prior to therapy. IFN-gamma production in ECL (mean +/- SD) was lower than in LCL (293 +/- 346 vs. 747 +/- 377 pg/mL, respectively; P<.01). In contrast, interleukin (IL)-10 production in ECL(mean +/- SD) was higher than in LCL(246 +/- 56 vs. 50 +/- 41 pg/mL, respectively; P <.01),Restoration of lymphoproliferative responses and IFN-gamma production was achieved when monoclonal antibody to IL-10 or IL-12 was added to the cultures. These results show that T cell responses during early-phase infection are down-regulated by IL-10 and may facilitate parasite multiplication.
C1 Univ Fed Uberlandia, BR-38400 Uberlandia, MG, Brazil.
   DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA.
   Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Immunol Lab, Serv Immunol, BR-40110160 Salvador, BA, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Immunol Lab, Serv Immunol, 3 Andar Rua Joao Botas,S N Canela, BR-40110160 Salvador, BA, Brazil.
RI Correia, Dalmo CD/B-2201-2013; almeida, roque/F-5609-2012; Rocha, Paulo
   N/E-9527-2013; Rocha, Paulo Novis/AAE-3776-2019; Barral,
   Aldina/B-4191-2009
OI Correia, Dalmo CD/0000-0002-0209-7016; Rocha, Paulo
   Novis/0000-0001-9598-6711; Barral, Aldina/0000-0002-7177-464X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER
CR BERG DJ, 1995, J EXP MED, V182, P99, DOI 10.1084/jem.182.1.99
   Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T
   Coutinho SG, 1996, EXP PARASITOL, V84, P144, DOI 10.1006/expr.1996.0100
   HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59
   MELBY PC, 1994, INFECT IMMUN, V62, P837, DOI 10.1128/IAI.62.3.837-842.1994
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447
   RUSSO DM, 1992, J IMMUNOL, V148, P202
   Scott P, 1996, EXP PARASITOL, V84, P178, DOI 10.1006/expr.1996.0103
NR 15
TC 62
Z9 64
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV
PY 1999
VL 180
IS 5
BP 1731
EP 1734
DI 10.1086/315071
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 252TZ
UT WOS:000083519500046
PM 10515843
OA Bronze
DA 2020-12-08
ER

PT J
AU Almeida, R
   D'Oliveira, A
   Machado, P
   Bacellar, O
   Ko, AI
   de Jesus, AR
   Mobashery, N
   Santos, JB
   Carvalho, EM
AF Almeida, R
   D'Oliveira, A
   Machado, P
   Bacellar, O
   Ko, AI
   de Jesus, AR
   Mobashery, N
   Santos, JB
   Carvalho, EM
TI Randomized, double-blind study of stibogluconate plus human granulocyte
   macrophage colony-stimulating factor versus stibogluconate alone in the
   treatment of cutaneous leishmaniasis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 25th Annual Meeting in Chagas Disease
CY NOV   14, 1998
CL CAXAMBU, BRAZIL
ID CSF; PENTAMIDINE; INFECTION; DONOVANI; THERAPY
AB The response to recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis was evaluated. Twenty patients with cutaneous leishmaniasis who had lesions for 60 days were enrolled in a double-blind placebo trial of GM-CSF with standard parenteral sodium stibogluconate (20 mg/kg(-1)/day(-1)) for 20 days. Ten patients were randomized to receive intralesionally injected GM-CSF (200 mu g) at enrollment and 1 week after, and 10 patients received saline as placebo. GM-CSF- and antimony-treated patients healed faster than patients who received antimony alone (49 +/- 32.8 vs. 110 +/- 61.6 days, P<.05). Seven of 10 patients were healed of their lesions before 40 days after therapy in the GM-CSF group, compared with only 1 of 10 patients in the placebo group (relative risk, 7; 95% confidence interval, 1.04-47.00), Thus, GM-CSF plus antimony significantly increased the chance of lesion healing in 40 days.
C1 Hosp Univ Prof Edgard Santos, Serv Immunol, BR-40110160 Salvador, BA, Brazil.
   Cornell Univ, Coll Med, New York Hosp, Div Int Hlth & Infect Dis,Dept Med, New York, NY 10021 USA.
RP Carvalho, EM (corresponding author), Hosp Univ Prof Edgard Santos, Serv Immunol, 3 Andar Rua Joao Botas,S N Canela, BR-40110160 Salvador, BA, Brazil.
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; Ko, Albert
   Icksang/P-2343-2015
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; Ko, Albert
   Icksang/0000-0001-9023-2339
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER
CR AlZamel F, 1996, ZBL BAKT-INT J MED M, V285, P92, DOI 10.1016/S0934-8840(96)80027-2
   BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   BOENTE P, 1993, LANCET, V341, P1154, DOI 10.1016/0140-6736(93)93174-Y
   BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3
   DOHERTY TM, 1993, J IMMUNOL, V150, P5476
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   JONES TC, 1993, EUR J CANCER, V29A, pS10, DOI 10.1016/0959-8049(93)90625-P
   Jones TC, 1996, MED ONCOL, V13, P141, DOI 10.1007/BF02990842
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99
   Modabber F., 1987, Tropical disease research: a global partnership. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases 8th Programme Report: the first ten years, with highlights of the 1985-86 biennium.., P99
   PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538
   SAMPAIO S A P, 1971, International Journal of Dermatology, V10, P179, DOI 10.1111/j.1365-4362.1971.tb01694.x
   SOTOMANCIPE J, 1993, CLIN INFECT DIS, V16, P417, DOI 10.1093/clind/16.3.417
   WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436
NR 15
TC 33
Z9 33
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV
PY 1999
VL 180
IS 5
BP 1735
EP 1737
DI 10.1086/315082
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 252TZ
UT WOS:000083519500047
PM 10515844
OA Bronze
DA 2020-12-08
ER

PT J
AU DEJESUS, AR
   COOPER, R
   ESPINOSA, M
   GOMES, JEPL
   GARCIA, ES
   PAUL, S
   CROSS, GAM
AF DEJESUS, AR
   COOPER, R
   ESPINOSA, M
   GOMES, JEPL
   GARCIA, ES
   PAUL, S
   CROSS, GAM
TI GENE DELETION SUGGESTS A ROLE FOR TRYPANOSOMA-CRUZI SURFACE GLYCOPROTEIN
   GP72 IN THE INSECT AND MAMMALIAN STAGES OF THE LIFE-CYCLE
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE TRYPANOSOMA CRUZI; FLAGELLUM; SURFACE GLYCOPROTEIN; GENE DISRUPTION
ID MONOCLONAL-ANTIBODY; ANTIGENS; MORPHOGENESIS; MIDGUT; FORMS
AB We have explored the biological function of a surface glycoprotein (GP72) of Trypanosoma cruzi by studying a null mutant parasite, generated by targeted gene deletion. GP72 deletion affected parasite morphology in several stages of the life cycle. Insect midgut (epimastigote) forms had a detached flagellum (apomastigote) in the null mutant. The abnormal flagellar phenotype persisted during development of the infective (metacyclic) forms but there was no impairment in the aquisition of complement resistance, sialidase expression or cell infectivity. The GP72 null mutant could efficiently infect and proliferate in mouse macrophages and non-phagocytic L6E9 cells. The mammalian stages of the life cycle also showed major morphological abnormalities. During early subcultures in L6E9 cells, few extracellular fully flagellated forms, expressing markers characteristic of trypomastigotes, were seen. The extracellular population consisted almost exclusively of rounded forms with short flagella (micromastigote), which expressed an amastigote-specific surface marker and no sialidase. The propagation of the parasite was not affected, despite the apparent lack of the trypomastigote forms, which are thought to be primarily responsible for cell invasion. After some subcultures, the extracellular population changed to about equal numbers of micromastigotes and a range of flagellated forms that still did not include true trypomastigotes. Instead, the kinetoplast remained close to the nucleus and the flagellum emerged from the middle of the cell (mesomastigote). Half of the flagellum adhered to the cell body and the remainder was free at the anterior end. In Triatoma infestans, the survival of the mutant was dramatically reduced, suggesting that either GP72 itself, or the altered properties of the flagellum, were critical for establishment in the insect vector.
C1 ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021.
   IPN,CTR INVEST & ESTUDIOS AVANZADOS,MEXICO CITY 07000,DF,MEXICO.
   OSWALDO CRUZ FDN,DEPT BIOCHEM & MOLEC BIOL,BR-21045900 RIO JANEIRO,RJ,BRAZIL.
OI Cross, George/0000-0003-1374-6955
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI026197, R01AI026197, R01AI026197, R01AI026197, R01AI026197,
   R01AI026197, R01AI026197, R01AI026197] Funding Source: NIH RePORTER; FIC
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI26197, AI01071] Funding Source: Medline
CR ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2
   CHAPMAN MD, 1984, J IMMUNOL, V132, P3149
   COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149
   COOPER R, 1991, MOL BIOCHEM PARASIT, V49, P45, DOI 10.1016/0166-6851(91)90129-T
   CROSS GAM, 1993, ANNU REV MICROBIOL, V46, P385
   FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313
   FRASCH ACC, 1991, PARASITOL TODAY, V7, P148, DOI 10.1016/0169-4758(91)90284-U
   GARCIA ES, 1991, PARASITOL TODAY, V7, P240, DOI 10.1016/0169-4758(91)90237-I
   Goldenberg S., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V42, P203
   HARTH G, 1992, MOL CELL BIOCHEM, V109, P25, DOI 10.1007/BF00230870
   Hoare CA, 1972, TRYPANOSOMES MAMMALS
   KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731
   NOGUEIRA N, 1981, J EXP MED, V153, P629, DOI 10.1084/jem.153.3.629
   NOGUEIRA N, 1982, P NATL ACAD SCI-BIOL, V79, P1259, DOI 10.1073/pnas.79.4.1259
   PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592
   PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326
   ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0
   SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567
   SHER A, 1982, NATURE, V300, P639, DOI 10.1038/300639a0
   SNARY D, 1981, MOL BIOCHEM PARASIT, V3, P343, DOI 10.1016/0166-6851(81)90035-9
   VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6
   WARBURG A, 1989, J PROTOZOOL, V36, P613, DOI 10.1111/j.1550-7408.1989.tb01104.x
NR 22
TC 35
Z9 35
U1 0
U2 3
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE, CAMBS,
   ENGLAND CB4 4DL
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD DEC
PY 1993
VL 106
BP 1023
EP 1033
PN 4
PG 11
WC Cell Biology
SC Cell Biology
GA MP529
UT WOS:A1993MP52900004
PM 8126090
DA 2020-12-08
ER

PT J
AU COOPER, R
   DEJESUS, AR
   CROSS, GAM
AF COOPER, R
   DEJESUS, AR
   CROSS, GAM
TI DELETION OF AN IMMUNODOMINANT TRYPANOSOMA-CRUZI SURFACE GLYCOPROTEIN
   DISRUPTS FLAGELLUM CELL-ADHESION
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID HOMOLOGOUS RECOMBINATION; MONOCLONAL-ANTIBODIES; GENE REPLACEMENT;
   BRUCEI; EXPRESSION; PROTOZOAN; ANTIGENS; TRANSFECTION; MORPHOGENESIS;
   TRANSCRIPTION
AB Null mutants of the Trypanosoma cruzi insect stage-specific glycoprotein GP72 were created by targeted gene replacement. Targeting plasmids were constructed in which the neomycin phosphotransferase and hygromycin phosphotransferase genes were flanked by GP72 sequences. These plasmids were sequentially transfected into T. cruzi epimastigotes by electroporation. Southern blot analyzes indicated that precise replacement of the two genes had occurred. No aberrant rearrangements occurred at the GP72 locus and no GP72 gene sequences had been translocated elsewhere in the genome. Western blots confirmed that GP72 is not expressed in these null mutants. The morphology of the mutants is dramatically different from wild-type. In both mutant and wild-type parasites, the flagellum emerges from the flagellar pocket. In the null mutant the normal attachment of the flagellum to the cell membrane of the parasite is lost.
C1 ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021.
RI Cross, George/B-7444-2011
OI Cross, George/0000-0003-1374-6955
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW 00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI26197] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI026197, R01AI026197, R01AI026197, R01AI026197,
   R01AI026197, R01AI026197, R01AI026197, R01AI026197] Funding Source: NIH
   RePORTER
CR ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2
   AUSUBEL FM, 1990, CURRENT PROTOCOLS MO
   BELLOFATTO V, 1990, PARASITOL TODAY, V6, P299, DOI 10.1016/0169-4758(90)90260-B
   BELLOFATTO V, 1989, SCIENCE, V244, P1167, DOI 10.1126/science.2499047
   CAPECCHI M, 1990, NATURE, V348, P109, DOI 10.1038/348109a0
   CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260
   CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036
   COOPER R, 1991, MOL BIOCHEM PARASIT, V49, P45, DOI 10.1016/0166-6851(91)90129-T
   COTRIM PC, 1990, J CLIN MICROBIOL, V28, P519, DOI 10.1128/JCM.28.3.519-524.1990
   CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170
   CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0
   DESOUZA W, 1978, J CELL SCI, V33, P285
   EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118
   ESQUENAZI D, 1989, MOL BIOCHEM PARASIT, V34, P197
   FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313
   GARCIA ES, 1991, PARASITOL TODAY, V7, P240, DOI 10.1016/0169-4758(91)90237-I
   HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X
   HARTH G, 1992, MOL CELL BIOCHEM, V109, P25, DOI 10.1007/BF00230870
   HOGAN JC, 1976, J PROTOZOOL, V23, P205, DOI 10.1111/j.1550-7408.1976.tb03757.x
   IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6
   IBANEZ CF, 1987, MOL BIOCHEM PARASIT, V25, P175, DOI 10.1016/0166-6851(87)90006-5
   KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731
   LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119
   LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779
   LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225
   LEWENGRUB S, 1988, CAN J ZOOL, V66, P1342, DOI 10.1139/z88-197
   LU HY, 1991, MOL BIOCHEM PARASIT, V44, P109, DOI 10.1016/0166-6851(91)90226-V
   MULLER N, 1992, PARASITOLOGY, V104, P111, DOI 10.1017/S0031182000060856
   Nicolle C, 1908, CR HEBD ACAD SCI, V146, P842
   NOGUEIRA N, 1981, J EXP MED, V153, P629, DOI 10.1084/jem.153.3.629
   Novy FG, 1904, J INFECT DIS, V1, P1
   OTSU K, 1993, MOL BIOCHEM PARASIT, V57, P317, DOI 10.1016/0166-6851(93)90207-E
   RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492
   SCHECHTER M, 1986, INFECT IMMUN, V53, P547, DOI 10.1128/IAI.53.3.547-552.1986
   SHER A, 1982, NATURE, V300, P639, DOI 10.1038/300639a0
   SNARY D, 1981, MOL BIOCHEM PARASIT, V3, P343, DOI 10.1016/0166-6851(81)90035-9
   SOUTOPADRON T, 1989, EUR J CELL BIOL, V50, P272
   TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0
   VICKERMAN K, 1969, J CELL SCI, V5, P163
   WOODS A, 1989, J CELL SCI, V93, P501
   WOODS A, 1989, J CELL SCI, V93, P491
   ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x
NR 42
TC 93
Z9 94
U1 0
U2 6
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD JUL
PY 1993
VL 122
IS 1
BP 149
EP 156
DI 10.1083/jcb.122.1.149
PG 8
WC Cell Biology
SC Cell Biology
GA LK410
UT WOS:A1993LK41000012
PM 8314840
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU BARRAL, A
   BARRALNETTO, M
   ALMEIDA, R
   DEJESUS, AR
   GRIMALDI, G
   NETTO, EM
   SANTOS, I
   BACELLAR, O
   CARVALHO, EM
AF BARRAL, A
   BARRALNETTO, M
   ALMEIDA, R
   DEJESUS, AR
   GRIMALDI, G
   NETTO, EM
   SANTOS, I
   BACELLAR, O
   CARVALHO, EM
TI LYMPHADENOPATHY ASSOCIATED WITH LEISHMANIA-BRAZILIENSIS CUTANEOUS
   INFECTION
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID AMERICAN VISCERAL LEISHMANIASIS; LYMPH-NODE INVOLVEMENT;
   MONOCLONAL-ANTIBODIES; SELECTION; ANTIGEN
AB Lymph node involvement by Leishmania during human cutaneous leishmaniasis was reported more than 90 years ago, but the importance of certain Leishmania strains in such dissemination remains largely speculative. We have examined 36 consecutively untreated cutaneous leishmaniasis patients early in their disease; 66.7% had enlarged lymph nodes. Patients with enlarged lymph nodes had higher anti-Leishmania immune responses than patients without such involvement, both at the IgG antibody level (mean +/- SD optical density at 492 nm = 0. 163 +/- 0.089 versus 0.098 +/- 0.086; P = 0.009) and in skin test responses (12.4 +/- 10.2 mm versus 5.7 +/- 7.3; P = 0.03). Thirteen (62%) of 21 lymph node cultures and 16 (53%) of 30 cultures from cutaneous sites were positive for Leishmania. Eleven of 13 isolates from lymph nodes were characterized by a panel of monoclonal antibodies, and all were typed as L. braziliensis. Our findings stress the importance of L. braziliensis as an agent involved in the early invasion of the lymphatic system.
C1 FDN OSWALDO CRUZ,RIO JANEIRO,BRAZIL.
RP BARRAL, A (corresponding author), UNIV FED BAHIA,FAMED,HUPES,SERV IMUNOL,BR-40140 SALVADOR,BA,BRAZIL.
RI Netto, Eduardo/D-1432-2013; Barral-Netto, Manoel/B-3904-2009; Barral,
   Aldina/B-4191-2009; almeida, roque/F-5609-2012
OI Netto, Eduardo/0000-0003-1691-6761; Barral-Netto,
   Manoel/0000-0002-5823-7903; Barral, Aldina/0000-0002-7177-464X; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P01AI016282, P50AI030639, P01AI016282, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P01AI016282, P50AI030639, P50AI030639,
   P50AI030639, P01AI016282, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P01AI016282, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P01AI016282, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P01AI016282, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P01AI016282, P01AI016282,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282, AI-30639]
   Funding Source: Medline
CR ALGINDAN Y, 1989, INT J DERMATOL, V28, P248, DOI 10.1111/j.1365-4362.1989.tb04814.x
   AZADEH B, 1985, AM J TROP MED HYG, V34, P447, DOI 10.4269/ajtmh.1985.34.447
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   BARRAL A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P579, DOI 10.1590/S0074-02761987000400018
   BERGER TG, 1985, J AM ACAD DERMATOL, V12, P993, DOI 10.1016/S0190-9622(85)70126-0
   CHIARI C. A., 1973, Revista do Instituto de Medicina Tropical de Sao Paulo, V15, P304
   Cuba Cuba C A, 1980, Bol Oficina Sanit Panam, V89, P195
   DARRIER J, 1901, ANN DERMATOL SYPHIL, V10, P380
   GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270
   JAFFE CL, 1984, J IMMUNOL, V133, P440
   MCMAHONPRATT D, 1982, J IMMUNOL, V129, P929
   MIMORI T, 1987, ANN TROP MED PARASIT, V81, P681, DOI 10.1080/00034983.1987.11812170
   MORIEARTY PL, 1982, CLIN EXP IMMUNOL, V47, P59
   PESSOA SB, 1948, MIN ED SAUDE, V1, P1
   POULTER LW, 1982, CLIN EXP IMMUNOL, V48, P396
   REED SG, 1986, CLIN EXP IMMUNOL, V64, P8
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   Sampaio R. N. R., 1980, Anais Brasileiros de Dermatologia, V55, P69
   SPLENDORE A, 1912, B SOC PATHOL EXOT, V5, P389
NR 20
TC 35
Z9 35
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 1992
VL 47
IS 5
BP 587
EP 592
DI 10.4269/ajtmh.1992.47.587
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KA498
UT WOS:A1992KA49800008
PM 1449199
DA 2020-12-08
ER

PT J
AU BARRAL, A
   PEDRALSAMPAIO, D
   GRIMALDI, G
   MOMEN, H
   MCMAHONPRATT, D
   DEJESUS, AR
   ALMEIDA, R
   BADARO, R
   BARRALNETTO, M
   CARVALHO, EM
   JOHNSON, WD
AF BARRAL, A
   PEDRALSAMPAIO, D
   GRIMALDI, G
   MOMEN, H
   MCMAHONPRATT, D
   DEJESUS, AR
   ALMEIDA, R
   BADARO, R
   BARRALNETTO, M
   CARVALHO, EM
   JOHNSON, WD
TI LEISHMANIASIS IN BAHIA, BRAZIL - EVIDENCE THAT LEISHMANIA-AMAZONENSIS
   PRODUCES A WIDE SPECTRUM OF CLINICAL-DISEASE
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID AMERICAN VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS;
   MONOCLONAL-ANTIBODIES; IDENTIFICATION; EPIDEMIOLOGY; AMASTIGOTES;
   SELECTION; ANTIGENS; WORLD
AB One hundred fourteen Leishmania isolates from patients with different clinical forms of leishmaniasis in the State of Bahia, Brazil, were characterized by indirect radioimmune binding assay using specific monoclonal antibodies (serodeme analysis). Seventy-five of these isolates were also analyzed by enzyme electrophoresis, based on 11 enzyme loci; parasite species were compared, according to their characteristic zymodemes, to those of WHO Leishmania reference strains. All isolates could be classified into one of three species: Leishmania amazonensis (n = 40), L. braziliensis (n = 39) or L. chagasi (n = 35). The most interesting information obtained from this study is the realization that L. amazonensis is capable of producing a wide spectrum of disease in humans. Infection with this parasite was associated with many different clinical presentations, including cutaneous leishmaniasis [CL] (20/49 cases), mucocutaneous leishmaniasis [MCL] (5/13 cases) and, of special note, visceral leishmaniasis [VL] (I 1/46 cases), as well as four cases of post kala-azar dermal leishmaniasis [PKDL]. In situ tissue parasite characterization, by immunoperoxidase assay and employing anti-L. amazonensis amastigote monoclonal antibodies, confirmed the infection with this species in two cases of CL, one case of DCL, one case of MCL and one case of PKDL. Our results also demonstrate the difficulty of parasite differentiation based on clinical grounds, since at least L. amazonensis infection can be associated with all types of leishmanial diseases, and different Leishmania species may be associated with indistinguishable clinical presentations. Since leishmanial parasites may vary in their biological behavior or in their response to treatment, it is important that their identification be made by reliable methods.
C1 CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
   INST OSWALDO CRUZ, RIO DE JANEIRO, BRAZIL.
   YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA.
RI Barral, Aldina/B-4191-2009; Momen, Hooman/A-1850-2008; almeida,
   roque/F-5609-2012; Barral-Netto, Manoel/B-3904-2009
OI Barral, Aldina/0000-0002-7177-464X; Momen, Hooman/0000-0002-2324-1515;
   Barral-Netto, Manoel/0000-0002-5823-7903
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, R01AI023004, P01AI016282, R01AI023004, R01AI023004,
   R01AI023004, P01AI016282, P01AI016282, P01AI016282, R01AI023004,
   P01AI016282, R01AI023004, R01AI023004, R01AI023004, R01AI023004,
   P01AI016282, P01AI016282, P01AI016282, R01AI023004, P01AI016282,
   P01AI016282, R01AI023004, R01AI023004, P01AI016282, P01AI016282,
   P01AI016282, R01AI023004, P01AI016282] Funding Source: NIH RePORTER;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 23004, AI 16282] Funding Source: Medline
CR ABDALLA RE, 1982, ANN TROP MED PARASIT, V76, P299, DOI 10.1080/00034983.1982.11687545
   ALTAQI M, 1978, T ROY SOC TROP MED H, V72, P56, DOI 10.1016/0035-9203(78)90302-4
   ANTHONY RL, 1987, AM J TROP MED HYG, V37, P271, DOI 10.4269/ajtmh.1987.37.271
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BARRAL A, 1983, AM J TROP MED HYG, V32, P277, DOI 10.4269/ajtmh.1983.32.277
   BARRAL A, 1986, AM J TROP MED HYG, V35, P732, DOI 10.4269/ajtmh.1986.35.732
   BELAZZOUG S, 1985, ANN PARASIT HUM COMP, V60, P1
   BITTENCOURT A, 1989, MEM I OSWALDO CRUZ, V84, P585, DOI 10.1590/S0074-02761989000400022
   CHULAY JD, IN PRESS REV SOC BRA
   Cuba C. C., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P161, DOI 10.1590/S0037-86821984000400002
   GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270
   GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687
   Grimaldi G Jr, 1991, Prog Clin Parasitol, V2, P73
   HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091
   JAFFE CL, 1984, J IMMUNOL, V133, P440
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   LAINSON R, 1987, LEISHMANIASES BIOL M, V1, P1
   LEON LL, 1990, T ROY SOC TROP MED H, V84, P678, DOI 10.1016/0035-9203(90)90144-4
   LYNCH NR, 1986, T ROY SOC TROP MED H, V80, P6, DOI 10.1016/0035-9203(86)90183-5
   MARSDEN PD, 1975, REV SOC BRASILEIRA M, V9, P309
   MOMEN H, 1985, AM J TROP MED HYG, V34, P1076, DOI 10.4269/ajtmh.1985.34.1076
   NETO MPO, 1986, ANN TROP MED PARASIT, V80, P587, DOI 10.1080/00034983.1986.11812072
   Oliveira Neto M P, 1986, Mem Inst Oswaldo Cruz, V81, P303, DOI 10.1590/S0074-02761986000300006
   PACHECO RS, 1984, 4 P JAP BRAZ S SCI T, V2, P58
   PAN AA, 1988, J IMMUNOL, V140, P2406
   PRATT DM, 1985, J IMMUNOL, V134, P1935
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   RIOUX JA, 1986, T ROY SOC TROP MED H, V80, P1004, DOI 10.1016/0035-9203(86)90300-7
   Sampaio R. N., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P273, DOI 10.1590/S0037-86821985000400015
   SCHILIRO G, 1978, T ROY SOC TROP MED H, V72, P656, DOI 10.1016/0035-9203(78)90027-5
   SCHNUR LF, 1985, T ROY SOC TROP MED H, V79, P134, DOI 10.1016/0035-9203(85)90259-7
   SCHNUR LF, 1981, ANN TROP MED PARASIT, V75, P131, DOI 10.1080/00034983.1981.11687421
   SELLS PG, 1981, T ROY SOC TROP MED H, V75, P461, DOI 10.1016/0035-9203(81)90121-8
   SILVEIRA FT, 1984, REV INST MED TROP SP, V26, P272, DOI 10.1590/S0036-46651984000500008
   WALTON BC, 1977, AM J TROP MED HYG, V26, P850, DOI 10.4269/ajtmh.1977.26.850
NR 37
TC 253
Z9 256
U1 0
U2 7
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 1991
VL 44
IS 5
BP 536
EP 546
DI 10.4269/ajtmh.1991.44.536
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FW270
UT WOS:A1991FW27000011
PM 2063957
DA 2020-12-08
ER

PT J
AU BITTENCOURT, A
   BARRAL, A
   DEJESUS, AR
   DEALMEIDA, RP
   GRIMALDI, G
AF BITTENCOURT, A
   BARRAL, A
   DEJESUS, AR
   DEALMEIDA, RP
   GRIMALDI, G
TI INSITU IDENTIFICATION OF LEISHMANIA-AMAZONENSIS ASSOCIATED WITH DIFFUSE
   CUTANEOUS LEISHMANIASIS IN BAHIA, BRAZIL
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Note
C1 UNIV FED BAHIA,HOSP PROF EDGARD SANTOS,IMMUNOL LAB,BR-40140 SALVADOR,BA,BRAZIL.
   INST OSWALDO CRUZ,DEPT IMUNOL,BR-20001 RIO DE JANEIRO,RJ,BRAZIL.
RP BITTENCOURT, A (corresponding author), UNIV FED BAHIA,DEPT ANAT PATOL & MED LEGAL,R JOAO DAS BOTAS S-N,BR-40140 SALVADOR,BA,BRAZIL.
RI Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
CR BARRAL A, 1989, IN PRESS AM J TROP M
   BITTENCOURT A. L., 1968, Medicina Cutanea, V2, P395
   FONSECA A, 1981, MED CUT ILA, V9, P317
   GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270
   GRIMALDI G, 1983, 10 REUN AN PESQ BAS
   GRIMALDI G, 1989, IN PRESS AM J TROP M
   GUIMARAES FN, 1951, HOSPITAL, V40, P11
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   Medina R., 1962, Archivos Venezolanos de Medicina Tropical y Parasitologia Medica, V4, P349
   MILES M, 1980, T R SOC TROP MED HYG, V74, P248
   PAN AA, 1988, J IMMUNOL, V140, P2406
   PORTUGAL H, 1960, Hospital (Rio J), V57, P813
   SILVA A. R., 1981, Revista do Instituto de Medicina Tropical de Sao Paulo, V23, P31
NR 13
TC 15
Z9 15
U1 0
U2 0
PU MEM INST OSWALDO CRUZ
PI RIO DE JANEIRO
PA SECRETARY CAIXA POSTAL 926, 20001 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD OCT-DEC
PY 1989
VL 84
IS 4
BP 585
EP 586
DI 10.1590/S0074-02761989000400022
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CK218
UT WOS:A1989CK21800022
PM 2487456
OA DOAJ Gold
DA 2020-12-08
ER

EF